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Tryptophan 2,3-dioxygenase catalyzes the first and the rate limiting step in the kynurenine 
pathway of tryptophan degradation to form N-formyl kynurenine. Mechanistic and 
kinetic studies were done on this enzyme and the results were shown to favor the Criegee 
rearrangement as the most likely pathway for the catalytic transformation. 
 There are two characterized catabolic routes for vitamin B6 degradation. Even 
though the enzymes involved in the degradation of vitamin B6 have been characterized, 
no information on the genes encoding for these enzymes were available for a long time. 
Recently, 4 out of the 7 genes involved in Vitamin B6 catabolism were identified from 
Mesorhizobium loti, while the other 3 genes remained elusive. Bioinformatics search 
revealed three candidates which could function as an oxidoreductase (mlr6793), a 
decarboxylase (mlr6791) and a hydrolase (mlr6787). These were cloned and heterologusly 
overexpressed in Escherichia coli. Each protein was purified to homogeneity and in vitro 
biochemical studies were carried out to rigorously characterize mlr6793, mlr6791 and 
mlr6787 gene-products to be 4-pyridoxic acid dehydrogenase, 3-hydroxy-2-
methylpyridine-4,5-dicarboxylate decarboxylase and 2-(acetamidomethylene)succinate 
hydrolase respectively.  
Apart from the well known reductive and oxidative catabolic pathway of uracil (or 
thymine) another novel pyrimidine degradation pathway was very recently discovered in 
Escherichia coli K12. The genes participating in this pathway were identified but no 
 information on the enzymology and intermediates involved in this pathway were known. 
Our work characterized the intermediates of the pathway and identified three enzymes in 
this novel pathway that were able to convert uracil to 3-oxopropionate. The first enzyme 
in this pathway is RutA which does a novel flavin dependant hydrolysis of uracil. With 
the crystal structure of this protein and model chemistry we were able to hypothesize a 
plausible mechanism for the reaction catalyzed by RutA. 
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CHAPTER 1 
Introduction 
1.1 Tryptophan 2,3-dioxygenase 
The amino acid tryptophan, first discovered in 1901 by F.G. Hopkins (1), is an 
essential amino acid which is not only required for protein synthesis but also is a 
precursor in important metabolic pathways like the biosynthesis of nicotinamide 
cofactors (NAD+, NADP) in eukaryotes (2, 3) and neurotransmitters like serotonin and 
melatonin in mammals (4). figure 1.1 shows the ‘kynurenine pathway’ (shown in blue) that 
catabolizes 99% of the dietary tryptophan, not assimilated into proteins, to either NAD+ 
(deficiency of which causes pellagra in humans (5, 6)) or to CO2, NH3 and H2O, while the 
alternative ‘serotonin pathway’ (shown in red) converts the rest to serotonin and 
melatonin (4). Quinolinic acid, which is the precursor to the biosynthesis of NAD also 
serves as an agonist for the N-methyl-D-aspertate (NMDA) receptors, while kynurenic 
acid (formed from kynurenine via kynurenine aminotranferase) serves as the antagonist 
for the NMDA receptors (7). Thus the flux of metabolites via the ‘kynurenine pathway’ 
has implication in the pathology of certain neurological conditions. Tryptophan-2,3-
dioxygenase, TDO, catalyzes the first and the rate limiting step in the ‘kynurenine 
pathway’ of tryptophan degradation to form N-formyl kynurenine (NFK) (8). The 
mechanism by which TDO catalyzes the oxidative ring opening of the indole ring of 
tryptophan is poorly understood.  
As outlined in the figure 1.2 the heme iron catalyzes the formation of the 
tryptophan hydroperoxide (13) most likely by a single electron transfer mechanism. From 
this intermediate, three mechanistic routes to NFK (2) can be postulated. According to 
mechanism A (red), addition of water to the endocylic imine would form (14) which can 
rearrange to give NFK. In mechanism B (in pink) rearrangement of the hydroperoxide 
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(13) to a dioxetane intermediate (16) followed by a retro [2+2] cycloaddition can form 
NFK (9, 10).  
Figure 1.1: The tryptophan catabolic pathway. The ‘serotonin pathway’ is shown in red 
and the ‘kynurenine pathway’ is shown in blue. (1) tryptophan; (2) N-formylkynurenine;  
(3) Kynurenine;  (4) 3-hydroxykynurenine;  (5) 3-hydroxyanthranilate;  (6) 2-amino-3-
carboxy muconate semialdehyde;  (7) quinolinic acid;  (8) 2-aminomuconate 
semialdehyde;  (9) nicotinamide adenine dinucleotide (NAD+);  (10) 5-hydroxytryptophan;  
(11) serotonin and  (12) kynurenic acid. 
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By mechanism C (blue) (analogous to the mechanism of extradiol dioxygenases (11)), a 
Criegee rearrangement would give the cationic intermediate (17) which could then 
undergo a nucleophilic attack by the iron-bound oxygen anion to give (18) followed by its 
collapse to form NFK.  Recombinant TDO from Ralstonia metallidurans was 
overexpressed in E. coli and purified. Efforts were made to elucidate the mechanism of 
this reaction, as detailed out in chapter 2 and 3.  
 
Figure 1.2: Three palusible mechanistic routes which the ternary complex (13) could 
possibly take to produce NFK. 
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1.2 PLP catabolic pathway 
The catabolic pathway of vitamin B6 (19) is probably the best studied amongst all 
other cofactors. In animals (including humans) 4-pyridoxic acid (22) is the primary 
catabolic product of vitamin B6, found in urine (12). It is formed by oxidation of 
pyridoxal (20) by a relatively non-specific FAD-dependent aldehyde oxidase. The 
catalytically active form of vitamin B6, pyridoxal-5’-phosphate, PLP (35),  does not 
undergo similar oxidation to form (22) (13, 14). The various forms of vitamin B6 (19, 20, 
33) and their respective phosphate esters (34, 35)) are readily enzymatically 
interconvertible (15). Further degradation of (22) is unlikely in humans as subjects 
administered with doses of (22), were found to excrete it quantitatively (16). Estimation 
of  (22) in urine serves as a nutritional marker, as lower than normal amounts of (22) is 
indicative of vitamin B6 deficiency (17). 
The catabolic pathway in microorganisms does not stop at (22). Selective culture 
techniques were used by Snell et al. to identify ten different bacterial strains and 1 yeast 
strain, able to grow on one or more forms of vitamin B6 as the sole source of carbon and 
nitrogen (18). The catabolic intermediates have been isolated and characterized from the 
growth medium (18-20), and two catabolic pathways have been proposed as shown in 
figure 1.3. Both these pathways are inducible and the enzymes catalyzing these steps have 
also been characterized.  
In pathway A figure 1.3, observed in Pseudomonas MA-1, pyridoxal (20) is produced 
from either pyridoxamine (33) by a transamination reaction with pyruvate catalyzed by 
pyridoxamine pyruvate transaminase (21-24), or from pyridoxine (19) by an oxidation 
reaction catalyzed by the FAD dependent pyridoxine 4-oxidase (25). Pyridoxal (20) is 
then oxidized to form the lactone (21) by the NAD dependent pyridoxal dehydrogenase 
(26) which is then hydrolyzed to form (22) by 4-pyridoxolactonase (26, 27). FAD 
dependent 4-pyridoxic acid dehydrogenase catalyzes the two electron oxidation of (22) to  
 5 
 
Figure 1.3: (a) The gene organization in Mesorhizobium Loti MAFF303099. The genes that 
have been identified to participate in PLP degradation are shown in catabolic pathway A. 
mlr6806 - Pyridoxamine pyruvate transaminase, mll6785 - pyridoxine 4-dehydrogenase, 
mlr6807 - pyridoxal dehydrogenase, mlr6805 - 4-pyridoxolactonase, mlr6793 - 4-
pyridoxic acid dehydrogenase, mlr6791- 2-methyl-3-hydroxypyridine-4,5-dicarboxylic acid 
decarboxylase, mlr6788 - 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, 
mlr6787 - 2-(N-acetamidomethylene) succinic acid hydrolase. 
(b) The vitamin B6 catabolic pathways. The pathway A is observed in Pseudomonas sp. MA-
1 while the pathway B is observed in Pseudomonas IA and in Arthrobacter Cr-7. A minor 
variation of pathway A is seen in Mesorhizobium loti MAFF303099. (19) pyridoxine; (20) 
pyridoxal; (21) 4-pyridoxolactone; (22) 4-pyridoxic acid; (23) 5-formyl-3-hydroxy-2-
methylpyridine-4-carboxylate; (24) 3-hydroxy-2-methylpyridine-4,5-dicarboxylate; (25) 3-
hydroxy-2-methylpyridine-5-carboxylate; (26) 2-(acetamidomethylene) succinate; (27) 
succinic semialdehyde; (28) isopyridoxal; (29) 5-pyridoxolactone; (30) 3-hydroxy-4-
hydroxymethyl-2-methylpyridine-5-carboxylate; (31) 2-(acetamidomethylene)-3-
(hydroxymethyl) succinate; (32) 2-(hydroxymethyl)-4-oxobutanoate; (33) pyridoxamine; 
(34) pyridoxamine-5-phosphate; (35) pyridoxal-5-phosphate.  
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Figure 1.3 (continued) 
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form the aldehyde (23) (28, 29), which then undergoes a two electron oxidation by the 
NAD dependent 5-formyl-3-hydroxy-2-methylpyridine-4-carboxylic acid dehydrogenase 
to form the diacid (24) (28, 30). The diacid (24) undergoes a decarboxylation  at C4 by a 
Mn2+ dependent 2-methyl-3-hydroxypyridine-4,5-dicarboxylic acid decarboxylase to form 
(25) (31), which undergoes a unique ring opening oxygenation reaction catalyzed by the 
FAD dependent 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, MHPCO, to 
produce the first acyclic compound (26) of the pathway, (32-34).  (26) is hydrolyzed to 
form succinic semialdehyde (27) , acetate, ammonia and carbon dioxide by 2-(N-
acetamidomethylene) succinic acid hydrolase (35, 36). 
In pathway B figure 1.3, observed in Pseudomonas IA and Arthrobacter Cr-7, 
pyridoxine (19) is oxidized to the aldehyde at C5 (28) by an FAD-dependent pyridoxine-
5-dehydrogenase (25, 37), which further undergoes oxidation by the NAD dependent 
isopyridoxal dehydrogenase to produce the lactone (29) (30), which then undergoes 
hydrolysis catalyzed by 5-pyridoxolactonase to produce 5–pyridoxic acid (30) (27). FAD 
dependent 5-pyridoxic acid oxygenase then catalyzes the ring opening reaction of (30) to 
form (31) (38, 39), which is hydrolyzed by 2-hydroxymethyl-(N-acetamidomethylene) 
succinc acid hydrolase to form 2-(hydroxymethyl)-4-oxobutanoate (32), acetate, ammonia 
and carbon dioxide (35, 36). 
Even though the participating catabolic enzymes were known and the various 
intermediates were characterized, the genes involved have only recently been identified. 
Yagi and coworkers identified five genes in Mesorhizobium Loti MAFF303099 involved in 
pyridoxine (19) catabolism. These genes encoded pyridoxamine pyruvate transaminase 
(mlr6806) (40), pyridoxine-4-oxidase (mlr6785) (41), 4-pyridoxolactonase (mlr6805) (42), 
pyridoxal-4-dehydrogenase (mlr6807) (43) and the 2-methyl-3-hydroxypyridine-5-
carboxylic acid oxygenase (mlr6788) (44). Efforts directed towards the identification and 
characterization of 4-pyridoxic acid dehydrogenase (mlr6793) (45), 3-hydroxy-2-
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methylpyridine-4,5-dicarboxylate decarboxylase (mlr6791) (46) and 2-(N-
acetamidomethylene) succinic acid hydrolase (mlr6787) (47) have been detailed out in 
chapter 4, 5 and 6. Chapter 7 deals with the studies directed towards elucidation of the 
mchanism for the MHPCO reaction.  
All the genes involved in the vitamin B6 degradation have been identified in 
Mesorhizobium loti MAFF303099. Apart from gene identification in Mesorhizobium loti, genes 
encoding for pyridoxal 4-dehydrogenase (48) and pyridoxine 4-oxidase (49), (50) have 
been identified and characterized in Microbacterium luteolum YK-1. The gene coding for 
pyridoxal 4-dehydrogenase has also been identified in Aureobacterium luteolum (51). The 
remaining PLP catabolic genes have not yet been identified.  
 
1.3 The rut pathway 
Apart from the well characterized reductive(52) and oxidative pathways (53) of 
degradation of uracil (36) (and thymine) a new pathway was discovered in Escherichia coli 
K12 very recently (54, 55). The b1012 operon, one of the largest cluster of genes of 
unassigned function in E.coli, is highly expressed under the control of the transcriptional 
activator nitrogen regulatory protein C (NtrC) thus suggesting in its participation in 
catabolism of a nitrogen source.  Mutants of each of the genes present in the operon did 
not grow when it was subjected to uracil (36) (or thymine) as the sole source of nitrogen 
at 25 ˚C (not at 37 ˚C). The parental strain could use them at 25 ˚C (not at 37 ˚C), thereby 
asserting the participation of these genes in the pathway. The end products of the 
pathway were characterized to be 3-hydroxy propionate (37), carbon dioxide and two  
Figure 1.4: A novel pathway of uracil (36) degradation in E.coli K12. 
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molecules of ammonia (54), figure 1.4.  
The first enzyme in the pathway is the gene product of rutA(b1012) which was 
annotated as a putative FMN dependent monooxygenase (56). This enzyme along with a 
flavin reductase was seen to convert uracil (or thymine) to another product which was 
shown to be the substrate for rutB(b1011), the next enzyme in the pathway. The 
intermediates of this pathway were not characterized and no information on the 
enzymology was known. Efforts directed towards the elucidation of the pathway 
intermediates and the enzymology required for their transformation is described in 
chapter 8. The studies towards understanding the reaction mechanism for the gene 
product of rutA is reported in chapter 9.  
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CHAPTER 2 
Mechanistic studies on Tryptophan 2,3-dioxygenase 
2.1 Introduction 
The mechanism by which tryptophan 2,3-dioxygenase (TDO) catalyzes the 
oxidative ring opening of the indole ring of tryptophan (1) to produce N-
formylkynurenine (NFK) (2) is still poorly understood. This reaction is significantly 
different form the well-studied oxidative aromatic ring opening reaction catalyzed by the 
non-heme dioxygenases. For the latter enzymes, the substrate and molecular oxygen are 
coordinated to the active site iron and this coordination is a key part of the catalytic 
mechanism (1). Such coordination is not possible for TDO because the heme has only 
one vacant coordination site, which is occupied by molecular oxygen during the reaction, 
thus preventing tryptophan (1) to be coordinated to the heme iron in TDO. 
The catalytically active form of TDO is the ferrous state of heme (2). From the 
works of Ishimura et al., (3) it has been established, based on kinetic and spectroscopic 
evidences, that tryptophan (1) first binds with the iron (II) heme containing enzyme 
inducing a conformational change which activates the heme to react with oxygen, thus 
forming an intermediary heme-tryptophan-oxygen ternary complex.  
As outlined in the figure 2.1 the heme iron catalyzes the formation of the 
tryptophan hydroperoxide (3) most likely by a single electron transfer mechanism (4). 
From this intermediate, three mechanistic routes to NFK (2) can be postulated. 
According to mechanism A (red), water can add to the endocylic imine to form (4) which 
can rearrange to give NFK (2). In mechanism B (in pink) rearrangement of the 
hydroperoxide (3) to a dioxetane intermediate (6) followed by a retro [2+2] cycloaddition 
can form NFK (2). Although there is no precedent of dioxetane formation in 
dioxygenase-catalyzed ring opening reactions of aromatic compounds, this is the 
mechanism proposed in the literature (5, 6). In mechanism C (blue) (analogous to the 
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mechanism of extradiol dioxygenases (7)), a Criegee rearrangement would give the 
cationic intermediate (7) which could then undergo a nucleophilic attack by the iron-
bound oxygen anion to give (8) which could collapse to form NFK (2).   
 
Figure 2.1: Three plausible mechanistic routes which the ternary complex (3) could 
possibly take to produce NFK (2).  
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It should be possible to differentiate between three mechanisms by running the 
reaction in presence of labeled oxygen. Mechanism A predicts that the oxygen of the 
formyl group of NFK (2) is derived from solvent and the ketone oxygen is derived from 
molecular oxygen. Mechanism B predicts that the formyl and the ketone oxygen atoms 
are both derived from molecular oxygen. Mechanism C predicts that the formyl oxygen is 
derived from molecular oxygen and that the ketone oxygen may be derived from solvent 
if the lifetime of intermediate (7) is sufficient for iron-bound oxygen to exchange with 
water. Such exchange has been observed for catechol dioxygenase when the 
corresponding intermediate was stabilized by an extra oxygen substituent on the catechol 
ring (8).  
Figure 2.2: Incorporation of labeled oxygen in kynurenine (8, 10) and formic acid (9, 11) 
as observed by Hayaishi et al (9) in 1957, when the TDO catalyzed oxidation of 
tryptophan (1), was performed in presence of labeled water and oxygen. 
 
Hayashi et al (9) reported the results of an oxygen incorporation study in 1957. 
The experiments, though providing solid data against mechanism A, if repeated today 
would be prohibitively expensive, specifically with the usage of 75 ml of H2O
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mixtures. Current techniques would significantly speed up the determination of the 18O-
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subsequent pyrolysis. Moreover 18O incorporation into NFK (2), the product of the 
reaction catalyzed by TDO, was never directly demonstrated. His experiments showed 
the incorporation of oxygen in kynurenine (8, 10) and formic acid (9, 11), the hydrolyzed 
products of NFK (2), figure 2.2. 
When the reaction was performed in presence of 18O2, 84% enrichment of oxygen 
in formate (9) and 82% enrichment in kynurenine (8) was observed, while in presence of 
18H2O, 94% enrichment was observed for formate (11) and 22% for kynurenine (10) (9). 
Though the data were mutually consistent with oxygen gas being the sole source of both 
the oxygen atoms in NFK (2), we felt that this important experiment must be repeated 
using better analytical tools with purified highly active and stable enzyme. If the reaction 
went via the Criegee intermediate (mechanism C) then the percentage of product, if any, 
with oxygen incorporation from labeled water would be in trace amounts. Detection of 
such trace amounts of labeled product would not be possible under the experimental 
conditions employed by Hayaishi et al (9). We looked into the solvent incorporation into 
NFK (2) by ESI-MS analysis. The results were confirmed by re-running the reaction 
using 18O2. Controls were run in order to determine the extent to which the carbonyl 
oxygen of NFK (2) would undergo exchange with buffer.  
Although there is no precedent of dioxetane formation in dioxygenase-catalyzed 
ring opening reactions of aromatic compounds, this is the mechanism proposed in the 
literature for TDO (5). The formation of dioxetane (14) is seen in case of firefly luciferase 
enzyme. Hydroperoxide intermediate (13) possess a high degree of nucleophilicity. The 
intermediate hydroperoxide (13) is formed next to the carbonyl group in case of 
adenylated D-luciferin (figure 2.3), which then undergoes a nucleophilic attack to form the 
dioxetane intermediate (14) (1). Decomposition of the dioxetane intermediate (14) is 
followed by light emission. 
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Figure 2.3: Mechanism of oxidation of D-luciferin by luciferase  
 
In the enzymatic reaction of tryptophan 2,3-dioxygenase (TDO), no light emission has 
been detected, which would be expected to accompany the decomposition of dioxetane 
provided that the dioxetane (6) formed underwent a retro [2+2] cycloaddition to produce 
NFK (2) in the excited state, which would releases energy in the form of light on its 
decomposition to product. Efforts were directed towards detection of light emission 
during the course of the reaction, if any, by stopped flow experiments.  
 
2.2 Experimental  
2.2.1. Protein Overexpression, Purification and Activity Assays 
2.2.1.1. Ralstonia metallidurans Tryptophan 2,3-dioxygenase: The protein was 
overexpressed and purified by the method described previously (10) with some 
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when the culture reached an A590 of 0.3. IPTG was added to a final concentration of 0.8 
mM when A590 was 0.6 and the culture was incubated for an additional 4-5 hours at 37°C. 
The cells were then harvested by centrifugation at 13,000 xg for 8 min at 4°C. The cell 
pellets were then frozen in liquid nitrogen and stored at -80°C. The purification 
procedure of TDO was same as previously described (10). The protein was buffer 
exchanged into 1 mM ammonium acetate buffer at pH 7.0. DTT, the reducing agent 
which is usually added to the desalting buffer was not added. The purified protein 
(appears as a single band on SDS-PAGE, figure 2.4(a)) was immediately lyophilized. Care 
was taken to degas the buffer and then purge it with argon to remove maximum possible 
dissolved air. The choice of ammonium acetate buffer was made as it is a volatile buffer 
and ideally suited ESI-MS.  
The activity of the green colored protein (absorbance at 405nm, figure 2.4(b)) was 
determined by detection of the formation of NFK (2) [λmax = 321nm] from L-tryptophan 
(1) by a UV-Visible spectrophotometer. The reaction mixture (500 µL) consisted of 800 
µM tryptophan (1), 200 µM ascorbic acid and 6 µM RmTDO in 100 mM ammonium 
acetate buffer at pH 7.0. UV-visible spectra in the region 200-800 nm were taken at one 
minute time intervals. The data is shown in figure 2.4(c).  
The protein was lyophilized in 1 ml aliquots and the green lyophilized protein was 
also found to be active, as shown in figure 2.4(d). The lyophilized protein was dissolved in 
appropriate volume of 100 mM ammonium acetate buffer at pH 7.0 such that the final 
concentration of the protein, determined by Bradford assay, was 150 µM. Exactly the 
same reaction condition as mentioned above was used for the activity assay for the 
lyophilized protein. The activity of the enzyme was assayed by monitoring the production 
of NFK (2) (characteristic λmax at 321 nm) over time.  
After allowing the reaction to go to completion, the enzyme was removed using 
Amicon Ultra-4 MWCO 5000 (Millipore) centrifugal membrane filter. A white powder 
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was obtained on lyophilization of the filtrate. It was characterized by 1H NMR and 
ESI-MS and was identified as NFK (2). (1H NMR ,300 MHz, CD3OD, ppm): 8.56 (d, 
1H), 8.44 (s, 1H), 8.06 (d, 1H), 7.63 (t, 1H), 7.28 (t, 1H), 4.05 (m, 1H), 3.82 (m, 1H) and 
3.63 (m, 1H). ESI-MS (positive ion mode), m/z = 237 
Figure 2.4: (a) SDS-PAGE analysis showing various stages of purification of recombinant 
RmTDO. (b) The UV-Visible spectrum of purified RmTDO showing the Soret at 405 
nm, which corresponds to the Fe(III)-bound heme (17). (c) UV-visible spectra, showing 
the formation of NFK (2) over time from tryptophan (1) by RmTDO. NFK (2) has a 
characteristic λmax at 321 nm. (d) The activity of RmTDO, before and after lyophilization, 
as observed by monitoring the absorbance at 321 nm, which corresponds to the 
formation of NFK (2). 
 
(17) 
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2.2.1.2. Ralstonia metallidurans Kynurenine formamidase: The protein was 
overexpressed and purified using the protocol described before (10). The protein was 
found to be 95% pure by SDS-PAGE analysis. A coupled assay was performed to test the 
activity of the pure protein(figure 2.5 (a)). Instead of adding NFK (2) as a substrate to 
kynurenine formamidase (KFA), tryptophan (1) was used as the substrate. The reaction 
mixture (500 µL) consisted of 30 mM tryptophan (1), 20 µM of RmTDO, 20 µM of 
ZnCl2 and 85 µM RmKFA in 100 mM Tris buffer at pH 8.0. The solution was vortexed 
and 20 µl reaction mixture was aliquoted from time to time and added to 480 µl of Tris 
buffer and an UV-vis scan was performed on the sample (figure 2.5(b)). Accumulation of 
NFK (2) was not observed under the experimental conditions, due to the much greater 
rate of reaction of KFA compared to that of TDO (10). Kynurenine (10) has a λmax at 365 
nm. On plotting the absorbance at 356 nm with time we get the rate of formation of 
kynurenine (10) from TDO by the coupled assay (figure 2.5(c)). 
A sample of 1 ml of this protein was lyophilized. The activity of the lyophilized 
protein, white powder, was determined by detection of the disappearance NFK (2) (λmax= 
321 nm) or formation of kynurenine (10) (λmax = 365 nm) by a UV-Visible 
spectrophotometer. The disappearance of the NFK (2) peak (figure 2.5 (d)) on addition of 
KFA showed that the protein was active. 
After allowing the reaction to go to completion, the enzyme was removed using 
Amicon Ultra-4 MWCO 5000 (Millipore) centrifugal membrane filter. A white powder 
was obtained on lyophilization of the filtrate. It was characterized by 1H NMR and 
ESI-MS and was identified as kynurenine. (1H NMR, 300 MHz, CD3OD, ppm): 7.75 (d, 
1H), 7.26 (t, 1H), 6.75 (d, 1H), 6.6 (t, 1H), 4.00 (m, 1H), 3.72 (m, 1H) and 3.51(m, 1H). 
ESI-MS (positive ion mode) 209 Da. 
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Figure 2.5: (a) SDS-PAGE analysis showing various stages of purification of recombinant 
RmKFA. (b) Coupled assay of RmTDO and RmKFA. The UV-Visible spectra showing 
the formation of kynurenine (10) (λmax = 365 nm) from tryptophan (1) over time. (c) 
Absorbance at 365 nm from (b) is plotted over time, showing the formation of 
kynurenine (10) from tryptophan (1) by the coupled reaction of RmTDO and RmKFA. 
(d) The activity of lyophilized KFA. The spectra above show the disappearance of the 
peak at 321 nm (corresponding to λmax NFK (2)) and appearance of peak at 365 nm 
(corresponding to λmax of kynurenine (10)) at pH 8.0 and wavelength scan at 1200 nm/sec 
was done between 400 nm-200 nm. 
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2.2.1.3. Homo sapiens Indoleamine 2,3-dioxygenase (IDO): Wild type human IDO 
cDNA was obtained from  Prof. Hiroshi Sugimoto, Japan. This plasmid contained a gene 
for ampicillin resistance and also coded for a 6x-His tag with a thrombin cleavage site. 
The plasmid was transformed into BL-21(DE-3) E. coli cells. While culturing the cells 
prior to induction 5-aminolevulinic acid hydrochloride (final concentration of 20 mg/L), 
which is a heme precursor, was added when the culture reached an A590 of 0.3. IPTG was 
added to a final concentration of 0.5 mM when A590 was 0.6 and the culture was 
incubated at 37°C for 12 hours (11). The cells were then harvested by centrifugation at 
13000 xg for 10 min at 4°C. The cell pellets were frozen in liquid nitrogen and stored at -
80°C. The purification procedure described for TDO was used for IDO, with one 
modification. Instead of washing with 100 mL wash buffer 200 ml of it was used to get a 
more pure protein preparation. SDS-PAGE of HuIDO showed the presence of 95% 
pure protein, figure 2.6(a). The protein purified out with the iron bound to the heme in its 
active +II oxidation state (18) (12) as evident from the UV-visible spectrum is shown in 
figure 2.6(c).  
The assay conditions for IDO were different from those of TDO. The assay 
mixture (500 µl total volume) consisted of 400 µM tryptophan (1), 20 mM ascorbic acid, 
0.2 mg/ml catalase, 10 µM methylene blue and10.5 µM HuIDO. All solutions were made 
in 50 mM phosphate buffer at pH 6.5. The pH of the ascorbic acid stock solution (200 
mM) was found to be 3.0 and was subsequently adjusted to 7.0 with 2M NaOH. Care was 
taken not to exceed pH 7.0. The stock solution of catalase (4 mg/ml, 2800 units/ mg of 
solid) from Bovine liver was made fresh in 50 mM phosphate buffer at pH 6.5. The activity 
was measured by monitoring the absorbance at 321 nm, characteristic for the production 
of NFK (2). Both the freshly purified protein as well as a lyophilized sample showed the 
same activity, figure 2.6 (b). 
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Figure 2.6: (a) SDS-PAGE analysis showing various stages of purification of recombinant 
HuIDO. (b) The activity of HuIDO, before and after lyophilization, as observed by 
monitoring the absorbance at 321 nm, which corresponds to the formation of NFK (2). 
(c) UV-Visible spectrum of HuIDO. It purified out as the active Fe(II) form (18), as 
evidenced from the Soret at 425 nm. On keeping it exposed to oxygen it slowly converts 
to the oxidized Fe(III) state (17) (inset).  
(17) 
(18) 
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2.2.2. Synthesis  
6-hydroxytryptophan (23) was prepared following literature procedure (13) with some 
modifications figure 2.7.  
Figure 2.7: The synthetic scheme for the preparation of 6-hydroxytryptophan (23) from 
6-methoxygramine (19). 
 
2.2.2.1 Ethyl-β-(6-methoxyindolyl-3)-α-carbethoxy-α-formamidopropionate (21). A 
mixture of 1.09 g (5.3 mmol) 6-methoxygramine (19), 1.36 g (6.7 mmol) 
diethylformamidomalonate (20) and 120 mg (2.9 mmol) powdered NaOH and 70 ml 
toluene was heated under reflux for 22 h, while a vigorous stream of argon was bubbled 
through. After running the reaction for 22 hours the hot suspension was filtered and 
extracted with water. On shaking with water three layers were seen, the top being the 
toluene layer, the bottom being the water and the middle which looked like an emulsion 
was white in color. The aqueous layer was separated and then the organic layer was 
extracted with 1 M HCl, 2 M NaOH and water respectively. The middle layer which 
looked like an emulsion remained after each extraction. The toluene layer was filtered in 
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filter paper. On filtering a white residue was obtained and clear toluene was the filtrate. 
On evaporating the toluene yellow grease was left behind, which, in accordance with the 
literature was not the product. TLC of the white solid that had crashed out during 
extraction was different from that of the substrate spot. NMR spectra of this compound 
revealed it to be the desired product. 1H NMR (300 MHz, CD3OD) δ 8.05 (s, 1H), 7.27 
(d, J = 8.7, 1H), 6.87 (s, 1H), 6.84 (d, J = 2.2, 1H), 6.66 (dd, J = 8.7, 2.3, 1H), 4.24 – 4.13 
(m, 4H), 3.79 (s, 4H), 3.31 (dt, J = 3.2, 1.6, 3H), 1.24 (d, J = 7.1, 6H). 
 
2.2.2.2 6-methoxytryptophan (22). A mixture of 663 mg (17 mmol) NaOH, 500 mg 
(1.4 mmol) of the methoxyformamidoester (21) and 15 ml water was refluxed for 3 h. 
After neutralization with 2 M HCl, the aminomalonic acid precipitated. After further 
addition of 700 µl (1.4 mmol) 2 M HCl refluxing was continued for 30 min and the solid 
went completely into solution with the evolution of CO2. The hot solution was filtered 
and the pH of the yellow filtrate was adjusted to 6.8 (isoelectric point of tryptophan (1)) 
with 1 M ammonia. On evaporating water the amino acid precipitated. The off white 
solid was collected, washed with cold ethanol and dried under high vacuum overnight. 
The entire dried sample was not soluble either in water or methanol. The NMR solution 
was centrifuged before loading into the tube. NMR spectra in D2O (both 
1H as well as 13C 
NMR) showed that all the peaks corresponded to 6-methoxytryptophan (22) as reported 
in literature. 1H NMR (300 MHz, D2O) δ 7.60 (d, J = 8.7, 1H), 7.20 (s, 1H), 7.10 (d, J = 
2.2, 1H), 6.87 (dd, J = 8.7, 2.3, 1H), 4.03 (dd, J = 8.0, 4.8, 1H), 3.88 (s, 3H), 3.44 (dd, J = 
15.1, 4.6, 1H), 3.26 (dd, J = 15.4, 8.1, 1H). 
 
2.2.2.3. 6-hydroxytryptophan (23). The reaction was carried out in a 5 ml screw cap 
glass vial, which was taped with a black tape on the outside, under argon. 100 mg (427 
µmol) of 6-methoxytryptophan (22) were suspended in 2 ml sulfolane. Then 72 µl (512 
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µmol) triethylamine and 700 µl (5.2 mmol) trimethylsilyliodide were added and the red 
solution was stirred and heated for 2 h at 50°C. Determining the extent of reaction by 
TLC was difficult as sulfolane caused the silica plate to streak. The intermediate 
trimethylsilylethers formed during the reaction were cleaved and excess 
trimethylsilyliodide was decomposed by addition of 2 ml methanol. After quenching the 
reaction with methanol the pH of the organic solution could not be determined by the 
pH meter, since the volume was very low. pH paper could not be used as the solvent was 
organic. So 2 drops of 1M ammonium hydroxide was added to the solution and loaded 
onto the column (10×50 mm), filled with cation-exchange resin Dowex-50W (H+ form). 
The column was washed first with 6 ml methanol-water (1:1, v/v), then with 10 ml water 
and eluted with 0.5 M ammonia at a flow-rate of 0.5 ml/min. 2ml fractions were collected 
using a fraction collector and all the fractions were tested for UV activity. Those fractions 
which were UV active were spotted on a TLC plate along with 6-methoxytryptophan (22) 
as a control. All of them showed a new spot and migrated with the same Rf.  On 
collecting the UV active fractions and putting it on high vacuum overnight, a grey colored 
solid (30 mg) was left behind. NMR of this gray solid showed no H1 NMR peak 
corresponding to the methoxy. This preparation resulted in 90-95% pure product. 
Following the literature procedure (13) this sample was passed through Dowex-1 anion 
exchange column to further purify the 6-hydroxytryptophan (23). The resins were washed 
with 1 M acetic acid (20 times the column volume) before loading on to the column 
(10×50 mm). The compound was eluted with 1 M acetic acid at a flow-rate of 0.5 ml/min 
and 2 ml fractions were collected using a fraction collector. The fractions which were UV 
active were accumulated and were subjected to a high vacuum overnight. A grey film was 
left behind [~15 mg]. NMR of the sample after anion exchange revealed it to be 
6-hydroxytryprophan (23). NMR (300 MHz, D2O) δ 7.50 (d, J = 8.7, 1H), 7.14 (s, 1H), 
6.93 (d, J = 2.0, 1H), 6.74 (dd, J = 8.6, 2.2, 1H), 4.23 (dd, J = 7.4, 5.2, 1H), 3.42 (dd, J = 
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15.3, 5.2, 1H), 3.31 (dd, J = 15.4, 7.4, 1H). Both 6-methoxytryptophan (22) as well as 
6-hydroxytryptophan (23) was a racemic mixture of D and L isomers.  
 
2.3. Results 
2.3.1. Reaction of RmTDO with tryptophan (1) in H2O
18. A solution of L-tryptophan 
(1) (2 mg/ml) in 1 mM ammonium acetate buffer at pH 7.0 was prepared and 1 ml of the 
solution was lyophilized. The lyophilized sample was dissolved in 1 g of H2O
18. 10 mg of 
lyophilized TDO was added to the resulting solution and the reaction mixture was briefly 
vortexed. All of enzyme did not dissolve. 150 µl of the reaction mixture was removed at 
20 minutes and filtered through a Microcon YM-10(MWCO 10 kDa) cellulose filter by 
centrifugation for 20 minutes. The filtrate was then mixed with equal volume of 
anhydrous methyl alcohol (such that the solvent system for ESI-MS was 1:1 methanol: 
water) and frozen immediately by immersion in an acetone-dry ice mixture. ESI-MS of 
the samples showed the presence of a peak at m/z = 237 which corresponded with the 
calculated mass of NFK (2) (figure 2.8).  
MS^MS of this peak indicated the presence of de-aminated compound (27) at 
m/z = 220 and another fragmentation peak (26) at m/z = 202 nm, probably produced by 
rearrangement with loss of water (figure 2.9).  When the reaction was carried out in H2O
18 
only the peak (m/z = 237) corresponding to NFK (2) with no 18O was observed, 
suggesting that no oxygen incorporation in NFK (2) from H2O
18 water occurred, as no 
peak at m/z = 239 (single 18O incorporation (25)) was seen. 
To eliminate the possibility of oxygen exchange from the solvent, pure NFK (2) 
(synthesized enzymatically and purified by HPLC) was incubated for 100 minutes (more 
than twice the reaction time) in H2O
18. No 16O/18O exchange was observed (figure 2.10).
 32 
 
Figure 2.8: The scheme on the top shows the expected incorporation pattern of 18O from 
labeled water via mechanism A and C. Bottom left: Positive mode ESI-MS analysis of the 
reaction mixture after 20 minutes. Bottom right: Fragmentation pattern of species at m/z 
= 237 is shown in the spectrum on the right.  
 
Figure 2.9: A plausible mechanism for the fragmentation of the species with m/z = 220 
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Figure 2.10: Exchange of the ketonic oxygen from NFK (2) over time. The mass spectra 
on the right show that no exchange occurs after 80 minutes of incubation of NFK (2) in 
H2O
18 water. However, exchange is seen after overnight incubation (MS analysis on the 
right).  
 
Only one oxygen exchange was observed on overnight incubation of pure NFK (2) in 18O 
water as indicated by the presence of a peak at m/z = 239 (24). This is probably the 
ketonic oxygen as it is more labile than the amide oxygen. Further experiments were 
performed to confirm this and the results are discussed later on. Thus oxygen atoms in 
NFK (2) do not come from water during the course of the enzymatic reaction. 
 
2.3.2. Reaction of RmTDO with tryptophan (1) in 18O2 gas. 1.5 ml of 1 mM 
ammonium acetate buffer at pH 7.0 was degassed by alternately stirring it under vacuum 
and purging it with argon for 2 hours. 18O2 gas was then passed through the buffer for 20 
minutes. The resulting 18O2 gas containing buffer was transferred to a sealed 10 ml pear 
shaped flask, pre-purged with argon, containing 6 mg of tryptophan (1) and 7.2 mg of 
lyophilized TDO. The reaction mixture was vortexed briefly to dissolve the tryptophan 
(1) and stirred at room temperature. After 20 minutes, 100 µl aliquot was taken and 
(24) (1) 
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frozen in acetone-dry ice mixture. Before taking ESI-MS of the sample it was diluted 4 
times (as the enzyme was not filtered off, to save time) and mixed with equal volume of 
anhydrous methyl alcohol. ESI-MS of the sample (figure 2.11) showed the presence of a 
peak at m/z = 241 (31) along with a peak at m/z = 237 (2). MS^MS of the species with 
peak at m/z = 241 (31) produced fragments at m/z = 194 (32), 204 (33) and 224 (34). 
The species at m/z = 224 (34) fragment probably corresponds to the de-amination of the 
molecule with the peak of m/z = 241 (31), the species with m/z peak of 204 (33) could 
be due to a rearrangement with loss of water (figure 2.10).   
Figure 2.11: The scheme on the top shows the expected incorporation pattern of labeled 
oxygen gas mechanism B and C. Bottom left: Positive mode ESI-MS analysis of the 
reaction mixture after 20 minutes. Bottom right: Fragmentation analysis of the species at 
m/z = 241 is shown in the spectrum on the right. 
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The presence of a peak at m/z = 241 (31) on carrying out the reaction in presence 
of 18O2 gas provides strong evidence that both the oxygen atoms in NFK (2) come from 
oxygen gas dissolved in water, thus it safely rules out the mechanistic route A for the 
formation of NFK (2) from tryptophan (1). There is however a peak at m/z =237 (2) the 
presence of which can be attributed to incomplete removal of 16O2 from the buffer prior 
to the reaction and/or because of diffusion of 16O2 from air.   
On letting the reaction run in presence of 18O2 for 4 hours and then carrying out 
an ESI-MS, a peak at m/z = 239 (25) was observed (figure 2.12(a, b)) along with peaks at 
m/z = 237 (2) and 241 (31). The peak at m/z = 239 (25), could be due to a single 18O 
incorporation into the unlabelled NFK (2) produced as a result 18O/16O exchange of 
either the ketone or the formyl oxygen with H2O
16. The species at m/z = 239 could be 
either (24) (if the formyl oxygen exchanges) or (25) (if the ketone oxygen exchanges) and 
they would react with KFA to give different products (figure 2.12(c)). The species (24) 
would produce labeled kynurenine (m/z = 211) (8) and (25) would produce unlabelled 
kynurenine (m/z = 209) (10).  
On the other hand the peak at m/z = 241 (31), which is due to two 18O 
incorporation in the NFK (2), will generate an 18O labeled kynurenine (m/z = 211) (8) on 
treatment with KFA. So if the m/z = 239 species is (24) then the prediction would be 
that we get only m/z = 211 (8), otherwise we will get both m/z = 209 (10) as well as 211 
(8). On treatment of the 4 hour reaction mixture with KFA, carried out under 18O2 gas 
saturated buffer condition, ESI-MS showed the presence of peaks at m/z = 209 (10) as 
well as 211 (8) (figure 2.13) which could only be derived from (25) as (24) would give rise 
to the only peak at m/z = 211 (8) and no peak at m/z = 209 (10). MS^MS of the species 
with peaks at m/z = 209 (10) and 211 (8) showed the presence of de-amidated peaks at 
m/z = 192 (36) and 194 (37) respectively. The evidence of (25), being the species 
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contributing to m/z = 239 is a proof in itself that the ketonic oxygen is the labile one and 
not the amide one. 
Figure 2.12: (a) ESI-MS analysis of the reaction mixture (tryptophan (1) and RmTDO in 
18O2 saturated buffer) after 4 hours. (b) Fragmentation analysis the species at m/z = 239 
(25) (c) Various outcome of the species with m/z = 239 (25) & 241 (31) on treatment 
with KFA is shown. The scheme at the bottom shows the product that would be formed 
upon reaction of the species at m/z = 241 (31) with KFA. 
 
2.3.3. Reaction of RmTDO with 6-methoxytryptophan (22) and 
6-hydroxytryptophan (23). Both 6-methoxytryptophan (22) as well as 
6-hydroxytryptophan (23) was tested as potential substrates for RmTDO. UV-visible scan 
was performed over time on an enzymatic reaction mixture (500 µL) containing 2 mM 
6-methoxytryptophan (22), 18 µM RmTDO and 500 µM L-ascorbic acid in 100 mM  
(31) (25) (35) 
(10) (25) (8) (24) 
(8) (31) 
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Figure 2.13: Top left: ESI-MS analysis of the two hour reaction of tryptophan (1) with 
RmTDO in 18O2 saturated buffer. Top right: ESI-MS analysis of the reaction mixture 
after addition of KFA to the reaction mixture at the left. Bottom: Fragmentation analysis 
of the species with peaks at m/z = 211 (8) and m/z = 209 (10).  
Figure 2.14: UV-Visible analysis of the RmTDO catalyzed oxygenation of 6-
methoxytryptophan (22) (left) and 6-hydroxytryprophan (23) (right) over time.   
 
(24) 
(31) 
(36) 
(10) 
(8) 
(37) 
(23) 
(22) 
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phosphate buffer at pH 7.0. An exactly identical assay was set up with 
6-hydroxytryptophan (23). The UV-visible spectrum of the reaction mixture, in both 
cases, in the region 250-700 nm did not change over the course of the reaction (figure 
2.14) thereby showing no turnover. Neither 6-methoxytryptophan (22) nor 
6-hydroxytryptophan (23) was a substrate for RmTDO. Both of them were assayed as 
potential inhibitors, but neither of them inhibited the rate of formation of NFK (2) over 
time to an appreciable extent.  
Figure 2.15: UV-Visible analysis of the reaction mixture containing (a) 
6-methoxytryptophan (22) and HuIDO and (b) 6-hydroxytryptophan (23) over time. 
Assay of HuIDO with 6-hydroxytryptophan (23) as a substrate. (c) The formation of 
6-hydroxy-NFK (39) was observed by monitoring the absorbance at 321 nm. (d) 
Formation of 6-hydroxykynurenine (40) over time upon addition of KFA to the previous 
reaction mixture. 
(22) 
(38) 
(23) 
(39) 
(39) 
(23) 
(39) (40) 
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2.3.4. Reaction of HuIDO with 6-methoxytryptophan (22). The reaction mixture 
(500 µl total volume) consisted of 400 µM 6-methoxytryptophan (22), 20 mM neutralized 
ascorbic acid solution, 0.2 mg/ml catalase solution, 10 µM methylene blue and 10.5 µM 
HuIDO in50 mM phosphate buffer at pH 6.5. The UV-visible spectrum between 200 and 
700 nm for the reaction mixture at various time points was monitored. It was observed 
that there was an increase in absorbance at 321 nm, the characteristic absorbance maxima 
of NFK (2), figure 2.15(a).  
A decrease in absorbance at the absorbance maximum of methylene blue (675 
nm) was observed, which was not investigated further. It has been reported by Sono (14) 
that methylene blue acts an electron mediator from ascorbic acid to the iron bound to the 
heme, thereby reducing any Fe(III) back to the active Fe(II) form.  
 
2.3.5. Reaction of HuIDO with 6-hydroxytryptophan (23). The reaction mixture 
(500 µl total volume) consisted of 400 µM 6-hydroxytryptophan (23), 20 mM neutralized 
ascorbic acid solution, 0.2 mg/ml catalase solution, 10 µM methylene blue and 10.5 µM 
HuIDO in50 mM phosphate buffer at pH 6.5.  UV-visible spectrum between 200 and 
700 nm for the reaction mixture at various time points was monitored. It was observed 
that there was an increase in absorbance at 321 nm, the characteristic absorbance 
maximum for NFK (2), figure 2.15 (b). The formation of 6-hydroxy-NFK (39) was 
quantified by the time dependent increase in absorbance at 321 nm wavelength (figure 
2.15(c)). 
An indirect proof for the production of 6-hydroxy-NFK (39) was obtained from 
the following experiment. 50 µl of KFA (unknown concentration), was added to the 
above reaction mixture (6-hydroxytryptophan (23) with HuIDO), and the absorbance at 
365 nm, characteristic of kynurenine (10), was monitored. This absorbance was found to 
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increase after addition of KFA, suggesting that KFA catalyzed the formation of 
6-hydroxykynurenine (40) from 6-hydroxy-NFK (39) (figure 2.15(d)).  
A 1 ml sample of HuIDO was lyophilized. The green lyophilized powder was 
dissolved in 500 µl of 50 mM phosphate buffer at pH 6.5. Bradford assay indicated the 
protein solution to be 219 µM in strength. This protein sample was assayed for activity by 
monitoring the production of 6-hydroxy-NFK (39) over time at 321 nm wavelength. The 
assay mixture (500 µl total volume) consisted of 400 µM 6-methoxytryptophan (23), 20 
mM neutralized ascorbic acid solution, 0.2 mg/ml catalase solution, 10 µM methylene 
blue and 10.5 µM HuIDO in50 mM phosphate buffer at pH 6.5. It was found that the 
protein was as active as before. 
 
2.3.6. Reaction of HuIDO with 6-hydroxytryptophan (23) in H2O
18 100 µl of 10 mM 
6-hydroxytryptophan (23), 100 µl of 200 mM ascorbic acid neutralized with 2 M 
ammonium hydroxide, 50 µl of 4 mg/ml catalase solution and 2 µl of 5 mM methylene 
blue were mixed together and lyophilized. 1 ml of 62.98 µM HuIDO was also lyophilized 
separately. All solutions were made in 20 mM ammonium acetate buffer at pH 7.0. 1 g of 
H2O
18 was added to the green colored lyophilized protein and the protein solution was 
added to the lyophilized reaction mixture. The reaction mixture was briefly vortexed and 
after three minutes 400 µl of it was filtered through YM-10(MWCO 10kDa) centrifugal 
filter for 15 minutes at 30,000 xg. 100 µl of the filtrate was mixed with 100 µl of 95% 
methanol and the sample was sprayed in the mass spectrometer. Had there been any 
incorporation of 18O from solvent then we would have expected a peak at m/z = 255 due 
to the incorporation of a single 18O atom. The mass spectrum for the reaction is shown in 
figure 2.16 (a). 
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Figure 2.16 (a) ESI-MS analysis of the reaction mixture containing HuIDO and 
6-hydroxytryptophan (23) in H2O
18 water. (b) Fragmentation analysis of the species with 
peaks at m/z = 253 (36). 
 
There was no peak at m/z = 255, indicating that there was no incorporation of 
18O from the solvent. Fragmentation of the species at m/z = 253 matched with the 
expected fragmentation pattern for 6-hydroxy-NFK (39), there is a de-aminated peak at 
m/z = 236 (43), a peak at m/z = 218 (42) which could be explained by a rearrangement 
with a loss of water and a peak at m/z = 208 (41) which can be explained by loss of 
carbon monoxide, thereby proving the validity of the reaction, figure 2.16 (b). It was not 
possible to isolate and fragment the species appearing at m/z = 255.  
 
2.3.7 Reaction of TDO with tryptophan (1) – light emission experiment. TDO was 
purified previously and lyophilized. Green lyophilized TDO powder was added to 500 µl 
of 50 mM phosphate buffer at pH 7.0 till a saturated enzyme solution was produced. The 
resulting solution was allowed to sit on ice for half an hour. A small amount of protein 
precipitated. The solution was centrifuged for 10 minutes at 30,000 xg. The supernatant 
was taken and the amount of dissolved enzyme was calculated by the Bradford assay (15). 
The enzyme solution was found to be 943 µM in strength. Maximum concentration of 
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intermediate is build up at single turnover concentrations. Two kinds of substrate 
solutions were prepared: Solution (a) :1 ml solution containing 900 µM tryptophan (1) 
and 225 µM ascorbic acid (prepared by adding 45 µl of 20 mM tryptophan (1) and 11.3 µl 
of 20 mM ascorbic acid to 944 µl of 50 mM phosphate buffer at pH 7.0) and Solution 
(b): 1 ml solution containing 900 µM tryptophan (1), 20 mM ascorbic acid, 0.2 mg/ml of 
catalase and 10 µM of methylene blue (prepared by adding 45 µl of 20 mM tryptophan 
(1), 100 µl of 200 mM ascorbic acid that was netralized by NaOH prior to addition, 50 µl 
of catalase (2800 units/mg of solid from Bovine liver) of strength 4 mg/ml, 2 µl of 5 mM 
methylene blue to 803 µl of 50 mM phosphate buffer at pH 7.0). 
Solution (a) is the solution that has been used for TDO assays through out and 
solution (b) was used for the assay of IDO. Both these substrate solution was used for 
the reaction to see any light emission during the course of the reaction. 
In the stopped flow instrument [KinTek cooperation, Model SF-2004.5], 500 µl 
of the substrate solution was loaded in one of the syringe and 500 µl of the enzyme 
solution was loaded into the other. Care was taken to remove any air bubble from the 
syringe. Filters were removed from the photomultiplier tube, such that light emitted at 
any wavelength would get detected and the photomultiplier tube voltage setting was kept 
at its maximum, 1000V, so that the instrument gives maximum sensitivity for any light 
emission.  
The enzyme and the substrate was mixed in the reaction chamber and the 
emission of light during the course of the reaction, if any, as a result of the decay of the 
dioxetane intermediate, was monitored over a time of 2 seconds, for reaction of solution 
(a), (b) as well as buffer (as a control) with the enzyme, figure 2.17(a). 
 
2.3.8. Reaction of luciferase with luciferrin – light emission experiment. An assay 
for detection of ATP using luciferase is reported in literature (16). Luciferase from 
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Photinus pyralis (firefly) was obtained as a lyophilized powder from Sigma. The activity of 
the protein was reported to be 18500000 light units/mg of protein by the manufacturer. 
D-luciferin (12) as the sodium salt was obtained from the same vendor. 25 mM Tris at pH 
7.5 was used as the buffer for this assay instead of 25 mM glycine glycine buffer as 
mentioned in the literature. Tris was chosen as a replacement for glycine glycine buffer 
because the lyophilized sample of the protein has Tris in it. A 200 µl solution containing 
40 µl of 80% glycerol, 2 µl of 200 mM Tris(2-carboxyethyl)phosphine hydrochloride 
(TCEP) and 158  µl of 25 mM Tris buffer at pH 7.5 (to a final concentration of 20% and 
20 mM respectively) was used to dissolving 1 mg of the protein in order to make a stock 
solution of 5 mg/ml. TCEP was added because luciferase is a sulfhydryl containing 
enzyme and requires two sulfhydryl group for catalytic activity. 5 mg of luciferin (12), was 
dissolved in 500 µl of 25 mM Tris buffer at pH 7.5; the final concentration of the stock 
solution being 33 mM. A 100 mM solution of ATP and MgSO4 was made using the same 
buffer. 
Figure 2.17: (a) Reaction of TDO with tryptophan (1). (b) Reaction of luciferase with D-
luciferin (12).  Light emission was monitored with the PMT voltage setting at the 
maximum in the stopped flow apparatus. 
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1 ml of the substrate solution was prepared by mixing 3.03 µl of 33 mM luciferin 
(12), 1 µl of 100 mM ATP, 10 µl of 100 mM MgSO4 and 986.7 µl of 25 mM Tris buffer 
at pH 7.5, such that the final concentration of luciferin (12), ATP and MgSO4 was 
100 µM, 100 µM and 1 mM respectively. The 5 mg/ml stock solution of the protein was 
diluted to 500 µL of 0.1 mg/ml of protein by dissolving 10 µL of protein stock solution 
in 490 µL of buffer. This solution was further diluted 10 times to yield a protein solution 
of 0.01 mg/ml strength. The protein solution and the substrate solution were loaded into 
two syringes of the stopped flow instrument. Care was taken to remove any air bubble 
from the syringe. Filters were removed from the photomultiplier tube, such that light 
emitted at any wavelength would get detected, even though the emission is known to 
occur at 615 nm, (16) in order to keep the settings consistent with that of the TDO 
experiment. The emission of light over 10 seconds due to the reaction was monitored 
with the photomultiplier tube voltage setting at 500 V and 600 V for 0.1 mg/ml and 0.01 
mg/ml of protein solution respectively. The result is shown in figure 2.17(b). 
 
2.4. Discussion 
2.4.1. 18O labeling studies. The results obtained from the 18O labeling studies done on 
RmTDO showed that the 18O2 experiment and the H2O
18 experiments are mutually 
consistent with one another and both the oxygen atoms incorporated into NFK (2) by 
RmTDO come from atmospheric oxygen. This agrees with the results of Hayaishi (9). 
Our experiment improves on that method, in that a significantly smaller quantity of 
H2O
18 was used and the time-consuming crystallization was avoided. This experiment also 
showed the presence of labeled oxygen in NFK (2) as well in kynurenine (10).  
It does not however distinguish between the mechanistic routes B and C (figure 
2.1). It cannot be excluded that the rate of exchange of the oxygen bound to Fe (as 
shown in mechanism C) with solvent, might be slower than the recombination reaction, 
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resulting in the presence of both the labeled oxygen atoms in NFK (2). There has been 
no evidence for dioxetane (mechanism B) playing a role in any of the characterized 
dioxygenase catalyzed ring opening reactions of aromatic compounds. The retro [2+2] 
cycloaddition could occur by emission of light as seen in the case of the enzyme 
luciferase, in firefly. No such evidence is reported in case of mechanism B. Sono in his 
review (4) points out that the high endothermicity of the formation of dioxetane and the 
high exothermicity of its decomposition makes this pathway the less likely one.  
If the reaction proceeds via mechanism C then, if by chemical means we could 
slow down the rate of recombination then it might be possible to observe exchange of 
the ketonic oxygen with the solvent enzymatically. This could be done by stabilizing the 
intermediate carbocation (7) formed. Such an effect would be expected to be maximal for 
tryptophan (1) derivatives possessing an electron donating group at the C-4 and/or C-6 
positions. Indoleamine 2,3-dioxygenase (IDO) catalyzes the same step in the degradation 
of tryptophan (1). TDO is localized in the liver, while IDO is ubiquitously present in the 
body. From the studies on tryptophan (1) analogues done in IDO it was seen that the 
enzyme was more tolerable to substituents at the C-6 position. It was thus decided to 
synthesize 6-methoxytryptophan (22) and 6-hydroxytryptophan (23) (instead of the 
analogues with substitution at the C-4 position) and use them as substrate, with the hope 
that they would be taken up by the enzyme, RmTDO, and methoxy or the hydroxyl 
group being electron donors would stabilize the intermediate carbocation such that the 
rate of the recombination would be slow enough to allow the exchange of the oxygen 
bound to iron with the solvent. 
Neither 6-methoxytryptophan (22) nor 6-hydroxytryptophan (23), that was 
synthesized were substrates for RmTDO.  
IDO accepts a wide variety of substrates like D-tryptophan, tryptamine, 
serotonin, as well as 5-hydroxytryptophan, 5-methoxytryptophan, 5-methyltryptophan, 
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6-methyltryptophan etc (4). The catalytic mechanism of both IDO and TDO are believed 
to be similar, proceeding via the hydroperoxide intermediate followed by either a 
dioxetane intermediate or undergo a Criegee rearrangement (1), neither of which have 
been established. Thus, IDO offered a more flexible system for mechanistic studies than 
is available with RmTDO. 
Both 6-methoxytryptophan (22) as well as 6-hydroxytryptophan (23) was found to 
be substrate for HuIDO. Hydroxy group, being a better electron donating group than the 
methoxy group was thought to be a better stabilizer of the intermediate carbocation (7), 
in case the reaction went via the Criegge mechanism. Moreover, it is less bulky than 
methoxy group and thus could be a better substrate for the enzyme. So, 
6-hydroxytryptophan (23) was used as a substrate for the reaction of the HuIDO in 
H2O
18. 
As evident from the results, no incorporation of 18O from solvent into 
6-hydroxy-NFK (39) was seen. We would have been able to see the incorporation of 18O 
from solvent, provided that: 
a) Criegge rearrangement was the catalytic route the enzyme took for the production of 
6-hydroxy-NFK (39), via the carbocation intermediate. 
b) The stabilization of a carbocation intermediate in the presence of the electron 
donating hydroxyl group decreases the rate of the recombination reaction sufficiently 
to allow the exchange of the oxygen bound to the heme with the solvent. This would 
lead to the incorporation the 18O from the solvent into the product. 
Based on the results of this experiment, it was not possible to differentiate 
between mechanism B and C using oxygen labeling. Even though there was no 18O 
incorporation in 6-hydroxy-NFK (39), we still could not rule out the mechanistic route C. 
The assumption (b) might not have been a very valid one. Even if the intermediate 
carbocation were stabilized by a hydroxyl group at position C-6 of tryptophan (1), the 
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stabilization might not be sufficient to slow the rate of recombination, thereby allowing 
the exchange of the oxygen bound to the heme with H2O
18. Moreover at neutral pH, the 
exchange of the oxygen bound to the heme with water will be very slow. Likelihood of 
the exchange could be enhanced at a lower pH. However the labiality of the ketonic 
oxygen in NFK (2) would also increase under these conditions, and this would pose a 
problem in accurate determination of whether the oxygen incorporated in the ketonic 
position of NFK (2) is due to exchange of the oxygen bound to heme or due to non-
enzymatic exchange of the labile oxygen with the solvent. If the two rates mentioned 
above are sufficiently different and if the reaction indeed went via the Criegee 
intermediate (mechanism C) then we would be able to observe 18O incorporation in 
6-hydroxy-NFK (39). 
 
2.4.2. Light emission studies. For the reaction of tryptophan (1) with TDO the final 
concentration of both enzyme and substrate was 450 µl in the reaction chamber. As seen 
in figure 2.17, no light emission occurs during the course of the reaction. If there were any 
detectable light emission we would have expected it to be above the noise level (buffer in 
this case).  
 Arguments can easily be made against the efficiency of the instrument and 
blaming it for not being able to detect low quanta of light emission. No information 
stating the lower limit of the photomultiplier tube was available from the manual of the 
instrument. Since firefly-luciferase enzyme is known to emit light, an assay for light 
emission by luciferase was performed in this instrument to test the latter’s ability for 
detection of low amounts of photon.  
For the reaction of luciferin (12) with luciferase, there was a rapid flash of light 
followed by slow decay over a long period of time. This proves beyond doubt that light 
emitted can be detected by the photomultiplier tube in the stopped flow. A difficulty with 
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using very low concentration of protein is that the enzyme gets deactivated on standing. 
A very low dilution of 0.1 ng/ml of protein solution was made and immediately used for 
the experiment. The photomultiplier tube setting was at its maximum, 1000V. The result 
of light emission from 0.1 ng/ml of enzyme concentration is superposed in the same 
graph obtained for TDO (figure 2.18).  
 
Figure 2.18: The reaction of TDO is compared with 0.1 ng/ ml of luciferase. Light 
emission was monitored with the PMT voltage setting at the maximum in the stopped 
flow apparatus. 
 
The flow cell volume is 10 µl. Equal volumes of substrate and enzyme enter the 
reaction cuvette. Thus, the enzyme concentration [0.1 ng/ml] is further diluted to 0.05 
ng/ml. 10 µl of the reaction mixture contains 5 × 10-13 g of protein i.e. 4.17 × 10-18 mol 
[MW: 120 kDa], which corresponds to 2.5 × 106 molecules of protein. Light emission 
could thus be detected from such a low number of protein molecules. In contrast to the 
luciferase concentration the amount of TDO used was 900 µM, which corresponds to 
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2.7 × 10-15 molecules of protein. Assuming that the entire TDO preparation was active 
the concentration of TDO (determined by Bradford assay) is 109 times more than that of 
luciferase. The quantum efficiency of light emission for luciferase is reported to be very 
close to 1 (7). Under the assumption that the efficiency of detection of photon emission 
from the two enzymes are same/comparable the experimental results suggest that the 
quantum efficiency of the decay of dioxetane (6) in TDO must be less than 10-9 when it 
could be said that the detection of light was not possible due to the limitation of the 
photomultiplier tube. 
This experiment does not suggest that dioxetane (6) is not the intermediate. It 
only proves that light is not emitted, or if emitted then not detectable, during the course 
of the reaction. Dioxetane (6) could very well be formed as an intermediate and then 
decompose to NFK (2) without emission of light. The emission of light is only possible if 
the dioxetane (6) undergoes a retro [2+2] cycloaddition and produces NFK (2) in the 
excited state and which then decays to the product in the ground state with emission of 
light. Moreover the decomposition of the dioxetane (6) may not be concerted (retro [2+2] 
cycloaddition) and could very well happen in a sequential manner. Moreover, if it did 
occur in the concerted manner then it could very well be possible that the decay to the 
ground state is non-radiative.  
This experiment did not nail any mechanism but showed that the photomultiplier 
tube in the stopped flow instrument could be used for detection of very low amount of 
light. This also paved a new method for detection of bioluminescence.  
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CHAPTER 3 
Kinetic studies on mutants of Tryptophan 2,3-dioxygenase∗ 
3.1 Introduction 
The crystal structure of tryptophan 2,3-dioxygenase (TDO) from Ralstonia 
metallidurans (PDB: 2NOX) with cofactor heme bound in the active site was solved by Dr. 
Yang Zhang (Ealick group). The crystal structure contains four tetramers per asymmetric 
unit. Each active site resides at the interface of two monomers, comprised mostly by one 
monomer and the N-terminus of the other monomer figure 3.1. Based on the active site 
information from the crystal structure, modeling as well as mutagenesis studies were 
carried out to investigate the enzyme mechanism. 
Figure 3.1: Crystal structure of RmTDO. Left: The four tetramers with heme bound at 
the active site. Right: The active sites at the interface of the two monomers. 
 
3.2 Experimental 
3.2.1. Molecular Cloning. Standard methods were used for DNA manipulations (1, 2).  
Plasmid DNA was purified with a Qiagen Miniprep kit.  E. coli strain MachI (Invitrogen) 
                                                 
∗ Reproduced in parts with permission from Yang Zhang, Seong A. Kang, Tathagata Mukherjee, Shridhar 
Bale, Brian R. Crane, Tadhg P. Begley and Steven E. Ealick.  (2007). Biochemistry, 46, 145-155. © [2007] 
American Chemical Society. 
The protein was crystallized by Seong, the X-ray crystallographic and analysis were done by Yang and 
modeling studies were done by Shridhar. 
 53 
was used as a recipient for transformations during plasmid construction and for plasmid 
propagation and storage. Site-directed mutagenesis was performed on pRmTDO.PXHta 
by a standard PCR protocol using PfuTurbo DNA polymerase per the manufacturer’s 
instructions (Invitrogen) and DpnI (New England Biolabs) to digest the methylated 
parental DNA prior to transformation. For each mutant, a third primer was designed to 
screen for the presence of the mutant by colony PCR with an appropriate vector-specific 
primer.  Only clones that produced a PCR product were sequenced.  In every case, the 
mutagenesis primer pair consisted of the primer whose sequence is in table 2.1 and its 
reverse complement. † 
 
Table 3.1: Primer sequences used for mutagenesis and screening. 
Mutant Mutagenesis Primer (top strand)/Screening Primer 
Y130F GATGACGCCGCCCGAGTTCAGCGCGATGCGCCCATACC 
TGACGCCGCCCGAGTTCAGC 
F68A GATCACAATGAGATGCTCGCAATCGTCCAACACCAGACCACC 
GATCACAATGAGATGCTCGC 
T271A GGTGCCGCCCGCGCCGCGCTTGAATCCGATTACCCGCTCGACTGTGG 
CTGACGCCTTCGGTGCCGCCCGC 
R134A GAGTACTCGGCCATGGCTCCATACCTGGGGGCATCGTCC 
GCCCCCAGGTATGGAGC 
 
3.2.2. Activity of TDO Mutants: Substrate solutions of varying concentrations were 
prepared by dissolving the required amount of L-tryptophan and ascorbic acid (reducing 
agent to keep the enzyme in the Fe(II) oxidation state) in molar ratio of 4:1 in 100 mM 
phosphate buffer at pH 7.0. 50 µL of freshly purified enzyme (strength varying from 100 
                                                 
†
 The molecular cloning was done by Dr. Cynthia Kinsland 
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to 200 µM depending on the preparation of enzyme) was added to 450 µL of the 
substrate solution (always ensuring that the steady state condition is not violated) and the 
apparent catalytic activity of all the mutants and wild type was determined by measuring 
the rate of product (N-formyl kynurenine) formation at 321 nm (ε = 3152 M-1cm-1 for 
NFK). The KM for tryptophan and kcat for the active mutants and wild type were 
determined by fitting the rate of product formation against tryptophan concentration to 
the Michaelis-Menten equation using Grafit 5.0.11 (Erithacus Software, Horley, UK).  
 
3.2.3. Activity with substrate analogues of tryptophan. 20 mM solutions of the 
tryptophan analogues were prepared. 5 µL of 20 mM solution was added to a mixture of 
25 µL of 100 µM RmTDO, 5 µL of 5 mM ascorbic acid and 465 µL of 100 mM 
phosphate buffer at pH 7.0. All solutions were made in 100 mM phosphate buffer at pH 
7.0. A solution of L-tryptophan was assayed in order to test the activity of the enzyme. 
Because of poor solubility of tryptamine; 20 µL of 5 mM solution was used in the assay. 
The final strength of each substrate was 200 µM, enzyme 5 µM and ascorbic acid 50 µM. 
For reference solution everything other than the substrate was added. UV-visible 
spectrum of this reaction mixture was taken at various time intervals.   
 
3.2.4. Modeling of the Tryptophan Hydroperoxide into the Active Site†. The 
modeling of the putative hydroperoxide intermediate (1, 2, 3, and 4) (figure 3.2) into the 
active site of TDO was carried out using the program Macromodel, version 7.2 (3). 
Modeling simulations were preformed in which the Cβ-Cγ torsion was either constrained 
(anti periplanar or syn coplanar) or allowed to freely rotate.  The base shell of atoms 
included all residues within 20.0 Å of the heme iron and was used as the starting model 
for energy minimization.  The intermediate was built into the active site, followed by 
                                                 
† The modeling studies were performed by Dr. Shridhar Bale 
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removal of water molecules and hydrogen atoms were added appropriately.  The starting 
structure was subjected to mixed Monte Carlo MCMM/lowmode conformational search 
steps allowing residues in the 4 Å shell around the active site to move.  This included the 
key residues His72, Tyr43 and Phe68.  The conformational search allowed torsional 
rotation about the Fe-O1, O1-O2, O2-Cγ, Cγ-Cβ, Cβ-Cα and Cα-C bonds (O1 and O2 
are the two incorporated oxygen atoms).  The generated structures were energy 
minimized to a gradient of 0.01 kJ/molA in vacuo using the AMBER* force field (4, 5), a 
distance dependant electrostatics further attenuated by a factor of 4 (4r electrostatics) and 
a TNCG minimization technique (6).  The AMBER* parameters for the heme were 
adapted from D. A. Giammona (7).  To test the effect of solvation on the minimization, 
the conformational search was repeated with a minimization that uses the GB/SA (8) 
solvation model.  This search yielded a global minimum similar to the one from the in 
vacuo search.  
Figure 3.2: The hydroperoxide compounds that were modeled into the active site of 
R. metallidurans TDO. 
 
3.3. Results 
3.3.1. Modeling of hydroperoxide intermediate. Although the substrate L-tryptophan 
was present in the crystallization condition, there was no corresponding electron density 
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product complex have so far been unsuccessful, we prepared a model of the hydroperoxy 
intermediate into the predicted active site (table 3.2).  
  
Table 3.2: The energies and torsion angles from the modeling 
Putative intermediate Energy 
(kJ/mol) 
Torsion angle 
1 -171.03 -173.6 
2 -228.06 163.0 
3 -172.15 13.8 
4 -202.58 -18.9 
1 - no torsional constraints -221.39 -51.0 
2 - no torsional constraints -234.82 90.6 
The global energy minimum structure for the hydroperoxy intermediate showed two 
residues with significant conformational change: Tyr43* and His72.  The rest of the heme 
binding site residues are essentially the same as the unliganded TDO structure. The 
tryptophan ring of the intermediate stacks perpendicularly to the side chain of Phe68.  
While the minimum energy structure corresponded to a Cβ-Cγ torsion angle in between 
anti periplanar (figure 3.3 (a), (d)) and syn coplanar (figure 3.3 (b), (c)), the constrained 
simulations showed a clear preference for the S-anti periplanar structure (2) over 
structures (1, 3 and 4).  In this model the substrate forms good hydrogen bonds between 
its carboxylate group and Tyr130, Arg134 and the amide group and side chain of Thr271, 
and hydrogen bonds between its amino group and Thr271 and a propionate of the heme 
group (figure 3.2(a)). 
 
3.3.2. Activities of Mutants and Substrate Analogs.   
Several mutants of TDO was made and tested for activity. The steady state kinetic 
parameters of the active ones are listed in table 3.3. Various substrate analogues 
(D-Tryptophan, tryptamine, indole propionic acid and indole) were used to test the 
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Figure 3.3: Model of (a) S-anti periplanar hydroperoxide (b) S-syn coplanar 
hydroperoxide (c) R-syn coplanar hydroperoxide and (d) R-anti periplanar 
hydroperoxide in the active site of RmTDO.  
 
Table 3.3: Steady state kinetic parameters RmTDO and its mutants. 
Mutant kcat 
(s-1) 
KM 
(µM) 
kcat/KM  
(µM-1s-1) 
Relative  
specificity 
Native 0.01 (-) 385 (42) 3.06x10-5 1  
H72A 0.13 (0.01) 5927 (725) 2.24x10-5 0.73 
R134A Inactive 
T271A Inactive 
Y130F 0.20(0.01) 438 (54) 45.8x10-5 15 
F68A Inactive 
F68C Inactive 
F68D Inactive 
F68E Inactive 
F68H 0.05 (-) 389 (30) 11.8x10-5 4 
F68Y 0.005 (-) 609 (74) 0.1x10-5 0.03 
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activity for TDO. TDO did not accept any of the analogues as alternative substrates.   
The F68A, F68C, F68D, F68E, R134A and T271A mutants of TDO were found to be 
inactive under the assay conditions. Activity of F68Y mutant was found to be 0.03 times 
that of the wild type enzyme, while the F68H was found to be 4 times more than the 
native enzyme (figure 3.4(a)). H72A mutant was found to be 0.73 times less active than the 
wild type, however, the Y130F mutants showed a 15-fold increase in specific activity 
compared to wild type TDO using L-tryptophan as the substrate (figure 3.4(b)). 
Figure 3.4: Steady state kinetic parameters of (a) F68H, F68Y and (b) Y130F, H72A 
mutants of RmTDO. 
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3.4. Discussion 
The Criegee rearrangement requires an anti periplanar arrangement of the O-O 
bond and the C2-C3 bond of the indole (i.e., 1 or 2) while the dioxetane mechanism 
requires a syn coplanar configuration (i.e., 3 or 4). These four putative intermediates have 
been modeled into the active site. The resulting energies and torsion angles are given in 
table 3. 2. The modeling suggests that the binding of the R-peroxides (1 and 3) is less 
favorable than the binding of the S-peroxides (2 and 4) and that binding of the anti 
periplanar conformation (2) is favored over binding of the syn coplanar conformation (4). 
While these results provide some support for the Criegee mechanism, this support is 
tentative: when the torsional angle constraint is removed, both the R and the S peroxides 
bind tightly with the oxygen located halfway between the syn and the anti conformations.  
The structures generated by modeling the S-peroxides (2 and 4) into the active 
site are shown in figure 3.3(a).  For the anti hydroperoxide (2) the carboxylate is anchored 
at the active site by hydrogen bonding interactions with Arg134, Tyr130 and the hydroxyl 
and amide NH of Thr271. The tryptophan amino group is hydrogen bonded to the 
hydroxyl of Thr271 and to the heme propionic acid side chain. The indole ring is stacked 
against Phe68. Overall, there is good structural complementarity between the 
intermediate and the active site functionality with only one possible exception: a basic 
residue for the deprotonation/reprotonation of the indole nitrogen is not apparent.  
 For the syn hydroperoxide (4), there are no interactions between the carboxylate 
and the enzyme, the tryptophan amino group is hydrogen bonded to the carbonyl group 
of Ser140 and the indole is stacked over the heme. A basic residue for the 
deprotonation/reprotonation of the indole nitrogen is also not apparent in this model. 
Overall, there is poor structural complementarity between this intermediate and the active 
site functionality. 
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From the alignment of RmTDO with all other TDO’s whose sequence are 
available, it was seen that the residues H-72 is fairly conserved, occasionally replaced by 
serine in some species. It is present at the axial side of the heme, close to the iron centre 
and was thought to be the potential base which could abstract the indole NH of 
tryptophan to trigger the reaction. On mutating it to alanine no large loss of activity was 
seen, as was expected had it been the base abstracting the indole proton.  
The oxidation of substrate analogs, as well as the catalytic properties of active site 
mutants, were examined to experimentally differentiate between the syn and anti 
conformations of the bound (S)-tryptophan hydroperoxide. The results are shown in 
table 3.3.  
 The model for the binding of the anti hydroperoxide (2) predicts specific strong 
interactions between the enzyme and the amino and carboxylate groups of the substrate 
as well as high selectivity for the L-isomer of tryptophan over the D-isomer. In contrast, 
the model for the binding of the syn hydroperoxide (4) predicts weak or no interactions 
between the enzyme and the amino and carboxylate groups of the substrate as well as low 
selectivity for the L-isomer of tryptophan. This suggests that that D-tryptophan (5), 
tryptamine (6), indole propionic acid (7), and indole (8) will be good substrates for the 
enzyme if the oxidation proceeds via the dioxetane mechanism and poor substrates if the 
oxidation proceeds via the Criegee mechanism. Our observation that none of these 
analogs are substrates for TDO (table 3.3) supports the model for the binding of the (S)-
tryptophan hydroperoxide in the anti periplanar conformation and suggests that the 
oxidation occurs by the Criegee mechanism. The results of active site mutagenesis 
experiments are generally in agreement with this analysis. In the model for the binding of 
the anti hydroperoxide 2, Phe68 forms the indole-binding pocket, Arg134 forms 
hydrogen bonds to the substrate carboxylate group and the hydroxyl of Thr271 forms 
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hydrogen bonds to the substrate amino and carboxylate groups. As predicted, the F68A, 
R134A and T271A mutants are inactive.  
Phe68 could be involved in hydrophobic interactions with the indole ring of 
tryptophan. Phe68 when mutated to non-aromatic residues like alanine, cystine, aspartate 
and glutamate, showed no activity. However the activity was restored on mutating it to 
aromatic residues. F68Y mutant showed much lower specific activity, while the F68H 
mutant has 4 times higher specific activity than native enzyme. The histidine group could 
interact favorably with the tryptophan group positioning it in a better catalytic 
orientation, while the tyrosine group interferes with the stabilizing hydrophobic 
interactions of phenylalanine which results in the lowering and raising of the specific 
activity of the mutant (with respect to the wild type) respectively. This explanation is 
consistent with the size of the mutants. Histidine is smaller than the phenyl group and 
hence do not interfere with the spatial orientation of the active site residues, where as 
tyrosine being bulkier than phenyl group because of the presence of the hydroxyl moiety 
might interfere with the conformation of the active site hence lowering the activity of the 
mutant 
The model suggests that the hydroxyl of Tyr130 also forms a hydrogen bond to 
the substrate carboxylate. The mutagenesis experiments do not support this interaction 
because the Y130F mutant shows a 15-fold increase in catalytic activity rather than the 
expected decrease. Y130 has been mutated by nature to phenylalanine in 39% of the 
sequences available. This mutation could interact with the F-68 which in turn interacts 
with the indole ring of tryptophan thereby positioning the intermediate better for 
catalysis. However no solid evidence to this fact is available currently to offer an 
explanation for higher turnover of the enzyme. All mutants bound the heme cofactor 
suggesting that loss of activity was not due to protein misfolding. The mutants were also 
analyzed using the model for the binding of the syn hydroperoxide. The large loss of 
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catalytic activity observed for the F68A, R134A and T271A mutants is not consistent 
with this model. 
In conclusion, the modeling of the tryptophan hydroperoxide into the active site 
of the enzyme coupled with substrate analog and active site mutagenesis studies are 
consistent with a Criegee mechanism for the indole oxidative ring opening reaction. 
Additional biochemical experiments are in progress to further elucidate the mechanistic 
details of this important oxidation.  
. 
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CHAPTER 4 
Identification of 4-pyridoxic acid dehydrogenase gene in 
Mesorhizobium loti MAFF303099∗ 
4.1 Introduction 
Only a few bacteria have been identified that are capable of surviving on vitamin B6 as a 
sole source of carbon and nitrogen (1) and two catabolic routes for vitamin B6 
degradation have been identified (2), figure 1.3. Each of the catabolic intermediates have 
been isolated, characterized and the enzymes which produce them have been identified 
over the past few decades (2). At the start of this project four genes in Mesorhizobium loti 
MAFF303099 involved in PLP catabolism had been identified. The genes that were 
identified encoded pyridoxine-4-oxidase (mlr6785) (3), 4-pyridoxolactonase (mlr6805) (4), 
pyridoxal-4-dehydrogenase (mlr6807) (5) and 2-methyl-3-hydroxypyridine-5-carboxylic 
acid oxygenase (mlr6788) (6). The genes that have been identified to date are clustered on 
the chromosome. Inspection of the nearby genes revealed two putative dehydrogenases 
mlr6793 and mlr6792. The former, mlr6793 was annotated as 3-hydroxybutyryl-CoA 
dehydrogenase (7). Both these genes looked to be the likely candidate for the oxidation of 
4-pyridoxic acid (1) to 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (3), figure 4.1. In this 
chapter, we report the cloning and overexpression of mlr6793 and demonstrate that the 
purified gene product has a dual dehydrogenase activity catalyzing the 4-electron 
oxidation of 4-pyridoxic acid (1) to 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (3). 
Figure 4.1 Reaction which could be catalyzed by mlr6793 or mlr6792. 
                                                 
∗
 Reproduced in parts with permission from Mukherjee, T., Kinsland, C. K., and Begley, T.P. (2007). 
Bioorganic Chemistry, 35, 458-464. © [2007] Elseiver. Molecular cloning was done by Dr. Kinsland. 
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4.2 Experimental 
4.2.1. Molecular Cloning.† Standard methods were used for DNA manipulations (8, 9). 
Plasmid DNA was purified with the Qiagen Miniprep kit and DNA fragments were 
purified from agarose gel with the Nucleospin Purification kit. E. coli strain MachI was 
used as a recipient for transformations during plasmid construction and for plasmid 
propagation.  Phusion DNA polymerase was used for PCR following the manufacturer’s 
recommendations.  The pENTR-TEV-D-TOPO and the Gateway system were used 
following the manufacturer’s instructions with slight modifications.  
 
4.2.2. Cloning of M. loti mlr6793: The M. loti mlr6793 gene was amplified from 
genomic DNA by PCR with the following primer pair:  5’-CAC CAT GAT CCG AAA 
TAT CGC CAT CAT C-3’ and 5’-CTA CTC CCG GCC TTC CAG GAT GCG TC-3’. 
The PCR product was purified and used in a topoisomerase mediated reaction with 
pENTR-TEV-D-TOPO essentially following the manufacturer’s instructions.  Clones 
were screened by PCR and verified by sequencing.  A correct clone was used in an LR 
recombination reaction with the plasmid pDESTF1, which is a Gateway adapted vector 
based on the pET-system.  The plasmid pDESTF1 encodes an N-terminal 6xHis tag and 
is under the control of the T7lac promoter. Clones were screened by restriction digestion.  
A correct clone was named pMl5337.XF1. 
 
4.2.3. Overexpression and purification. The plasmid pMl5337.XF1 was used to 
transform Escherichia coli BL21(DE3). A starter culture was prepared by growing a single 
colony of transformed cells in 10 ml of LB media containing 100 µg/ml of ampicillin at 
37°C with overnight agitation. 1 liter LB medium (20 g/L), containing 100 µg/ml of 
ampicillin, was inoculated with this starter culture. The cells were grown at 37°C with 
                                                 
† The molecular cloning was done by Dr. Cynthia Kinsland 
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agitation until the culture reached an OD590 of 0.6 at which point they were induced by 
adding IPTG to a final concentration of 0.8 mM, the temperature was lowered to 15°C 
and the cells were allowed to grow for a further 12 hours. The cells were then harvested 
by centrifugation at 10000 xg for 8 min at 4°C.  
Cells from 1 liter of culture were re-suspended in 20 ml of binding buffer (50 mM 
NaH2PO4, 150 mM NaCl, 10 mM imidazole, pH 7.7) and approximately 2 mg of 
lysozyme was added. The cells were then lysed by sonication (Misonix Sonicator 3000, 
pulse ‘on’ time 1.0 sec, pulse ‘off’ time 1.0 sec, output level 0.8, 30 cycles) 5 times on ice. 
The cell debris was removed by centrifugation at 30,000 xg for 40 minutes at 4°C. The 
clarified supernatant was loaded on to a 2 ml Ni-NTA-affinity column pre-equilibrated 
with binding buffer kept at 4°C. The Ni-NTA-affinity column was then washed with 100 
ml wash buffer (50 mM NaH2PO4, 150 mM NaCl, 20 mM imidazole, pH 7.7). The 
protein was eluted from the column with elution buffer (50 mM NaH2PO4, 150 mM 
NaCl, 200 mM imidazole, pH 7.7) at 4°C. The fractions containing protein were pooled 
and concentrated using YM-10 Amicon Ultracentrifugal filters at 5000 xg to a final 
volume of 500 µl. The concentrated sample was desalted into 100 mM phosphate buffer 
at pH 8.0 using an Econo-Pac 10DG disposable chromatography column. The yield of 
the purified protein was 6 mg/liter. 
 
4.2.4. Enzymatic assay based on NADH production. The reaction mixture consisted 
of: enzyme (5 µM), NAD (1 mM) and 4-pyridoxic acid (1) (50 µM) in 100 mM potassium 
phosphate buffer at pH 8.0. The enzymatic activity was monitored by measuring the 
increase in absorbance at 340 nm due to the production of NADH. A control reaction 
without NAD showed negligible background activity, figure 4.2.  
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Figure 4.2: Assay for mlr6793 gene product. NADH is only formed (monitored by 
absorbance change at 340 nm, λmax for NADH) when all the components of the 
reaction mixture are present, as mentioned in section 4.2.4. 
 
4.2.5. HPLC analysis.  HPLC analysis of the enzymatic reaction mixture was performed 
on a Hewlett-Packard 1100 instrument using a Supelcosil LC-18-T (15 cm X 4.6 mm, 3.0 
µM) column. Solution A contained water with 0.1% TFA, and solution B contained 
methanol with 0.1% TFA. The following linear gradient mixing solution A with solution 
B was used: 100% solution A for 0 to 2 min, 100% to 80% solution A from 2-12 min, 
80% to 0% solution A in 12-13 min, 0% to 100% solution A in 13-14 min and 100% 
solution A  in 14-17 minutes. Flow rate was 1 ml/min, absorbance was measured at 
254 nm (characteristic for NAD) and 320 nm (characteristic of 4-pyridoxic acid, 1). Under 
these conditions the following compounds were readily separated (retention time in 
parenthesis): 4-pyridoxic acid (1, 9.8 min), 3-hydroxy-2-methylpyridine-4,5-dicarboxylate 
(3, 7.35 min), NAD (8.75 min).  
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4.2.6. Reaction time course. A time course was determined with a reaction mixture 
(1 mL) containing 17 mM NAD, 1.5 mM 4-pyridoxic acid (1) and 150 µM of pure 
enzyme. At various time points, 100 µl of the reaction mixture was quenched by addition 
to 100 µl of 10% TFA. This mixture was filtered through Microcon YM-10 and 100 µl of 
the filtrate was analyzed by HPLC.  
 
4.2.7. Product purification. A reaction mixture (5.5 ml) containing 78 mg of NAD (20 
mM), 6 mg of 4-pyridoxic acid (1) (6 mM) and freshly purified enzyme (final 
concentration of 50 µM) was incubated overnight at room temperature. It was then 
filtered through a YM-10 Microcon centrifugal filter at 14,000 xg for 30 minutes and the 
filtrate was analyzed by HPLC. The enzymatic product (retention time 7.35 minutes) was 
collected over multiple injections. Methanol was removed by rotary evaporation; TFA 
and water were removed under high vacuum overnight. The resulting white powder was 
characterized by NMR and ESI-MS analysis. 
 
4.2.8. Steady state kinetic analysis. The steady state kinetic parameters for 4-pyridoxic 
acid dehydrogenase were determined by monitoring the absorbance at 370 nm over time. 
To a reaction mixture (500 µl) containing 243 nM enzyme and 400 µM of NAD, varying 
concentration of 4 –pyridoxic acid (1) was added. The rate of formation of NADH was 
monitored over 15 minutes at 370 nm for each concentration of the substrate. The 
extinction coefficient of NAD in 100 mM phosphate buffer at pH 8.0 at 370 nm was 
determined to be 2600 M-1cm-1. The KM for 4-pyridoxic acid (1) and kcat for the production 
of NADH by the enzyme was determined by fitting the rate of product formation versus 
substrate concentration using non-linear regression to the Michaelis-Menten equation 
using Grafit 5.0.11 (Erithacus Software Limited, Surrey, UK). In order to determine the 
KM for NAD a similar experiment was done in which the reaction mixture (500 µL) 
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contained 243 nM enzyme and 100 µM of 4-pyridoxic acid (1) and the concentration of 
NAD was varied. All solutions were made in 100 mM phosphate buffer at pH 8.0. 
 
4.3 Results and Discussion 
4.3.1. Reaction time course. The formation of 3-hydroxy-2-methylpyridine-4,5-
dicarboxylate (3) and the disappearance of 4-pyridoxic acid (1) as a function of time is 
shown in figure 4.3.   Neither 320 nm nor 254 nm wavelength showed the presence of any 
other peaks which indicated that under the reaction conditions, the two electron 
oxidation of 4-pyridoxic acid (1) to 5-formyl-3-hydroxy-2-methylpyridine-4-carboxylate 
(2) was not observed. Under the acidic conditions used to quench the enzymatic reactions 
NADH is degraded to a non-chromophoric compound at 320 nm and is therefore not 
detected in the HPLC-chromatogram, monitored at 320 nm.  
Figure 4.3: HPLC trace showing the disappearance of the reactant (retention time of 9.8 
minutes) and the appearance of the product (retention time of 7.35 minutes). 
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4.3.2. Product characterization. The white colored compound obtained as a result of 
the enzymatic reaction mixture was identified as 3-hydroxy-2-methylpyridine-4,5-
dicarboxylate (3) by NMR and MS analysis. 1H NMR (300 MHz, D2O) δ  2.69 (s, 3H, 
CH3) and 8.42 (s, 1H, C6-H), figure 4.4. Negative ion mode ESI-MS (Esquire-LC_00146 
instrument, Bruker) showed a species with m/z = 196, which corresponded to the 
calculated mass of mono anionic 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (3). 
Fragmentation analysis resulted in the formation of a species with m/z =152 (single 
decarboxylation, -44), which when isolated and fragmented further, showed the 
formation of the species with m/z = 108 (double decarboxylation, -88).  
Figure 4.4:  (a) 1H NMR of the substrate, 4-pyridoxic acid (1). (b) 1H NMR of the 
product, purified by HPLC, i.e. 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (3).  
(c) Negative mode ESI-MS analysis of the product (3). 
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4.3.3. Steady state kinetic analysis. The steady state kinetic parameters for the enzyme 
were determined by monitoring the production of NADH in a UV-visible 
spectrophotometer. The kcat for the NADH production is 0.01s
-1. The KM for 4-pyridoxic 
acid (1) (under saturating concentration of NAD) is 5.8 (± 0.9) µM.  The KM for NAD 
(under saturating concentration of 4-pyridoxic acid, 1) is 6.6 (± 1.3) µM, figure 4.5.  The 
absorbance for NADH production was monitored at 370 nm instead of 340 nm (λmax for 
NADH) since both 4-pyridoxic acid (1) and 3-hydroxy-2-methylpyridine-4,5-
dicarboxylate (3) have some absorbance at 340 nm.  
Figure 4.5:  The steady state kinetic parameters of mlr6793 gene product were determined 
by measuring the rate of NADH formation over time for different substrate 
concentration. The experimental parameters have been detailed out in section 4.2.8. 
 
4.4. Conclusion.  
We have demonstrated that the mrl6793 gene product catalyzes the 4-electron oxidation 
of 4-pyridoxic acid (1) to 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (3) using NAD as 
a cofactor. The intermediate 5-formyl-3-hydroxy-2-methylpyridine-4-carboxylate (2) did 
not accumulate in the enzymatic reaction mixture. This implies that the enzyme catalyzes 
the oxidation of (2) to (3), faster than the oxidation of (1) to (2). Since we see no 
reduction of NAD in absence of the substrate and the reaction product has been 
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unambiguously identified, it is reasonable to assume that two moles of NAD are 
consumed for each mole of substrate oxidized. Sequence analysis indicates only one 
nucleotide binding site so we assume that both hydride transfer reactions are occurring at 
the same active site. The mrl6793 encoded pyridoxic acid dehydrogenase is different from 
the previously characterized enzyme from Pseudomonas sp. MA-1 which uses FAD as a 
cofactor and only catalyzes the 2-electron oxidation of 4-pyridoxic acid (1) to 5-formyl-3-
hydroxy-2-methylpyridine-4-carboxylate (2). FAD is not required by the mrl6793 encoded 
pyridoxic acid dehydrogenase that has been characterized in this paper.  
Later work by Yagi et al. showed that the mlr6792 actually coded for 4-pyridoxic 
acid dehydrogenase which catalyzed the two electron oxidation of 4-pyridoxic acid (1) to 
the 5-formyl-3-hydroxy-2-methylpyridine-4-carboxylate (2), which in turn undergoes a 
further 2-electron oxidation to form the 3-hydroxy-2-methylpyridine-4,5-dicarboxylate 
(3), catalyzed by 5-formyl-3-hydroxy-2-methylpyridine-4-carboxylic acid dehydrogenase 
(mlr6793) (10). However, no structural evidence for the reaction products has been 
provided and would hopefully appear in due course of time. 
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CHAPTER 5 
Gene identification and structural characterization of the PLP 
degradative protein 3-hydroxy-2-methylpyridine-4,5-dicarboxylate 
decarboxylase from Mesorhizobium loti MAFF303099∗ 
5.1 Introduction 
In the PLP catabolic pathway 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (1), the 
product of 4-pyridoxic acid dehydrogenase, undergoes a decarboxylation to form 3-
hydroxy-2-methylpyridine-5-carboxylate, (2), figure 5.1. The gene coding for the enzyme 
producing this metabolite has not previously been discovered and is the subject of this 
chapter.  
Figure 5.1: Reaction catalyzed by mlr6791 gene product. 
 
All the genes participating in PLP catabolism that have been identified in Mesorhizobium 
Loti are not part of an operon, but are all close to each other on the M. loti chromosome. 
This suggested that other PLP catabolic genes might also be found in this region. In 
particular, we felt that the mlr6791gene, annotated as ribulose-5-phosphate 4-
epimerase (1), was a likely candidate for  the decarboxylase gene because the epimerase 
and the decarboxylase catalyzed reactions both proceed via enzyme stabilized enolate 
intermediates. In this chapter, the cloning and overexpression of mlr6791 is reported, the 
purified gene product is shown to catalyze the decarboxylation of 3-hydroxy-2-
methylpyridine-4,5-dicarboxylate (1) and the structure of this enzyme has been described. 
                                                 
∗ Reproduced in parts with permission from Mukherjee, T., Kathryn M. McCulloch, K. M., Ealick, S. E., 
and Begley, T.P. (2007). Biochemistry, 46, 13606-13615. © [2007] American Chemical Society  
All crystallographic studies and analysis were done by Kathryn. 
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While the decarboxylation of hydroxy-substituted benzene rings is a common motif in 
biosynthesis, the mechanism of this reaction is still poorly characterized. The structural 
studies described here suggest that catalysis of such decarboxylations proceeds by an 
aldolase-like mechanism. 
 
5.2 Experimental.  
5.2.1. Molecular Cloning‡. Standard methods were used for DNA manipulations (2,3). 
Plasmid DNA was purified with the Qiagen Miniprep kit and DNA fragments were 
purified from agarose gel with the Nucleospin Purification kit. Escherichia coli strain 
Mach1 was used as a recipient for transformations during plasmid construction and for 
plasmid propagation. Phusion DNA polymerase was used for PCR following the 
manufacturer’s recommendations. The pENTR-TEV-D-TOPO and the Gateway system 
were used following the manufacturer’s instructions with slight modifications.  
 
5.2.2. Cloning of M. loti mlr6791. The M. loti mlr6791 gene was amplified from 
genomic DNA by PCR with the following primer pair: 5’-CAC CAT GCG TCG GAA 
GGT CTT CGA AGA G-3’ AND 5’-TCA GGC GAG GCC TGC TTG CCT GAG G-
3’. The PCR product was purified and used in a topoisomerase mediated reaction with 
pENTR-TEV-D-TOPO essentially following the manufacturer’s instructions. Clones 
were screened by PCR and verified by sequencing. In initial sequencing, no clones were 
found with a completely correct sequence.  One clone was subjected to standard site-
directed mutagenesis with the following complementary primer pair: 5’-GGA TAC GTT 
CGG GCA CAT ATC TGC CCG TGA CCC CGA G-3’ and 5’-CTC GGG GTC ACG 
GGC ACA TAT GTG CCC GAA CGT ATC C-3’.  Colonies from the mutagenesis were 
screened with the M13-reverse primer and the mutant specific primer 5’-GAT ACG TTC 
                                                 
‡
  Molecular cloning was done by Dr. Cynthia Kinsland. 
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GGG CAC ATA TC-3’.  PCR positive clones were sequenced and a correct clone was 
used in an LR recombination reaction with the plasmid pDESTF1, which is a Gateway 
adapted vector based on the pET-system. The plasmid pDESTF1 encodes an N-terminal 
6xHis tag and is under the control of the T7/lac /promoter. Clones were screened by 
restriction digestion. A correct clone was named pMl5335.XF1. 
 
5.2.3. Overexpression and Purification.  The plasmid pMl5335.XF1 was used to 
transform E. coli BL21(DE3). The cells were grown in 1L LB medium, containing 100 
µg/mL of ampicillin, at 37 °C with agitation until the culture reached an OD590 of 0.6, at 
which point overexpression was induced by adding IPTG to a final concentration of 0.5 
mM, the temperature was lowered to 15 °C and the cells were allowed to grow for a 
further 12 h before being harvested. The protein was purified by Ni-affinity 
chromatography following the purification procedure described in section 4.2.1.  
For crystallographic studies†, the selenomethionine (SelMet) protein was prepared 
by transforming the plasmid pMl5335.XF1 into E. coli B834(DE3) cells, a strain 
auxotrophic for methionine. Cells were grown at 37 °C with shaking in minimal M9 
media which was supplemented with 20 mg/L of all amino acids except methionine, 1X 
MEM vitamin mix, 0.4% glucose, 50 mg/L L-selenomethionine, 2 mM MgSO4, 0.1 mM 
CaCl2, 25 mg/L FeSO4, and 100 mg/L ampicillin.  An identical purification procedure 
was followed. In both preparations, SDS-PAGE analysis showed 95% pure protein and 
the yield of the purified protein was 20 mg/liter. The protein concentration was measured 
by the Bradford assay (4). 
 
5.2.4. HPLC analysis.  HPLC analysis of the enzymatic reaction mixture was performed 
on a Hewlett-Packard 1100 instrument using a Supelcosil LC-18-T (15 cm X 4.6 mm, 
                                                 
†
 All crystallographic studies and analysis were done by Kathryn McCulloch 
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3 µM) column. Solution A contained water, solution B contained 100 mM sodium 
phosphate buffer at pH 6.6 and solution C contained methanol. The following linear 
gradient was used: 0% to 10% solution A and 100% to 90% solution B for 0 to 5 min, 
10% to 48% solution A, 90% to 40% of solution B and 0% to 12% of solution C from 
5-12 min, 48% to 50% solution A, 40% to 30% of solution B and 12% to 20% of 
solution C in 12-14 min, 50% to 30% solution A, 30% to 10% of solution B and 20% to 
60% of solution C in 14-18 min, 30% to 0% solution A, 10% to 100% of solution B and 
60% to 0% of solution C in 18-20 min and 0% of solution A, 100% of solution B and 0% 
of solution C in 20-25 minutes. The flow rate was 1 mL/min and the absorbance was 
measured at 254 nm (characteristic for NAD, 3-hydroxy-2-methylpyridine-5-carboxylate 
(3)) and 320 nm (characteristic of 4-pyridoxic acid (3), 3-hydroxy-2-methylpyridine-4,5-
dicarboxylate (1) and  3-hydroxy-2-methylpyridine-5-carboxylate, (2)). Under these 
conditions the following compounds were readily separated (retention time in 
parenthesis): 4-pyridoxic acid (3), (17.8 min), 3-hydroxy-2-methylpyridine-4,5-
dicarboxylate (1) (2.8 min), 3-hydroxy-2-methylpyridine-5-carboxylate (2) (5.5 min) and 
NAD (12.9 min).  
Figure 5.2: Reaction catalyzed by 4-pyridoxic acid dehydrogenase, mlr6793. 
 
5.2.5. Enzymatic Assay. The substrate, 3-hydroxy-2-methylpyridine-4,5-dicarboxylate 
(1) was not available commercially. A coupled reaction was set up with 4-pyridoxic acid 
dehydrogenase, mlr6793 whose product is compound (1), figure 5.2. The reaction mixture 
consisted of: 4-pyridoxic acid dehydrogenase (2 µM), 3-hydroxy-2-methylpyridine-4,5-
dicarboxylate decarboxylase (HMPDdc) (1 µM), NAD (1 mM), MnCl2  (10 µM) and 4-
(3)
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N
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(1)
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pyridoxic acid (3) (100 µM) in 100 mM Tris HCl at pH 8.0 containing 100 mM NaCl and 
2 mM DTT. It was incubated at room temperature for 30 minutes, filtered using 
Microcon YM-10 to remove the enzyme, and analyzed by HPLC. The analysis was 
performed at 320 nm as well as 254 nm in order to see each component of the reaction 
mixture. A control reaction without mlr6791 gene product was set up and analyzed in an 
identical fashion, figure 5.3.Unreacted 4-pyridoxic acid (3) and NAD as well as NADH 
formed due to the 4-pyridoxic acid catalyzed reaction is also seen. In the control reaction, 
where no decarboxylase is present, one can see the product of 4-pyridoxic acid 
dehydrogenase, mlr6793, ie 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (1). The assay 
clearly shows the conversion of 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (1) to a 
new species that eluted at 5.5 min. 
Figure 5.3: HPLC analysis of the assay mixture with (1) and without (2) the decarboxylase 
enzyme, mlr6791. The analysis was performed at 320 nm as well as 254 nm in order to 
see each component of the reaction mixture. 
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5.2.6. Enzymatic synthesis of the substrate. 3-hydroxy-2-methylpyridine-4,5-
dicarboxylate (1) was enzymatically synthesized from 4-pyridoxic acid (3), figure 5.2. The 5 
mL enzymatic reaction mixture containing 12 mM NAD, 6 mM 4- pyridoxic acid (3) and 
100 µM freshly purified 4-pyridoxic acid dehydrogenase (5) in 100 mM sodium 
phosphate buffer at pH 8.0 was incubated overnight at room temperature. The reaction 
mixture was subsequently concentrated by lyophilizing and redissolving in a minimum 
volume of water. It was then filtered through YM-10 Microcon centrifugal filter at 14,000 
g for 30 min to remove the protein and the filtrate was purified by HPLC. 100 mM 
Ammonium acetate, pH 6.6, was used instead of 100 mM sodium phosphate buffer at pH 
6.6 as solution B, to facilitate removal of the buffer salts from the isolated 3-hydroxy-2-
methylpyridine-4,5-dicarboxylate (1) during lyophilization. Compound (1) is a stable white 
solid. 1H NMR (300 MHz, D2O) δ  2.69 (s, 3H, CH3) and 8.42 (s, 1H, C6-H).  
Figure 5.4: HPLC trace showing the disappearance of 3-hydroxy-2-methylpyridine-
4,5-dicarboxylate (1) (retention time of 2.8 minutes) and the appearance of 3-hydroxy-
2-methylpyridine-5-carboxylate (2) (retention time of 5.5 min). 
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5.2.7. Reaction time course. A time course was determined with a reaction mixture (1 
mL) containing 1.58 mM 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (1), 2 µM pure 
HMPDdc and 10 µM MnCl2 in 100 mM Tris HCl at pH 8.0 containing 100 mM NaCl 
and 2 mM DTT (6). At various time points, 100 µL of the reaction mixture was quenched 
by addition to 100 µL of 10% TFA. This mixture was filtered through Microcon YM-10 
and 100 µL of the filtrate was analyzed by HPLC, figure 5.4. 
 
5.2.8. Product purification and characterization. A reaction mixture (10.0 ml) 
containing 12 mM NAD, 6 mM 4-pyridoxic acid (4), 100 µM 4-pyridoxic acid 
dehydrogenase, 100 µM of HMPDdc and 1mM MnCl2 in 100 mM Tris HCl at pH 8.0 
containing 100 mM NaCl and 2 mM DTT was incubated overnight at room temperature. 
It was then filtered through an YM-10 Microcon centrifugal filter at 14,000g for 30 min. 
The desired enzymatic product (retention time 5.5 min) was purified by HPLC over 
multiple injections. Methanol was removed by rotary evaporation; TFA and water were 
removed under high vacuum overnight. The resulting white powder was characterized by 
NMR and ESI-MS. 1H NMR (300 MHz, D2O) δ  2.46 (s, 3H, CH3), 7.68 (s, 1H, C4-H) 
and 8.12 (s, 1H, C6-H). ESI-MS (Esquire-LC_00146 instrument, Bruker, Negative ion 
mode) m/z = 152, (mono anionic 3-hydroxy-2-methylpyridine-5-carboxylate (2)). 
Fragmentation analysis resulted in the formation of a species with m/z = 108 (M-44, 
decarboxylation of (2)).  
 
5.2.9. Steady state kinetic parameters. The steady state kinetic parameters for 
HMPDdc were determined by monitoring the change in absorbance at 265 nm over time. 
To a reaction mixture (500 µL) containing 1 µM enzyme and 5 µM MnCl2, varying 
concentrations of 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (1) were added. The rate 
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of formation of 3-hydroxy-2-methylpyridine-5-carboxylate (2) was monitored over 3 min 
at 265 nm for each concentration of the substrate. The KM and kcat for the enzyme were 
determined by fitting the rate of product formation as a function of substrate 
concentration using non-linear regression to the Michaelis-Menten equation using Grafit 
5.0.11 (Erithacus Software Ltd., Surray, UK). All solutions were made in 100 mM Tris 
HCl at pH 8.0 containing 100 mM NaCl and 2 mM DTT. 
 
5.2.10. Protein Crystallization.  The hanging drop vapor diffusion method was used 
with 1 µL of SelMet protein solution and 1 µL of reservoir solution at 22 °C.  Sparse 
matrix screens were used to determine initial hits (Crystal Screen and Crystal Screen 2, 
Hampton Research).  Optimized crystallization conditions consisted of 6-9% 
polyethylene glycol 8000 and 100 mM Tris buffer with a pH ranging from 7.0 to 7.5.  
Crystals grew in a conical shape to a size of approximately 0.3 mm x 0.1 mm in roughly 
one week and were cryoprotected by a quick transfer into crystallization conditions with 
an additional 17% glycerol.  SelMet-HMPDdc crystals were then flash frozen by plunging 
in liquid nitrogen and stored frozen until data collection.  Crystals belong to the space 
group I4 with unit cell parameters a = 72.0 Å and c = 90.4 Å.  The unit cell contains one 
monomer per asymmetric unit with a solvent content of 45% and a Matthews coefficient 
of 2.24 Å3/Da (7).   
 
5.2.11. X-Ray Data Collection and Processing.  A single wavelength anomalous 
diffraction dataset was collected on a SelMet-HMPDdc crystal at the NE-CAT 24-ID-C 
beamline at the Advanced Photon Source using a Quantum315 detector (Area Detector 
Systems Corp).  The dataset was collected at the maximum f″ for selenium as determined 
using a fluorescence scan of the SelMet-HMPDdc crystal.  The crystal diffracted to 1.9 Å 
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resolution and data was collected over 360° using a 1° oscillation range.  The HKL2000 
suite of programs was used to index, integrate, and scale the data (8).   
 
5.2.12. Structure Determination, Model Building, and Refinement.  The computer 
program hkl2map was used to determine the positions of the Se atoms using data cut off 
at 2.2 Å resolution to maximize the anomalous signal (9).  Three of the possible five 
selenium atoms were located.  The program autoSHARP was used for refinement of the 
heavy atom positions, phasing, calculation of residual maps, density modification, and 
automated model building (10).  Automated model building built 222 of 234 residues with 
the correct side chain.  Examination of the density modified maps allowed the manual 
building of residues 139-141, 209-216, and 234 using COOT (11).  Refinement of the 
HMPDdc model was then performed using CNS (12).  A metal binding site was 
identified and modeled as a manganese ion, based on the magnitude of the electron 
density, coordination geometry, and the results of a fluorescence scan performed (results 
not shown).  Water molecules were added as refinement continued also using CNS. The 
HMPDdc structure was verified using PROCHECK and no residues were located in 
disallowed regions of the Ramachandran plot (13). Figures were generated using 
Pymol (14). 
 
5.3. Results  
5.3.1. Product purification and characterization. The product of the enzymatic 
reaction was purified as a stable white powder. It was identified as 3-hydroxy-2-
methylpyridine-5-carboxylate (2) by NMR and ESI-MS analysis, figure 5.5. The presence 
of a singlet at 7.68 ppm in the aromatic region, corresponding to the C-4 hydrogen of (2), 
indicated a clean conversion of substrate (1) to product (2). The time course for the 
HMPDdc catalyzed decarboxylation of 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (1) 
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to 3-hydroxy-2-methylpyridine-5-carboxylate (2), as analyzed by HPLC is shown in figure 
5.4.  
Figure 5.5: (a) NMR spectra of the substrate, 3-hydroxy-2-methylpyridine-4,5-
dicarboxylate (1). (b) NMR spectra of the product, purified by HPLC, i.e. 3-hydroxy-2-
methylpyridine-5-carboxylate (2). 
 
5.3.2. Steady state kinetic parameters. UV visible spectra of the enzymatic reaction 
mixture (500 µL), containing 1.58 mM of 3-hydroxy-2-methylpyridine-4,5-dicarboxylate 
(1), 4 µM MnCl2 and 780 nM of the HMPDdc in 100 mM Tris HCl at pH 8.0 containing 
100 mM NaCl and 2 mM DTT, taken at various time points, figure 5.6(a), showed an 
increase in absorbance at 265 nm. Both 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (1) 
and 3-hydroxy-2-methylpyridine-5-carboxylate (2) absorb at this wavelength. The 
extinction coefficients of 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (1) and 3-
hydroxy-2-methylpyridine-5-carboxylate (2) at 265 nm in 100 mM Tris HCl at pH 8.0 
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containing 100 mM NaCl and 2 mM DTT were determined to be 1017 M-1cm-1 and 3623 
M-1cm-1 respectively.  The rate of product formation was determined using the difference 
in molar extinction coefficients (∆ε265 = 2615 M-1cm-1). Steady state kinetic parameters 
were obtained from the concentration dependence of the rate of formation of 3-hydroxy-
2-methylpyridine-5-carboxylate (2) at constant concentration of HMPDdc under 
saturating concentration of MnCl2. The enzymatic reaction exhibited Michealis Menten 
kinetics with KM and kcat of 366 µM and 0.6 s-1 respectively. The kcat/KM for HMPDdc was 
determined to be 1530 M-1s-1, figure 5.6(b). 
Figure 5.6: (a) UV visible spectra of the enzymatic reaction mixture (500 µL) containing 
1.58 mM of 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (1), 4 µM MnCl2 and 780 nM 
of the HMPDdc in 100 mM Tris HCl at pH 8.0 containing 100 mM NaCl and 2 mM 
DTT were taken at 1 minute intervals over 20 minutes. (b) The steady state kinetic 
parameters for HMPDdc were determined by monitoring the absorbance at 265 nm over 
time. 
 
5.3.3. Monomeric Structure of HMPDdc.  The structure of HMPDdc was determined 
at 1.9 Å resolution using SAD phasing.  All 234 residues of the protein and 3 residues 
from the 6X N-terminal His tag were modeled into the final structure of the monomer, as 
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well as 205 water molecules and a manganese ion.  The monomer is composed of a single 
domain with an α/β/α fold, figure 5.7.   
 
Figure 5.7:  Monomeric structure of MlHMPDdc.  (a).  Ribbon diagram of HMPDdc at 
two orientations 90° rotated from each other.  The secondary structure is labeled and α-
helices are colored in blue, β-strands are colored in green, and loop regions are yellow.  
The manganese ion is shown as a non-bonded red sphere.  (b)  Topology diagram of 
HMPDdc. 
(b) 
(a) 
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The central 7 stranded mixed β-sheet is mostly antiparallel with a strand order of 
β5↑β6↑β7↓β4↑β1↓β2↑β3↓ where only β5 and β6 run parallel to each other as seen in 
figure 5.7(b).  The β-sheet forms a half-barrel with four α-helices flanking one side of the 
β-sheet and two α-helices flanking the opposite side.  Three of the α-helices, α1, α4 and 
α6, are unusually long with 19, 24 and 18 amino acids, respectively.  There are also three 
310 helices.   
Figure 5.8:  Stereoview diagram of the tetrameric structure of HMPDdc.  The tetramer 
has been color coded by subunit.  The manganese ion is shown in magenta. 
 
5.3.4.Tetrameric Structure of HMPDdc.  The quaternary structure of HMPDdc is a 
tetramer formed by using the fourfold crystallographic axis of the space group I4 and is 
shown in figure 5.8. The tetramer is roughly 65 Å wide, 45 Å tall and 80 Å across the 
diagonal.  A channel with a diameter of 10 Å runs through the tetramer.  α-Helices α1, 
α4, and α6 face the channel and it is composed mostly of hydrophilic side chains and 
backbone carbonyl groups.  The opening is much wider on the top, near the N and C 
termini, and nearly closed on the bottom by the last turn of α4 and the side chain of 
Lys194.  The subunit interface is formed by interactions between the C-terminal end of 
one HMPDdc subunit (α4, α5, α6, and the connecting loops) and the loops between β2 
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and β3, β6 and β7, and the loop between the third 310 helix and α3 from a neighboring 
subunit.  The first 310 helix also contributes to the interface between subunits. 
Approximately 3000 Å2 of surface area is buried at the interface between subunits 
(15).  The residues lining the subunit interface are mostly hydrophobic, including a patch 
rich in aromatic residues, including Phe25, Phe177, Phe180, and Tyr181.  There are two 
sets of salt bridges at the interface, one between Arg128 and Glu205 and the second 
between Arg162 and Glu126.  The arginine residues are found close to each other and 
there also appears to be some stacking between these side chains.  The interface is also 
stabilized by five hydrogen bonds: Asp23 and Thr24 both hydrogen bonding to Tyr181, 
Ser48 to His223, and Asp105 to Asn197.  Three backbone carbonyl groups form 
hydrogen bonds: the carbonyl group from Ile195 to the side chain of Thr106, the 
carbonyl group of Asp133 to the hydroxyl group of Ser202, and the carbonyl oxygen 
atom of Glu134 to the oxygen of the Thr208 side chain.    
 
5.3.5. Metal Binding Site.  A cleft 13 Å long, 8 Å wide, and 10 Å deep forms near the 
hydrophobic patch at the interface between two subunits.  The cleft is found in the 
middle of the tetramer and lies closer to the external solvent than to the channel that runs 
through the tetramer.  This cleft contains six histidine residues in close proximity to each 
other:  His27, His92, His94, His163, and His177 from one subunit and His113* from the 
neighboring subunit.   
 In addition to the histidine residues, a large unexpected peak in the electron 
density was found in this cleft and was modeled as a manganese ion.  No metal was 
added during purification, and treatment of the protein sample with EDTA was 
unsuccessful in removing the metal, showing that the metal is tightly bound in 
MlHMPDdc.  A fluorescence scan identified the metal as a manganese ion.  The metal 
has a tetrahedral coordination to His92, His94, His163, and Glu73, figure 5.9.  The 
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bonding distance between the manganese ion and His92 is 2.2 Å, while the distances to 
the other residues coordinated to the metal are longer than expected with a distance of 
2.7 Å for His94, His163 and Glu73.  Adjacent to the bound metal is a pocket 8 Å long 
and 7 Å wide, which could potentially accommodate 3-hydroxy-2-methylpyridine-4,5-
dicarboxylate 6 .  Hydrophobic residues that protrude into and line the cleft include 
Phe25, Phe28, and Tyr71 and hydrophilic residues in the pocket include His113*, 
Gln216*, and Arg219*.   
Figure 5.9:  Stereoview diagram of the metal binding site.  Composite omit density is 
shown around the manganese ion at a contour level of 1.0 σ and is shown in blue.  The 
manganese ion is magenta.  Residues shown in green are from one subunit and the 
residues shown in yellow are from the neighboring subunit.   
 
5.4. Discussion 
5.4.1. Comparison of HMPDdc to other proteins.  An iterative BLAST (16) search 
using the non-redundant protein sequence database revealed a large cluster of proteins 
with sequence identities to HMPDdc ranging from 20 to 40%.  Most of these proteins are 
annotated as class II aldolases/adducins or hypothetical proteins.  Alignment of the top 
hits identified five strictly conserved residues and several highly conserved residues (17, 
18).  Pro47 is strictly conserved and is found at the interface between monomers as the 
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first residue of a 310 helix in HMPDdc.  Two of the residues coordinating to the 
manganese ion, Glu73 and His94, are also absolutely conserved.  The two other histidine 
residues, His92 and His163, are mostly conserved among the proteins, with His92 being 
replaced by an arginine and His163 being replaced by asparagine in a class II aldolase 
from Nocardioides sp. JS614.  His77 is strictly conserved, and is one of the six histidine 
residues found near the putative active site cleft at the interface.  The final conserved 
residue, Gly164, is adjacent to His163, which coordinates to the manganese ion and is the 
first residue of a β-strand.   
A BLAST search was then conducted on a class II aldolase/adducin-like protein 
from Burkholderia sp. 383, which had the highest sequence similarity to MlHMPDdc in the 
initial BLAST search.  Most of the sequences with significant alignments were the same 
class II aldolases/adducins and hypothetical proteins identified using HMPDdc as a 
search subject; however, at a lower similarity level several 3,4-dihydroxyphthalate 2-
decarboxylase (DHPdc) sequences were identified.  DHPdc is found in the phthalate 
catabolism pathway of gram-positive bacteria and catalyzes a decarboxylation reaction of 
an aromatic ring very similar to the reaction catalyzed by HMPDdc (19, 20).  Alignment 
of these DHPdc sequences with the sequence of HMPDdc and the nearest class II 
aldolase identified several residues that are conserved (18). All metal coordinating residues 
are conserved and His77 and His27, two histidine residues found near the cleft between 
subunits, are also conserved.  The aromatic residues near the active site, Phe25, Tyr71, 
His113, and Phe138, are not conserved in DHPdc but are replaced by hydrophobic 
residues.  Gln216 in HMPDdc is found to be an asparagine residue in DHPdc and 
Arg219 is replaced by a threonine residue.   
The MlHMPDdc monomer was submitted to DALI to identify structurally 
related proteins (21).  Five proteins were identified as being structurally similar to 
HMPDdc with Z-score greater than 10; all other proteins have Z scores less than 4.  Top 
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hits included two L-fuculose 1-phosphate aldolases, one L-ribulose 5-phosphate 
epimerase, a rhamnulose 1-phosphate aldolase, and the C terminal fragment of 
phosphomethylpyrimidine kinase from Pyrococcus furiosus (22-24).  The aldolases and 
epimerase belong to the superfamily of AraD-like proteins and class II aldolases.  L-
Fuculose 1-phosphate aldolase from E. coli showed the highest structural similarity with a 
Z score of 24.4 and an r.m.s.d. of 2.4 Å for 205 of a possible 210 residues.  The sequence 
identity between HMPDdc and the aldolase is about 20%.  The Z score for E. coli L-
ribulose 5-phosphate epimerase was 22.5 with an r.m.s.d. of 2.4 Å for 207 of 223 
residues.   
The structures of the L-fuculose 1-phosphate aldolases, L-ribulose 5-phosphate 
epimerase, and the rhamnulose 1-phosphate aldolase superimpose well on the structure 
of HMPDdc, as seen in figure 5.10.  The topology of the long β-sheet is conserved for 
each of the aldolases and HMPDdc; however, HMPDdc has a C-terminal α-helix not 
observed in the other structures.  Rhamnulose 1-phosphate aldolase is the least similar to 
HMPDdc and has two extra β-strands and four extra α-helices.  All of the enzymes 
shown in figure 5.10 adopt a tetrameric oligomeric state.   
Despite the strong structural similarity between HMPDdc and the class II 
aldolase family, there is low sequence conservation and apart from the coordination of 
the metal ion few of the putative active site residues are conserved.  The class II aldolase 
superfamily members each bind a zinc ion in the active site, while HMPDdc has a 
manganese ion bound.  L-fuculose 1-phosphate aldolase from Bacterosides thetaiotaomicron 
has the highest sequence identity at 20% and the sequence identity between HMPDdc 
and rhamnulose 1-phosphate aldolase from E. coli is only 15%.  The zinc ion is found in 
the same cleft and coordinated by three conserved histidine residues.  The fourth residue 
coordinated to the metal ion is a glutamate residue in HMPDdc and the three aldolases, 
and an aspartate residue in the epimerase.  Several glycine and proline residues are 
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conserved, most likely playing roles in positioning structural elements.  His77 is 
conserved, as is Ser29, which is hydrogen bonded to His 77.  Arg31, Arg84, Pro85, and 
Asp86 are all structurally conserved and are found in turns directly exposed to solvent.  
Glu183 is conserved and is found within α4 and faces the channel that runs through the 
tetramer.   
 
Figure 5.10: Stereoview diagram of the superposition of the top four DALI hits on 
HMPDdc.  HMPDdc is shown in red, 1-ribulose-5-phosphate-4-epimerase is shown is 
blue, rhamnulose-1-phosphate aldolase is in cyan, 1-fuculose-1-phosphate aldolase from 
E. coli is green, and 1-fuculose-1-phosphate aldolase from B. thetaiotaomicron is colored 
yellow. 
 
5.4.2. Active Site Comparison.  The structure of L-fuculose 1-phosphate aldolase from 
E. coli with an inhibitor bound (PDB ID: 4FUA) was used to compare the active sites of 
the class II aldolase and HMPDdc figure 5.11 (22).  The zinc ion is located closer to the 
coordinating residues in the aldolase structure, only 2.0 Å from His94 and His 155 and 
2.1 Å from His 92.  The corresponding distances in HMPDdc to the manganese ion are 
2.7 Å for His 94 and His163 and 2.2 Å for His92.  With the inhibitor 
phosphoglycolohydroxamate bound Glu73 has been pushed out of position for 
coordination to the zinc ion, suggesting the same could occur upon binding of 3-
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hydroxy-2-methylpyridine-4,5-dicarboxylate (1).  His113* is replaced by Tyr113*, which 
points toward the zinc ion.  The adjacent residue, Met114*, is found in both structures.  
His27 is replaced by Asn29.  Phe138 is conserved, although adopting a different side 
chain orientation.  Gly28 still composes the floor of the binding pocket and the pocket is 
roughly the same size in both structures.  No other residues are conserved within the 
binding pocket, unsurprising given that the substrates are very different.  
Figure 5.11: Stereoview diagram of the active sites of HMPDdc and 1-fuculose1-
phosphate aldolase.  HMPDdc is colored in green and 1-fuculose1-phosphate aldolase is 
colored in pink. The phosphoglycolohydroxamate ligand is abbreviated as PGH. 
 
5.4.3. Structural Implications for Mechanism. Enzyme-catalyzed decarboxylations 
constitute a well-studied family of reactions and the role of pyridoxal phosphate, the 
pyruvoyl cofactor, imine formation with lysine and metal ions in the catalysis of these 
reactions is now well established. The general rule for the catalysis of such 
decarboxylations is that the enzyme provides a mechanism for the stabilization of an 
enolate intermediate by charge delocalization (25). The decarboxylation of orotidine 
monophopshate that occurs during pyrimidine biosynthesis is a well-known exception  
(26). The decarboxylation of hydroxy-substituted benzene rings is a common motif in 
polyketide biosynthesis. It is generally assumed that this reaction proceeds by initial 
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tautomerization of the phenol, followed by decarboxylation of the resulting keto-acid. 
However, this proposal has not been experimentally validated and only one structure of a 
hydroxybenzoic acid decarboxylase has been reported (PDB ID: 2DVX).  
Figure 5.12: (a) The retroaldol condensation reaction catalyzed by fuculose aldolase.  
(b) The proposed mechanism for the decarboxylation of 3-hydroxy-2-methylpyridine-4,5-
dicarboxylate (1). 
 
The Protein Data Bank contains three zinc-dependent decarboxylases: 2,6-
dihydroxybenzoate decarboxylase (PDB ID: 2DVX), α-amino-β-carboxymuconate-ε-
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semialdehyde decarboxylase (PDB ID: 2HBV) and a protein of unknown function similar 
to α-acetolactate decarboxylase (PDB ID: 1XV2) (27); however, none of these are 
structurally similar to HMPDdc.  In contrast several members of the class II 
aldolase/adducin family were revealed by a DALI search.  The structural similarity 
between fuculose aldolase and HMPDdc suggests that the two reactions share common 
mechanistic features (28).  For the aldolase catalyzed reaction, Tyr113 initiates the 
retroaldol reaction by alcohol deprotonation, figure 5.12(a). The resulting enolate is 
stabilized by the active site zinc ion. Protonation of this enolate by Glu73 followed by 
product release completes the reaction. In the resting state of the enzyme, Glu73 is 
coordinated to the zinc ion and is released from the metal upon substrate binding. Based 
on this proposal, we suggest an analogous mechanism for HMPDdc. In this mechanism, 
binding of the substrate displaces Glu73 from the manganese ion replacing it with the 
substrate hydroxyl. Glu73 then provides the proton for the keto-enol tautomerization to 
give (9), figure 5.12(b). The decarboxylation reaction is analogous to the retroaldol reaction 
except that is does not need a base as the carboxylate is likely to be deprotonated under 
the reaction conditions. Displacement of the product from the manganese ion by Glu73 
followed by product dissociation completes the reaction. The testing of this mechanistic 
proposal is in progress and will require additional structural and mechanistic studies. 
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CHAPTER 6 
Identification of the 2-(acetamidomethylene)succinate hydrolase gene 
in Mesorhizobium loti MAFF303099∗ 
6.1 Introduction 
The gene encoding for 2-(acetamidomethylene)succinate hydrolase, which 
catalyzes the last step in the degradation of vitamin B6 (1) was the last gene in the 
catabolic pathway that remained to be identified. The genes that have been identified to 
date are all clustered on the chromosome. Inspection of the nearby genes revealed a 
putative hydrolase (mlr6787) which is currently annotated as a ‘putative DHNA-CoA 
thioesterase’ proposed to be involved in menaquinone biosynthesis (2). This chapter 
details out the purification and characterization of the mlr6787 gene product and shows 
that it catalyzes the hydrolysis of 2-(acetamidomethylene) succinate (1) to form succinic 
semialdehyde (2), acetic acid, ammonia and carbon dioxide, figure 6.1. The enzyme was 
shown to utilize the E isomer of 2-(acetamidomethylene)succinate.  
Figure 6.1: Hydrolysis reaction catalyzed by mlr6787. 
  
6.2 Experimental Section 
6.2.1. Over-expression and purification. The plasmid pMl5331.XF1 was used to 
transform Escherichia coli BL21(DE3). A starter culture was prepared by growing a single 
colony of transformed cells in 10 ml of LB media containing 100 µg/ml of ampicillin at 
                                                 
∗ Reproduced with permission from Mukherjee, T., Hilmey, D. G., and Begley, T.P. (2008). Biochemistry, 47, 
6233-4. © [2008] American Chemical Society.  
The chemical synthesis was carried out by Dr. Dave Hilmey. 
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37 °C with overnight agitation. 1 liter LB medium (20 g/L), containing 100 µg/ml of 
ampicillin, was inoculated with this starter culture. The cells were grown at 37 °C with 
shaking at 250 rpm until the culture reached an OD590 of 0.6 at which point they were 
induced by adding IPTG to a final concentration of 0.8 mM, the temperature was 
lowered to 15 °C and the cells were allowed to grow for a further 12 hours. The cells 
were then harvested by centrifugation at 10,000g for 8 min at 4 °C.  
The protein was purified by Ni-affinity chromatography following the purification 
procedure described in section 4.2.1. SDS-PAGE analysis showed 95% pure protein. The 
yield of the purified protein was 25 mg/liter. The protein concentration was measured by 
the Bradford assay (3). 
 
6.2.2. Overexpression and purification of succinic semialdehyde dehydrogenase. 
The gene product of MtbH37Rv gabD1 (Rv0234c) gene from Mycobacterium tuberculosis is 
reported to be succinic semialdehyde dehydrogenase (4). The MtbH37Rv gabD1 
(Rv0234c) gene in pET28b vector was overexpressed and purified in a similar manner as 
described above. Kanamycin was used as the antibiotic to the final concentration of 40 
µg/mL. After loading the protein onto the Ni-NTA-affinity column pre-equilibrated with 
binding buffer kept at 4°C, the column was washed with 300 ml of wash buffer 
containing 50 mM NaH2PO4, 150 mM NaCl, 40 mM imidazole, pH 7.7.  The purified 
protein was 80% pure by SDS-PAGE. Bradford assay (3) was used to measure the 
protein concentration and the yield of the purified protein was 2 mg/liter. 
 
6.2.3. HPLC analysis.  HPLC analysis of the enzymatic reaction mixture was performed 
on a Hewlett-Packard 1100 instrument using a Supelcosil LC-18-T (15 cm X 4.6 mm, 3.0 
µm) column. Two different methods were used. Method A: solution A contained water, 
solution B contained 100 mM sodium phosphate buffer at pH 6.6 and solution C 
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contained methanol. The following linear gradient was used: 0% to 10% solution A and 
100% to 90% solution B for 0 to 5 min, 10% to 48% solution A, 90% to 40% of solution 
B and 0% to 12% of solution C from 5-12 min, 48% to 50% solution A, 40% to 30% of 
solution B and 12% to 20% of solution C in 12-14 min, 50% to 30% solution A, 30% to 
10% of solution B and 20% to 60% of solution C in 14-18 min, 30% to 0% solution A, 
10% to 100% of solution B and 60% to 0% of solution C in 18-20 min and 0% of 
solution A, 100% of solution B and 0% of solution C in 20-25 minutes. Flow rate was 
maintained at 1 mL/min and the following compounds were readily separated (retention 
time, wavelength in parenthesis): 2-(acetamidomethylene)succinate (1) (2.1 min, 254 nm), 
3-hydroxy-2-methylpyridine-4,5-dicarboxylate (8) (2.8 min, 320 nm), 3-hydroxy-2-
methylpyridine-5-carboxylate (5.5 min, 320 nm),  NAD (12.9 min, 254 nm), NADH (14.3 
min, 254 nm),  and FAD (19.3 min, 254 nm). Method B: solution A contained water with 
0.1% TFA and solution B contained methanol with 0.1% TFA. The following linear 
gradient mixing solution A with solution B was used: 100% solution A for 0 to 2 min, 
100% to 60% solution A from 2-7 min, 60% to 0% solution A in 7-10 min, 0% to 100% 
solution A in 10-11 min and 100% solution A  in 10-15 minutes. Flow rate was 1 ml/min, 
and by this method the following compounds were readily separated (retention time, 
wavelength in parenthesis): 2-(acetamidomethylene)succinate (1) (4.3 min, 261 nm), DNP 
(14)(11.3 min, 261 nm) and DNP hydrazone of succinic semialdehyde (15) (11.65 min, 
261 nm). 
 
6.2.4. Synthesis 
6.2.4.1. 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (8). The synthesis of 3-
hydroxy-2-methylpyridine-4,5-dicarboxylate (8) began with the known protocols for 
making N-formyl alanine (4) from L-alanine (3) (5) figure 6.2(a), which was then converted 
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to 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (8) according to literature procedures(6), 
m.p. 270-272oC; 1H NMR (D2O, 300 MHz) δ 2.60 (s, 3H), 8.21 (s, 1H); 13C 
NMR (D2O, 75 MHz) δ 173.7, 171.2, 155.3, 146.1, 135.7, 130.1, 110.0, 16.0.† 
Figure 6.2: Synthetic scheme for the preparation of substrate and reference compounds 
(a) 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (8); (b) E- and Z isomer of 2-
(acetamidomethylene) succinate (1 and 13) (c) DNP hydrazone of succinic 
semialdehyde (15). 
                                                 
†
 The synthesis of (8) was carried out by Dr. Dave Hilmey. 
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6.2.4.2.. 2-(acetamidomethylene)succinic acid (1). 2-(acetamidomethylene)succinic 
acid (1) was synthesized starting from diethyl succinate (9) according to the scheme 
shown in figure 6.2(b). α-Formyl diethyl succinate (10) was prepared from diethyl succinate 
(9) and ethyl formate in accordance with known literature procedure(7). 
Acetamidomethylene diethyl succinate (11, 12) was prepared from acetamide and α-
formyl diethyl succinate (10) from known literature procedure (8). After workup 
following the literature protocol, yellow colored oil was produced. TLC in 30% ethyl 
acetate and hexane showed three well separated spots with rf values of 0.48, 0.37 and 
0.15. The three compounds were isolated by flash chromatography. The spot with an rf 
value of 0.48 was found to be unreacted starting material, while the other two spots 
corresponded to the E and Z geometric isomers (11, 12), both as pale yellow solids. The 
assignment of E and Z isomer was made based on their 2D-NOESY spectra (figure 6.6). 
The spot with an rf value of 0.37 was assigned the Z form (11) and the one with an rf 
value of 0.15 was assigned the E form (12). For the Z-form (11), 1H NMR (CDCl3, 600 
MHz) δ 1.17 (t, J = 7.2 Hz, 3H), 1.19 (t, J = 7.2Hz, 3H), 2.07 (s, 3H), 3.10 (s, 2H), 4.05 
(q, J = 7.2 Hz, 2H), 4.12 (q, J = 7.2 Hz, 2H), 7.37 (d, J = 11.4 Hz, 1H), 10.40 (d, J = 11.4 
Hz, 1H) and for the  E-form (12), 1H NMR (CDCl3, 600 MHz) δ 1.23 (t, J = 7.2 Hz, 3H),  
1.25 (t, J = 7.2 Hz, 3H), 2.12 (s, 3H), 3.34 (s, 2H), 4.11 (q, J = 7.2 Hz, 2H), 4.17 (q, J = 
7.2 Hz, 2H), 8.11 (d, J = 11.4 Hz, 1H), 8.9 (d, J = 11.4 Hz, 1H). The E-2-
(acetamidomethylene) diethyl succinate (12) (13 mg, 0.05 mmol) was dissolved in MeOH 
(75 µL) and H2O (0.5 mL) and treated with K2CO3 (27 mg, 0.2 mmol).  After heating to 
90 oC for 24 h, the solution was acidified with 4 M HCl and the solvent was evaporated in 
vacuo.  The residue was dissolved in EtOH and filtered to remove salt.  Evaporation of 
the filtrate resulted in a precipitate which proved to be the E-2-
(acetamidomethylene)succinic acid (1) (8 mg, 86%) as a white solid; mp  218-220 oC  1H 
NMR (D2O, 300MHz) δ 2.14 (s, 3H), 3.41 (s, 2H), 8.05 (s, 1H). The Z-2-
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(acetamidomethylene) diethyl succinate (11) on similar treatment as mentioned above 
produced Z-2-(acetamidomethylene)succinic acid (27) in 80% yield as a white solid; mp 
215-218 oC  1H NMR (D2O, 300MHz) δ 2.14 (s, 3H), 3.06 (s, 2H), 7.09 (s, 1H). 
 
6.2.4.3. DNP hydrazone of succinic semialdehyde (15). Succinic semialdehyde (2) 
(200 µL of 15% solution in water) was added to 2.2 ml of ethanol, to which 63 mg of 
DNP in 600 µL of concentrated sulfuric acid was added. The hydrazone formation was 
rapid and the orange product was filtered and dried (figure 6.2(c)) It was purified by flash 
chromatography with 5% methanol-chloroform. 1H NMR (CD3OD, 300MHz)  δ 2.48 - 
2.64 (m, 4H), 7.7 (t, J = 3.9 Hz, 1H), 7.86 (dd, J = 1.2, 9.6 Hz, 1H), 8.21 (ddd, J = 1.5, 
2.7, 9.6 Hz, 1H), 8.92 (dd, J = 1.5, 2.7 Hz, 1H). 
 
6.2.5. Enzymatic synthesis of the 2-(acetamidomethylene)succinate (1). The 
biologically relevant isomer of 2-(acetamidomethylene)succinate (1)  was synthesized 
enzymatically from 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (8). A reaction mixture 
(10 ml) containing 20 µM freshly purified 3-hydroxy-2-methylpyridine-4,5-dicarboxylate 
decarboxylase (9), 10 µM 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase (10),  2 
mM of 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (8), 120 mM β-mercaptoethanol, 
600 µM FAD and 4 mM NADH in 100 mM sodium phosphate buffer at pH 8.0 was 
incubated overnight at room temperature. It was filtered using YM-10 Amicon 
ultracentrifugal filter at 5000 xg to remove all protein, lyophilized, redissolved in a 
minimum volume of 100 mM sodium phosphate buffer at pH 8.0, and then purified by 
HPLC using method A. It was then rotary evaporated to remove methanol and 
lyophilized again. The lyophilized sample was then redissolved in a minimum volume of 
water containing 0.01% TFA and desalted by HPLC over multiple injections using 
method B. Methanol was removed by rotary evaporation and TFA was removed in vacuo. 
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Trace amounts of TFA and methanol were finally removed by lyophilization, leaving a 
white solid. NMR of this sample was identical with the chemically synthesized E-2-
(acetamidomethylene) succinic acid (1).  
 
6.2.6. Reaction time course - depletion of substrate. A time course was determined 
by monitoring the disappearance of E-2-(acetamidomethylene) succinate (1) by UV-
visible spectrophotometry as shown in figure 6.3. UV-visible scans were taken every 20 sec 
from 300 nm to 250 nm at the rate of 800 nm/sec. The reaction mixture (500 µL) 
contained 60 µM E-2-(acetamidomethylene) succinate (1) and 2 µM freshly purified 
enzyme in 100 mM sodium phosphate buffer at pH 8.0.  
Figure 6.3: UV-visible scan of the enzymatic reaction mixture over time. 
 
6.2.7. Reaction time course - formation of DNP hydrazone of succinic 
semialdehyde (15). To a 3 mM solution of E-2-(acetamidomethylene)succinate (1) (500 
µL) in 100 mM sodium phosphate buffer at pH 8.0, 1 µM of freshly purified E-2-
(acetamidomethylene)succinate hydrolase was added. At various time intervals, 40 µL of 
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the reaction mixture were removed and quenched by addition to 50 µL of 8 mM DNP 
(14)(prepared in 3mM HCl) and extracted with ethyl acetate (2 x 300 µL). 100 µL of the 
extracted sample were analyzed by HPLC, figure 6.4. Enzyme and substrate negative 
controls were run in a similar fashion in which buffer was substituted for the enzyme and 
the substrate, respectively. A standard of the DNP hydrazone of succinic semialdehyde 
(15) was also treated similarly. 
 
Figure 6.4: HPLC trace showing the formation of the DNP hydrazone of succinic 
semialdehyde (15) with time. 
 
6.2.8. Assay for Ammonia. The assay for ammonia was done by monitoring the 
disappearance of NADPH over time in a coupled assay with α-ketoglutarate and 
glutamate dehydrogenase (11). The assay mixture (500 µL) consisted of 10 U of glutamate 
dehydrogenase (unit is defined as the amount of glutamate dehydrogenase that will reduce 
1 µmol of α-ketoglutarate to glutamate per min at pH 8.3 at 30 ˚C), 10 mM α-
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ketoglutarate, 1 mM EDTA, 250 µM NADPH, 123 µM E-2-(acetamidomethylene) 
succinate (1) and 2.4  µM of E-2-(acetamidomethylene)succinate hydrolase. The 
reduction of α-ketoglutarate to glutamate was not rate limiting under these assay 
conditions. The reaction was started by the addition of E-2-(acetamidomethylene) 
succinate hydrolase and was monitored at 340 nm. All the solutions were made in 
100 mM sodium phosphate buffer at pH 8.0. 
 
6.2.9. Assay for succinic semialdehyde. The enzymatic hydrolysis of E-2-
(acetamidomethylene)succinate (1) was coupled with an assay for succinic semialdehyde 
dehydrogenase in order to detect the formation of succinic semialdehyde (2). Succinic 
semialdehyde dehydrogenase catalyzes the oxidation of succinic semialdehyde (2) to 
succinic acid using NAD. Succinic semialdehyde dehydrogenase was used in excess and 
was not rate limiting. The enzymatic reaction mixture (500 µL) consisted of 2 mM NAD, 
1 mM 2-mercaptoethanol, 135 µM E-2-(acetamidomethylene)succinate (1), 1.2  µM of E-
2-(acetamidomethylene)succinate hydrolase and 17 µM of succinic semialdehyde 
dehydrogenase. The E-2-(acetamidomethylene)succinate hydrolase was added last and the 
reaction was monitored at 340 nm. All the solutions were made in 100 mM sodium 
phosphate buffer at pH 8.0. 
 
6.2.10. Steady state kinetic parameters. The E-2-(acetamidomethylene)succinate (1) 
has a λmax at 261 nm and an extinction coefficient at 261 nm of 18,600 M-1cm-1(1). The 
extinction coefficient of this molecule was also determined at 280, 290 and 295 nm from 
the absorbance measurements at various concentration of E-2-(acetamidomethylene) 
succinate (1). For lower concentrations of E-2-(acetamidomethylene)succinate (1) the rate 
of the reaction was determined from the change in absorbance at 261 nm over time. At 
higher concentrations of substrate the rate of change of absorbance of E-2-
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(acetamidomethylene)succinate (1) was monitored at higher wavelengths (see figure legend 
6.5 for details). To a reaction mixture (500 µL) containing 250 nM enzyme, varying 
concentrations of E-2-(acetamidomethylene)succinate (1) were added. The rate of 
depletion of E-2-(acetamidomethylene)succinate (1) was monitored over 2 min. The KM 
and kcat for the enzyme were determined by fitting the initial rate (less than 10% 
conversion) of substrate depletion as a function of substrate concentration to the 
Michaelis-Menten equation by non-linear regression using Grafit 5.0.11 (Erithacus 
Software Ltd., Surrey, UK) figure 6.5. All solutions were made in 100 mM sodium 
phosphate buffer at pH 8.0.  
Figure 6.5: The steady state kinetic parameters for 2-(acetamidomethylene)succinate 
hydrolase with E- 2-(acetamidomethylene)succinate as a substrate were determined by 
monitoring the absorbance at 261 nm (for substrate concentrations of 10, 20, 30 and 50 
µM ), 280 nm (for substrate concentrations of 75 and 150 µM), 290 nm (for substrate 
concentrations of 200, 400 and 600 µM) and 295 nm (for substrate concentration of 750 
µM) over time. Amount of substrate depleted was determined by dividing the change in 
the absorbance at a particular wavelength by the extinction coefficient at that wavelength. 
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6.3. Results and Discusssion 
6.3.1. Protein overexpression and purification: E-2-(acetamidomethylene)succinate 
hydrolase was overexpressed and  25 mg of protein per liter of cells were obtained at 95% 
purity by SDS-PAGE analysis. In contrast, even though the succinic semialdehyde 
dehydrogenase overexpressed well the best preparation yielded only 2 mg of protein per 
liter of cells at 80% purity. 
 
6.3.2. Substrate identification: 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase 
catalyzes the  oxidative pyridine ring opening reaction in vitamin B6 catabolism, figure 1.3 
(12). This enzyme has been characterized in Pseudomonas sp. MA-1 (13-18). The product, 2-
(acetamidomethylene)succinate (1) could exist as two geometric isomers, E (1) and Z (13). 
The stereochemistry of the enzymatic product had not been previously determined and 
the rate of isomer conversion was unknown. 
During the chemical synthesis of  2-(acetamidomethylene)succinate (1), we 
observed that treatment of acetamide with α-formyl diethyl succinate resulted in two 
compounds which were purified by flash chromatography and characterized by two 
dimensional nuclear overhauser enhancement spectroscopy (NOESY) as the E (1) and Z 
(13) isomers of acetamidomethylene diethyl succinate, figure 6.6. In the case of the E- 
isomer (1) the amide hydrogen at 8.9 ppm has a cross peak that correlates with the allylic 
hydrogen at 3.3 ppm, while no cross peak is seen between the vinyl hydrogen at 8.1 ppm 
and the allylic hydrogen at 3.3 ppm. In case of the Z isomer (13) no cross peak is 
observed between the amide hydrogen at 10.4 ppm and the allylic hydrogen at 3.1 ppm 
while the vinyl hydrogen at 7.37 ppm has a cross peak that correlates with the allylic 
hydrogen at 3.1 ppm.  
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Figure 6.6: Phase sensitive 2D NOESY was acquired with a sweep width of 9.6 kHz. 200 
points were collected in the indirectly detected dimension with 8 scans and 5758 points 
per increment. The resulting matrix was zero filled to 4096 X 4096 complex data points 
and Gaussian window functions were applied in both dimensions prior to Fourier 
transformantion. (a) 2D NOESY of E- 2-(acetamidomethylene)succinate (1). (b) 2D 
NOESY of Z- 2-(acetamidomethylene)succinate (13). 
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The biologically relevant isomer of 2-(acetamidomethylene)succinate was 
enzymatically synthesized starting from 3-hydroxy-2-methylpyridine-4,5-dicarboxylate (8) 
using 3-hydroxy-2-methylpyridine-4,5-dicarboxylate decarboxylase (9) and 2-methyl-3-
hydroxypyridine-5-carboxylic acid oxygenase (10). NMR analysis demonstrated that the 
enzymatic product was the E isomer of 2-(acetamidomethylene)succinate (1).  
Figure 6.7: (a) Assay of the mlr6787 gene product with Z- 2-(acetamidomethylene) 
succinate (13). Assay mixture consisted of 75 µM of Z- isomer (13) and 250 nM freshly 
purified enzyme. (b) Assay of  mlr6787 gene product with E- 2-(acetamidomethylene) 
succinate (1). Assay mixture consisted of 75 µM E- isomer (1) and 250 nM freshly 
purified enzyme. (c) Plot showing the decrease in absorbance at 261 nm over time for the 
E and Z substrate isomers. Solid line: Z- 2-(acetamidomethylene)succinate (13) Dotted 
line: E- 2-(acetamidomethylene) succinate (1). 
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Both the E and the Z isomers of 2-(acetamidomethylene)succinate (1, 13) were 
tested as substrates for the mlr6787 gene product. The E - isomer (1) was readily 
hydrolyzed. In contrast, no hydrolysis was observed for the Z- isomer (13), indicating that 
the enzyme was specific for the hydrolysis of (1) figure 6.7. There is no detectable non-
enzymatic isomerization of E-2-(acetamidomethylene)succinate (1) over a period of 15 
days in 100 mM sodium phosphate buffer at pH 8.0 in D2O kept at room temperature. 
 
6.3.3. Product characterization: The 2,4-dinitrophenyl hydrazone of sucinnic 
semialdehyde was chemically synthesized and found to elute at 11.65 min by HPLC, using 
method B. The reaction time course shown in figure 6.4, indicates the depletion of the E-
2-(acetamidomethylene)succinate (1) at 4.26 min  and the formation of the DNP 
hydrazone of succinic semialdehyde (15) at 11.65 min over time, thereby showing that 
succinic semialdehyde (2) is the product of the enzymatic reaction. No hydrazone (15) 
was formed in the absence of either the enzyme or the substrate. 
A further proof that succinic semialdehyde (2) is a product of the enzymatic 
hydrolysis of  E-2-(acetamidomethylene)succinate (1) comes from the coupled assay with 
succinic semialdehyde dehydrogenase (4) in which NADH formed as a result of the 
coupled enzymatic reaction can be monitored at 340 nm. An increase in absorbance at 
340 nm was seen on addition of succinic semialdehyde dehydrogenase to the reaction 
mixture containing NAD, E-2-(acetamidomethylene)succinate (1) and the E-2-
(acetamidomethylene)succinate hydrolase. No NADH was formed in the absence of the 
succinic semialdehyde dehydrogenase or the E-2-(acetamidomethylene)succinate 
hydrolase figure 6.8 (a). 
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Figure 6.8: Enzymatic assays for the production of succinic semialdehyde and ammonia. 
(a) Trace (i) shows the formation of NADH (at 340 nm) for the enzymatic reaction 
mixture (500 µL) consisting of 2 mM NAD, 1 mM β-mercaptoethanol, 135 µM E-isomer 
(1), 1.2  µM of the hydrolase and 17 µM of succinic semialdehyde dehydrogenase. Traces 
(ii), (iii) and (iv) shows the formation of NADH for the reaction mixture which had all 
the components of trace (i) except E-isomer (1), the hydrolase and succinic semialdehyde 
dehydrogenase, respectively. (b) Trace (iv) shows the formation of NADH (at 340 nm) 
for the enzymatic reaction mixture (500 µL) consisting of 10 U of glutamate 
dehydrogenase, 10 mM α-ketoglutarate, 1 mM EDTA, 250 µM NADPH, 123 µM 
E-isomer (1) and 2.4  µM of the hydrolase. Traces (i), (ii) and (iii) shows the formation of 
NADH for the reaction mixture (500 µL) which had all the components of trace (iv) 
except glutamate dehydrogenase, E-isomer (1) and the hydrolase, respectively.  
 
A coupled assay with glutamate dehydrogenase in the presence of α-ketoglutarate 
was used for the detection of ammonia (11). In the presence of ammonia, α-imino 
glutarate is formed and subsequently reduced to glutamine by glutamate dehydrogenase. 
This enzyme requires NADPH as the cofactor, which is oxidized to NADP during the 
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reaction resulting in a decrease in absorbance at 340 nm. The coupled assay with mlr6787 
showed a decrease in absorbance at 340 nm. No decrease in absorbance at 340 nm was 
seen in the absence of either the glutamate dehydrogenase or the E-2-
(acetamidomethylene)succinate hydrolase. This confirmed the production of ammonia 
during the enzymatic hydrolysis of E-2-(acetamidomethylene)succinate (1) figure 6.8(b). 
The previously reported hydrolysis of 2-(acetamidomethylene)succinate (1) in 
Pseudomonas MA-1 (1) and Mesorhizobium Loti also yields the same products. 
 
6.3.4. Steady state kinetic parameters: The E-2-(acetamidomethylene)succinate (1) has 
a λmax at 261 nm and the extinction coefficient at 261 nm has been reported as 18,600 M-1 
cm-1 (1). A continuous assay at 261 nm at higher concentrations of the substrate was not 
possible as the initial absorbance was too high to obtain an accurate measurement. To 
avoid using a discontinuous assay, the extinction coefficients at longer wavelengths were 
measured. The extinction coefficients of  E-2-(acetamidomethylene)succinate (1)  at 280, 
290 and 295 nm in 100 mM sodium phosphate buffer at pH 8.0 were determined to be 
6900, 2000 and 700 M-1cm-1, respectively.  Steady state kinetic parameters were obtained 
from the concentration dependence of the rate of depletion of E-2-(acetamidomethylene) 
succinate (1) at constant concentration of the hydrolase. The enzymatic reaction exhibited 
Michealis Menten kinetics with KM and kcat of 143 µM and 0.6 s-1 respectively. The kcat/KM 
for HMPDdc was determined to be 4196 M-1s-1, figure 6.5.  
 
6.3.5. Mechanistic analysis: Two mechanisms for the production of succinic 
semialdehyde are shown in figure 6.9. In mechanism A (1) the amide bond of E-2-
(acetamidomethylene)succinate (1) is first hydrolyzed to give acetic acid and the 
intermediate (18) which could then undergo a decarboxylation followed by deamination 
to generate succinic semialdehyde (2). The order of these two steps could also be 
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reversed. Mechanism B predicts a conjugate addition of water to the E-2-
(acetamidomethylene)succinate (1) to generate intermediate (23) which could then 
eliminate acetamide resulting in (24). Facile tautomerization would give (21) which could 
then decarboxylate to produce succinic semialdehyde (2).  Since the enzymatic hydrolysis 
of E-2-(acetamidomethylene)succinate (1) generates ammonia rather than acetamide and 
acetamide is stable under our reaction conditions, the hydrolysis of E-2-
(acetamidomethylene)succinate (1) is likely to proceed via mechanism A.  
 
Figure 6.9: Mechanism of hydrolysis of E-2-(acetamidomethylene)succinate (1). 
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6.3.6. Comparative genomics analysis: E-2-(acetamidomethylene)succinate hydrolase 
catalyzes the last step in the degradative pathway of PLP, generating products that can be 
directly incorporated into primary metabolism. The identification of its gene completes 
the gene assignment of all the enzymes involved in PLP catabolism in M. loti. 
Surprisingly, when we search for an equivalent pathway in available sequenced bacterial 
genomes using the SEED database, we find that this pathway is unique to M. loti, 
suggesting that other PLP catabolic pathways still remain to be discovered.  
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CHAPTER 7 
Mechanistic studies of 2-Methyl-3-hydroxypyridine-5-carboxylic acid 
oxygenase from Mesorhizobium loti MAFF303099∗ 
7.1 Introduction 
The most interesting enzyme in the PLP catabolic pathway is the 2-methyl-3-
hydroxypyridine-5-carboxylic acid oxygenase (MHPCO) that catalyzes the ring opening of 
2-methyl-3-hydroxypyridine-5-carboxylic acid (MHPC) (1) with the incorporation of two 
oxygen atoms producing E-2-acetaminomethylene succinate (2), the first acyclic 
intermediate on the pathway, figure 7.1. MHPCO (E.C. 1.14.12.4) has been classified as a 
flavin-dependent monooxygenase based on its sequence and biochemical similarity to 
other enzymes in this family. This class of enzymes utilize FAD and molecular oxygen to 
form a C(4a)-hydroperoxy-FAD intermediate which then donates one oxygen atom to 
the substrate (1). The pyridine ring-opening is an unusual reaction for this enzyme family 
because most oxidative ring-opening reactions of aromatic compounds are catalyzed by 
iron-dependent dioxygenases.  
Figure 7.1: The reaction catalyzed by MHPCO (mlr6788) 
 
MHPCO has been characterized in sufficient detail in Pseudomonas sp. MA-1. The 
binding studies (2) and effect of substrate and FAD analogues (3) have been reported, the 
mechanism of hydroxylation (4) and oxygen atom transfer and product rearrangement (5) 
                                                 
∗ Reproduced in parts with permission from K. M. McCulloch, T. Mukherjee, T. P. Begley and S. E. Ealick 
(2009). Biochemistry, 48 (19), pp 4139–4149. © [2009] American Chemical Society. The crystallography and 
its analysis was done by K. M. McCulloch. 
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has been investigated and the kinetic (6) and thermodynamic characterization (7) has been 
done. Previous work has shown the Pseudomonas MA-1 MHPCO to crystallize and diffract 
to reasonable resolution, although the structure was not reported (8). In this chapter the 
cloning and overexpression of mlr6788 is reported, along with a brief description of the 
X-ray crystal structures of M. loti MHPCO which was determined at 2.1 Ǻ resolution†. 
The crystal structure was also obtained for the protein complex with MHPC (1).  These 
structures confirm the relationship of MHPCO to other members of the flavin 
monooxygenase family and provide insight into the catalytic mechanism. Based on the 
active site information from the crystal structure, mutagenesis studies were carried out to 
investigate the enzyme mechanism. Substrates analogous were designed and chemical 
reactions were carried out to probe into the mechanism of MHPCO.  
 
7.2 Experimental  
7.2.1. Cloning of M. loti MHPCO. Standard methods were used for DNA 
manipulations (9, 10).  The M. loti MHPCO gene was amplified from genomic DNA 
(purified from ATCC strain # 700743) by PCR with the following primer pair:  5’-CAC 
CAT GGC CAA TGT AAA CAA AAC TCC-3’ and 5’-CTA CTG CGG CCA CGA 
GTA GAC ACG GCG CAG C-3’. The PCR product was purified and used in a 
topoisomerase-mediated reaction with pENTR-TEV-D-TOPO (Invitrogen) following 
the manufacturer’s instructions.  Clones were screened by PCR and verified by 
sequencing.  A correct clone was used in an LR reaction with the plasmid pDESTF1, a 
Gateway-adapted vector based on the pET-system from Novagen that encodes an N-
terminal 6xHis tag under the control of the T7lac promoter.  Clones were again screened 
by restriction digestion. A correct clone was named pMl5332.XF1‡. 
                                                 
†
 All crystallographic studies and analysis were done by Kathryn McCulloch.  
 
‡
  The molecular cloning was done by Dr. Cynthia Kinsland. 
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7.2.2. Protein overexpression and purification.  E. coli Tuner (DE3) was transformed 
first using the chaperone-encoding plasmid pGro7 (Takara Bio Inc.) and then using 
pMl5332.XF1. The cells were grown in 1L LB medium, containing 100 µg/mL of 
ampicillin at 37 °C with agitation. Chaperone proteins GroES and GroEL were induced 
at cell culture inoculation by addition of 2.5 g/L L-arabinose. When the culture reached 
an OD590 of 0.6, it was induced by adding IPTG to a final concentration of 0.5 mM, the 
temperature was lowered to 15 °C and the cells were allowed to grow for a further 12 h 
before being harvested. The protein was purified by Ni-affinity chromatography 
following the purification procedure described in section 4.2.1. 60 mM imidazole was 
used to wash the Ni-column in order to get rid of the chaperone protein as it stuck non 
specifically to the column.  
For crystallographic studies†, the selenomethionine (SelMet) protein was prepared 
by transforming the plasmid pMl5332.XF1 into E. coli B834(DE3) cells, a strain 
auxotrophic for methionine. Cells were grown at 37 °C with shaking in minimal M9 
media which was supplemented with 20 mg/L of all amino acids except methionine, 1X 
MEM vitamin mix, 0.4% glucose, 50 mg/L L-selenomethionine, 2 mM MgSO4, 0.1 mM 
CaCl2, 25 mg/L FeSO4, and 100 mg/L ampicillin.  After NiNTA chromatography and 
additional step of size exclusion chromatography was followed. In both preparations, 
SDS-PAGE analysis showed 95% pure protein and the yield of the purified protein was 
1-2 mg/liter. The protein concentration was measured by the Bradford assay (11). 
 
7.2.3. Synthesis  
7.2.3.1. Enzymatic synthesis of substrate (1).  The enzymatic synthesis and 
purification of 2-methyl-3-hydroxypyridine-4,5-dicarboxylic acid (MHPD) has been 
                                                 
†
 All crystallographic studies and analysis were done by Kathryn McCulloch.  
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previously described (12).  MHPC (1) was enzymatically synthesized from MHPD in a 10 
mL reaction mixture containing 5 mM MHPD and 100 µM of MHPD decarboxylase in 
100 mM sodium phosphate buffer (pH 8.0) incubated over night at room temperature.  
MHPC was purified by the HPLC (12, 13) and upon lyophilization yielded a stable white 
solid.  1H NMR (300 MHz, D2O) δ 2.46 (s, 3H, CH3), 7.68 (s, 1H, C4-H), and 8.12 (s, 1H, 
C6-H).  The purified MHPC was dissolved in 100 mM Tris (pH 7.7) to a final 
concentration of 100 mM and stored frozen at -20 °C until use. 
 
7.2.3.2. 3-hydroxy-5-(methoxycarbonyl)-1-methylpyridinium (4). 3-hydroxy-5-
(methoxycarbonyl)-1-methylpyridinium (4) was synthesized in one step from methyl-5-
hydroxynicotinate (3) and methyl iodide following literature procedure (2). Quantitative 
yield was seen and the NMR agreed with that reported.  
 
7.2.3.3. 3-methoxy-5-(methoxycarbonyl)-1-methylpyridinium (6). 3-methoxy-5-
(methoxycarbonyl)-1-methylpyridinium (6) was synthesized in a similar manner as 
described above from methyl-5-methoxynicotinate (5). 1H NMR (400 MHz, D2O) δ 9.01 
(s, 1H), 8.75 (s, 1H), 8.55 (s, 1H), 4.44 (s, 3H), 4.09 (a, 3H), 4.03 (s, 3H).  
Figure 7.2: Synthetic scheme (a) 3-hydroxy-5-(methoxycarbonyl)-1-methylpyridinium (4) 
and (b) 3-methoxy-5-(methoxycarbonyl)-1-methylpyridinium (6) 
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7.2.4. Reaction with H2O2. Compound (4) (4.3 µmol) was treated with H2O2 (60 µmol) 
in presence and absence of NaOH. In the later case the H2O2 was premixed with the base 
for 30 min before its addition to (4). The reaction mixture was allowed to sit at 25 ˚C for 
1 hour before analyzing by HPLC. Compound (6) was treated identically as (4). 
 
7.2.5. Reaction with mCPBA. m-Chloroperbenzoic acid (25 mM) has sparing solubility 
in water so the reaction was done in 50% methanol. Compound (4) (25 mM) was treated 
with mCPBA (50 mM) in presence and absence of K2CO3 (50 mM). In the later case the 
mCPBA was premixed with the base for 30 min before adding to (4). The reaction 
mixture was allowed to sit at 25 ˚C for 2 hour before analyzing by HPLC. Compound (6) 
was treated in an identical fashion. 
 
7.2.6. Activity Assay for MHPCO The recombinant His-tagged MHPCO was assayed 
by monitoring the disappearance of NADH absorbance at 340 nm as previously 
described (13). 
 
7.2.7. HPLC. HPLC analysis of the enzymatic reaction mixture was performed on a 
Hewlett-Packard 1100 instrument using a Supelcosil LC 18 T (15 cm X 4.6 mm, 3.0 µm) 
column. Solution A contained water with 0.1% TFA and solution B contained acetonitrile 
with 0.1% TFA. The following linear gradient mixing solution A with solution B was 
used: 100% solution A for 0 to 2 min, 100% to 40% solution A from 2-7 min, 40% to 
100% solution A in 7-10 min, 100% to 0% solution A in 10-11 min and 100% solution A  
in 11-15 minutes. Flow rate was 1 ml/min, and by this method the following compounds 
were readily separated (retention time, wavelength in parenthesis): compound (4) (7.7 
min), N-methyl-5-hydroxynicotinate (4.6 min), compound (6) (7.87 min), N-methyl-5-
methoxynicotinate (6.8 min) and mCPBA (11.7 min).
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7.3. Results and Discussion 
7.3.1. Protein overexpression and purification. The protein over expressed very well 
and but had problems with its solubility. Heterologus overexpression of the protein in 
BL21 (DE-3) cell lines grown in LB media with reduced IPTG concentration did not 
improve the solubility of the protein. BL-21(DE-3) cells have lacY gene which codes for 
β-galactosides permease, thus the local concentration of IPTG in the cells cannot be 
regulated by lowering the overall concentration of IPTG, during induction in the cell 
culture. To enhance correct protein folding and preventing the formation of inclusion 
body it was necessary to decrease the local concentration of IPTG. Tuner (DE-3) cell 
lines are same as Bl-21(DE-3) cell lines but do not have the lacY gene in them. Thus they 
were be used for overexpression in LB media with very low IPTG concentration (0.2 
mM). No improvement on the protein solubility was observed. In order to give more 
time for the protein to fold properly Tuner (DE-3) cell transformed with MHPCO gene 
was grown in minimal media with 0.2 mM IPTG concentration, however no 
improvement in protein solubility was observed.  
 The plasmid for MHPCO was then co-expressed with each of the plasmids 
containing various combinations of genes encoding for a mixture of chaperone proteins, 
table 7.1.  
 
Table 7.1: The various plasmids marketed by Takara Bio Inc. containing various 
combinations of chaperone proteins. 
No. Plasmid Chaperone Promoter Inducer 
1 pG-KJE8 dnaK-dnaJ-grpE 
groES-groEL 
araB 
Pzt1 
L-Arabinose 
Tetracyclin 
2 pGro7 groES-groEL araB L-Arabinose 
3 pKJE7 dnaK-dnaJ-grpE araB L-Arabinose 
4 pG-Tf2 groES-groEL-tig Pzt1 Tetracyclin 
5 pTf16 Tig araB L-Arabinose 
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  All the combinations were tried and pure soluble yellow colored protein was 
obtained when pMl5332.XF1 was co-expressed with pGro7 in competent Tuner (DE-3) 
and induced with 0.5 mM IPTG. 1mg of protein was obtained from 1 L of cells. 
 .  
7.3.2. MHPCO activity  The recombinant His-tagged MHPCO was purified using metal 
affinity chromatography and was found to be active; however, the His-tagged MlMHPCO 
was found to be approximately five-fold slower than the MlMHPCO purified by classical 
methods without a His tag (13).  The activity of recombinant MHPCO with the His-tag 
cleaved by digestion with TEV protease was comparable to the activity of the His-tagged 
MHPCO sample.   
 
Figure 7.3: Stereoview diagram of the active site of MHPCO with FAD and MHPC 
bound.  Water molecules are shown as nonbonded red spheres.  Hydrogen bonds 
between MHPC, water molecules and the protein are shown as dashed lines. 
 
7.3.3. Active Site of MHPCO. The active site of MHPCO is a large pocket lined mostly 
by hydrophobic and aromatic residues, figure 7.3. These residues include Tyr54, Tyr82, 
Tyr223, Phe358, Trp203, Asp 203, and Arg211. The hydroxyl groups of the tyrosine 
residues point into the active site, and the side chain of Arg211 is also positioned within 
 127 
the active site. These residues are hydrogen bonded to the many water molecules that are 
found within the active site in both structures. Comparisons of the active sites of flavin 
aromatic monooxygenases whose structures are available show some similarities.  
All structures have an absolutely conserved proline residue above the FAD isoalloxazine 
ring containing C7 and C8 (Pro295 in MHPCO). The other commonality is the presence 
of several aromatic residues at the back of the binding pocket. MHPCO has three 
tyrosine residues, two tryptophan residues, and two phenylalanine residues in the rear of 
the active site, and none form any direct contacts with the substrate MHPC (1). p-
Hydroxybenzoate hydroxylase, PHBH (PDB ID 1pbe)(14) and 2,6-dihydroxypyridine 
hydroxylase (15) have a similar wall in the active site. p-Hydroxybenzoate, p-OHB, the 
substrate of PHBH, forms a hydrogen bond to a tyrosine hydroxyl group, which can 
deprotonate p-OHB for activation. The carboxylate group of p-OHB forms a salt bridge 
with an arginine side chain, helping correctly orient the substrate within the active site. 
The binding of MHPC within the active site of MHPCO is quite different. Unlike PHBH, 
MHPCO makes no direct interactions with its substrate, figure 7.3. The 3-hydroxyl group 
of MHPC forms a water-mediated hydrogen bond to Tyr223, and the N1 atom is 
hydrogen bonded to Tyr82 through a water molecule. The carboxyl oxygen atoms are 
each hydrogen bonded to two water molecules that lead into the tunnel. Arg211 is one of 
the few charged residues found in the active site, and it is poorly positioned to help 
stabilize MHPC. The surprising lack of direct interactions between MHPC (1) and 
MHPCO and the large open cavity of the active site is unusual and differentiates 
MHPCO from other members of this enzyme family. 
 
7.3.4. Mechanistic implications of the MHPCO Structure. Four plausible mechanism 
for the catalytic transformation of MHPC (1) is shown in figure 7.4. All four mechanisms 
are consistent with all previous 18O2 and H2
18O labeling experiments, substrate analogue 
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Figure 7.4: Possible mechanisms for the reaction catalyzed by MHPCO. Flavin 
hydroperoxide can act both as an electrophile (a) and (b) or a nucleophile (c) and (d).  
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studies, and kinetics data (3, 5-7, 16). Mechanism (b) and (c) have been proposed 
previously by Ballou and co workers (2). Although there are no experimental evidences 
against the nucleophilic attack of the flavin hydroperoxide Ballou and coworkers favors 
electrophilic attack of the flavin hydroperoxide on the pyridine ring based on favorable 
sequence homology of MHPCO with other aromatic flavoenzymes which have been 
shown to react as electrophilic flavin hydroperoxide, chemical calculations and more 
similarity in certain properties of MHPCO with aromatic hydroxylases than nucleophilic 
monooxygenase.     
Alternative mechanisms for the catalysis by MHPCO for both electrophilic and 
nucleophilic attack by the flavin hydroperoxide is shown in (a) and (d) respectively, figure 
7.4. According to mechanism (a), the hydroxylation of MHPC (1) first occurs by an 
electrophilic attack by the flavin hydroperoxide on C2 of pyridine (1) to give (7), which 
could then undergo an electrocyclic ring opening to produce ketene (8). Tautomerization 
to (9) followed by addition of water to the ketene would generate the product E-2-
acetaminomethylene succinate (2). Such a ketene intermediate can also be traversed by 
the route of nucleophilic attack by the flavin hydroperoxide on the pyridine ring, figure 
7.4(d). The arguments against nucleophilic attack of the flavin hydroperoxide are still valid 
with the alternative mechanistic hypothesis, but in absence of hard experimental 
evidences it is difficult to rule it out with certainty.  The current structure of MHPCO 
bound with MHPC (1) seems to position the substrate optimally for hydroxylation by the 
flavin hydroperoxide.  
The structure of MHPCO complexed with the substrate MHPC (1) clarifies many 
of the details of the active site and provides further insight into the catalytic mechanism. 
The C2 of MHPC (1) is located 5.3 Ǻ from C4a of the isoalloxazine ring. This separation, 
in addition to the orientation of the planes of the pyridine and the isoalloxazine rings, 
gives a reasonable geometry for reaction of the distal oxygen atom of the flavin  
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Figure 7.5: Stereoview diagrams of the active site with possible bases for the ring-opening 
reaction. All residues and ligands are shown in ball and stick representation and colored 
according to atom type. Red nonbonded spheres are water molecules. The 2-hydroxy-
MHPC (X) was manually modeled into the active site using the binding of MHPC (1) as a 
guide. (A) Tyr223 as the active site acid. Tyr223 activates a water molecule for attack at 
the C3 carbonyl and could provide stabilization of the intermediate. (B) Arg181 as the 
active site base. Arg181 could protonate the carbonyl and stabilize the intermediate after 
attack of water at the carbonyl. Arg181 has adopted a different conformation than that 
seen in the crystal structure. 
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hydroperoxide with C2 of the substrate. The position of this oxygen is indicated by 
structurally conserved water molecules seen in both structures of MHPCO described 
here. Comparable substrate-C4a distances have been observed in other aromatic ring 
oxidizing flavin-dependent monooxygenases. Tyr223 and Tyr82 are likely catalytic 
residues, figure 7.5(A). Tyr223 could activate the water molecule located 2.7 Ǻ from the 
substrate C3 oxygen and facilitate the conversion of (1) to (8). Tyr82 is hydrogen bonded 
to the water molecule located 2.6 Ǻ from the pyridine nitrogen and may facilitate the 
conversion of (8) to (9). Arg181 is also a possible candidate for an active site base. In the 
crystal structure, this residue is oriented along the isoalloxazine ring, but a conformational 
change of the side chain may position the guanidinium group within hydrogen bonding 
distance of the substrate C3 oxygen (modeled in figure 7.5B). However, for Arg181 to 
adopt this conformation some conformational changes of the active site would have to 
occur to avoid close contacts between the isoalloxazine ring and the arginine.  
Removal of the hydroxyl group of Tyr223 (Y223F) or substitution of the 
guanidinium group of Arg181 with an amide group (R181Q) both render the enzyme 
inactive. Arg211 is located below the plane of the pyrimidine ring, and its guanidinium 
group is facing the C5 carboxylate of MHPC. While poorly positioned to form a salt 
bridge in the enzyme-substrate complex, conformational changes during the course of the 
reaction could increase the strength of this interaction. 
 
7.3.5. Model chemistry. There has been no precedence of a ketene intermediate (8), 
figure 7.4 (a, d) in an enzyme catalyzed reaction. Also, there are no evidence for or against 
the electrophilic and the nucleophilic mechanism. To explore the possibility of such 
reactions and to investigate the mechanism we decided to do the oxygenation reaction 
with model compounds which are easy to handle. Two such model compounds, 3-
hydroxy-5-(methoxycarbonyl)-1-methylpyridinium (4) and 3-methoxy-5-
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(methoxycarbonyl)-1-methylpyridinium (6) were synthesized and their oxygenation in 
presence of the peracid and hydrogen peroxide were studied.  
Figure 7.6: Postulated reaction scheme for oxidation of 3-hydroxy-5-(methoxycarbonyl)-
1-methylpyridinium (4) in presence of peracids and peroxides. 
 
7.3.6. 3-hydroxy-5-(methoxycarbonyl)-1-methylpyridinium (4). Possible reaction of 
3-hydroxy-5-(methoxycarbonyl)-1-methylpyridinium (4) with peracid and H2O2 is shown 
in figure 7.6. There are two pathways in which the final ring open product (22) can be 
formed. The first one involves the ketene intermediate (24) and the second involves the 
Bayer-Villiger type of ring expansion of (19) to give the lactone (20) which can then 
undergo a nucleophilic attack by water to give the final ring opened product (22). It was 
treated with hydrogen peroxide as well as peracid (in presence and absence of base) at 
25 ˚C for 1 hour and then analyzed by HPLC. No new product was seen. Reaction 
samples in which base was present hydrolyzed the ester (4) to form N-methyl-5-hydroxy-
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nicotinic acid. No new species were seen on elevating the temperature to 50 ˚C. The fact 
that 3-hydroxy-5-(methoxycarbonyl)-1-methylpyridinium (4) did not react with peracid or 
peroxide was not very surprising as the presence of the hydroxide group at C3 makes C2 
of the pyridine ring less electrophilic for nucleophilic attack of the peracid or the 
peroxide.  
Figure 7.7: Postulated reaction scheme for oxidation of 3-methoxy-5-(methoxycarbonyl)-
1-methylpyridinium (6) in presence of peracids and peroxides. 
 
7.3.7. 3-methoxy-5-(methoxycarbonyl)-1-methylpyridinium (6). Possible reaction of 
3-methoxy-5-(methoxycarbonyl)-1-methylpyridinium (4) with peracid and H2O2 is shown 
in figure 7.7. Unlike compound (4), (6) can form the ring opened product (29) in only one 
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peak at a 10.0 min (for only H2O2) and 10.1 min (for H2O2 premixed with NaOH) are 
likely to be the same since they have the same absorption spectra and the presence of 
base in a non buffered solvent system could change the retention time of the species. 
This new species is highly chromophoric with a very high extinction coefficient. Attempt 
to isolate this compound over multiple injections by HPLC have failed to generate 
sufficient amount to characterize by NMR. The tiny tail of the peak corresponding to (6), 
present at 10.0 min is all that is seen after collection of 10.0 min peak over multiple 
injections of a ten fold scaled up reaction mixture.  
Figure 7.8: Treatment of (6) with H2O2 in presence and absence of NaOH-HPLC trace. 
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as the one produced on treatment of (6) with H2O2.  
Figure 7.9: Treatment of (6) with mCPBA in presence and absence of K2CO3-HPLC 
trace. 
 
This product needs to be characterized. It could likely be the ring opened product 
(29) in which case if not NMR (for the difficulty in isolation) at least ESI-MS would be 
able to confirm it. The high extinction coefficient lends hope that it could be the ring 
opened product since E-2-(acetamidomethylene)succinate (2), which is the enzymatic 
product of MHPCO, also has a very high extinction coefficient. 
Methyl-5-methoxy nicotinate which lacks the N-methyl group does not undergo 
any reactions on treatment with H2O2 both in presence and absence of NaOH. The 
presence of methyl group on the nitrogen of the pyridine ring in (4) and (6) is essential to 
maintain the positive charge on the nitrogen which in turn makes the position C2 of the 
pyridine ring susceptible for electrophilic addition reaction with peracids and/or 
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peroxides. More over the presence of the methoxy group also make the position C2 of 
the pyridine ring more electrophilic in (6) than (4), which facilitate the attack of peracid as 
well as peroxide and do the ring opening chemistry. 
 
7.3.8. Engineering the enzyme as a mechanistic probe. In order to distinguish 
between the electrophilic and the nucleophilic mechanism an effort was made to engineer 
the enzyme active such that one can bias the enzyme towards the formation of a desired 
product which can be formed by only one mechanism. When 5-hydroxynicotinate (30) 
was used as a substrate for MHPCO, it did not undergo rearomatization but instead 
produced the ring opened product, α-(N-formyl-N-methyl-amino-methylene) succinate 
(2). If flavin hydroperoxide acts as a nucleophile then it will form intermediate (31) and if 
it acts as an electrophile it would form the intermediate (34), figure 7.10 (a, b). If by some 
mechanism the hydrogen at C2 (31 & 34) could be abstracted then we would have a way 
to distinguish between the electrophilic and the nucleophilic mechanism. When we 
looked into the active site of the protein we found a hydrophobic residue (Leu 213) close 
to C2 of the pyridine ring which when mutated to an Asp or a Glu could act as a base and 
assists in the abstraction of the C2 hydrogen, thereby biasing the reaction towards the 
rearomatization of the pyridine ring (instead of ring opening) to form 5,6 
dihydroxynicotinate (33), figure 7.10. If flavin hydroperoxide acts as a nucleophile, for the 
ring opening to happen the C-C bond in the intermediate (13, 14 & 31) must be 
transperiplanar to O-O bond, which excludes the possibility of the C-H bond being 
transperiplanar to the O-O bond. Thus, when the mutant of MHPCO is used and if the 
reaction goes via flavin hydroperoxide acting as a nucleophile, then the reaction will stop 
at the stage of the intermediate (31). This is because the C-H bond is not trans-periplanar 
with the O-O bond to facilitate its cleavage in order to release flavin hydroxide.  If 5,6 
dihydroxynicotinate (33) is seen, then it has to be via the electrophilic mechanism.   
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Figure 7.10: Postulated mechanism of MHPCO mutant in which an active site base is 
introduced with 5-hydroxynicotinate (30) when flavin hydroperoxide acts as (a) a 
nucleophile and (b) an electrophile. (c) The active site of MHPCO showing Leu 213 
which could be mutated to Asp or Glu. (d) Few examples of 2-methoxy pyridine 
derivatives which are stable and do not undergo spontaneous rearomatization.  
 
2-methoxy pyridine derivatives do not spontaneously rearomatize and are stable which 
suggests that (33) can be formed only via the electrophilic mechanism figure 7.10(b).  
Leu 213 was mutated to Asp and Glu. Both the mutants did not turnover (30). 
However L213D mutant was found to oxidize NADH in absence of the 
substrate. In the wild type MHPCO, the reduction of the flavin by NADH is greatly 
enhanced by the presence of the substrate within the active site.  The L213D mutant 
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seems to have decoupled these two events.  It can be speculated that, the presence of a 
highly charged, hydrophilic residue in the floor of the active site (containing only 
hydrophobic residues) could somehow mimic the charges seen on the natural substrate 
MHPC or trigger a change in the FAD binding from the IN conformation to the OPEN 
(or READY) conformation, where it can be reduced by NADH.  The water molecules 
could relay these changes to the FAD in the absence of MHPC. 
 
7.4. Conclusion  
The work done towards elucidation of the mechanism of the reaction catalyzed by 
MHPCO is far from complete and lot more studies must be done to prove the 
mechanism. Chemical synthesis of compound (29) must be done and co-injected with the 
compound (6) and H2O2 reaction mixture to see if it co-elutes with the new product that 
was seen. If this is the case, then the nucleophilic attack of the flavin hydroperoxide on 
the pyridine ring is the mechanism by which the reaction proceeds. Moreover, no ketene 
intermediate can be formed from compound (6). This information is valuable to 
distinguish between all the plausible reaction mechanism for the very interesting and 
unique oxidative ring opening reaction catalyzed by MHPCO.  
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CHAPTER 8 
A novel pyrimidine degradation pathway in Escherichia coli K12∗ 
8.1 Introduction 
There are two well characterized catabolic pathways for pyrimidines. The first one 
is the reductive pathway (1), which is more prevalent, has been discovered in bacteria, 
archaea as well as in humans. The pyrimidine bases are first reduced to their respective 
dihydro derivatives (2), which then undergoes two hydrolysis reactions to produce 
ammonia, carbon dioxide and β-alanine (4) as end products.  The other pathway is the 
oxidative pathway which is less prevalent and has been reported in some bacteria. The 
pyrimidine bases undergo oxidation to form barbituric acid (5) which undergoes two 
hydrolysis reactions to produce urea (7) and malonic acid (8) (2), figure 8.1.  
Figure 8.1: Two well known pathways of pyrimidine catabolism. 
 
Apart from these two pathways, another new pathway of degradation of uracil (1) 
(or thymine) was recently discovered in Escherichia coli K12 (3, 4). Even though the 
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genome of E.coli was sequenced a decade ago, date one-fifth of it still remained 
uncharacterized. The b1012 operon in E.coli was one of the largest clusters of 
uncharacterized genes which were regulated under the control of the transcriptional 
activator, nitrogen regulatory protein C (NtrC). Kustu and coworkers, made mutants for 
each of the genes in the b1012 operon and the E.coli mutants were grown in the presence 
of various nitrogen sources. It was found that the wild type grew in the presence of uracil 
(1) and thymine as the sole nitrogen source at 25 ˚C (not 37 ˚C) while none of the 
mutants did. This highlighted the importance of all the genes in the operon participating 
in a catabolic pathway of uracil (1) (and thymine) which ultimately produced utilizable 
nitrogen in the form of ammonia. Each molecule of uracil (1) produces two molecules of 
ammonia, one molecule of carbon dioxide and 3-hydroxy propionate (9), figure 8.2. The 
b1012 operon which contained seven genes of unassigned functions were named as rutA-
rutG (pyrimidine utilization). However, the enzymology and intermediates involved in this 
pathway were not known. In this chapter the identification and characterization of the 
intermediates in this new pathway are reported.  
Figure 8.2: A novel pathway of uracil (1) degradation in E.coli K12 (3). 
 
8.2 Experimental 
8.2.1. Cloning, over-expression and purification. The pCA24N plasmid containing 
genes encoding for the Rut proteins (b1012, b1011, b1010, b1009, b1008 and b1007 
genes) was transformed into Escherichia coli BL21(DE3). A starter culture was prepared by 
growing a single colony of transformed cells in 10 ml of LB media containing 20 µg/ml 
of chloramphenicol at 37 °C with overnight agitation. 1 liter LB medium (20 g/L), 
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containing 20 µg/ml of chloramphenicol, was inoculated with this starter culture. The 
cells were grown at 37 °C with shaking until the culture reached an OD600 of 0.6 at which 
point they were induced by adding IPTG to a final concentration of 0.5 mM, the 
temperature was lowered to 15 °C and the cells were allowed to grow for a further 12 
hours. The cells were then harvested by centrifugation at 10,000g for 8 min at 4 °C.  
Cells from 1 liter of culture were re-suspended in 20 ml of binding buffer (50 mM 
KH2PO4, 150 mM NaCl, 10 mM imidazole, pH 7.7) and approximately 2 mg of lysozyme 
was added. The cells were then lysed by sonication (Misonix Sonicator 3000, pulse ‘on’ 
time 1.0 sec, pulse ‘off’ time 1.0 sec, output level 0.8, 30 cycles) on ice for 5 times. The 
cell debris was removed by centrifugation at 39,000g for 40 minutes at 4 °C. The clarified 
supernatant was loaded onto a 2 mL Ni-NTA-affinity column pre-equilibrated with 
binding buffer kept at 4°C. The Ni-NTA-affinity column was then washed with 100 ml 
wash buffer (50 mM KH2PO4, 150 mM NaCl, 20 mM imidazole, pH 7.7). The protein 
was eluted from the column with elution buffer (50 mM KH2PO4, 150 mM NaCl, 
200 mM imidazole, pH 7.7) at 4°C. The fractions containing protein were pooled and 
concentrated using YM-10 Amicon Ultracentrifugal filters at 5000g to a final volume of 
500 µl. The concentrated sample was desalted into 100 mM phosphate buffer at pH 8.0 
containing 100 mM NaCl and glycerol to a final concentration of 30% using an Econo-
Pac 10DG disposable chromatography column.  
RutA, RutB, RutC and RutD over expressed well and soluble protein was 
obtained upon purification by Ni-affinity chromatography, figure 8.3. 25, 23, 12 and 11 mg 
of RutA, RutB, RutC and RutD respectively were obtained per liter of cell culture. The 
protein concentration was measured by the Bradford assay (5). RutE and RutF had good 
over expression patterns but very little soluble protein was obtained upon purification. 
RutE was subcloned into a pET28b vector and soluble protein was obtained. RutF was 
subcloned into pET28b vector and then had to be co-expressed with chaperon plasmid 
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pG-Tf2 (encoding for chaperone proteins groES-groEL-tig, marketed by the TaKaRa Bio 
Inc.) in order to get the soluble fraction. Kanamycin (40 mg/L) was used in the later case 
as the choice of antibiotic. 
Figure 8.3: SDS-PAGE analysis showing pure proteins of the Rut pathway which were 
purified by Ni-affinity chromatography. 
 
The clone for the Fre protein did not code for 6xHis tag. The fre gene was excised from 
the pET30LIC vector by digestion with NdeI and EcoRI and ligated into similarly digested 
pTHT (which is a pET-28 derived vector which allows attachment of a modified 
6xHisTag followed by a TEV protease cleavage site onto the N-terminus of the expressed 
protein) to construct pFRETHT1. It was then over expressed and purified by the Ni-
affinity chromatography according to the procedure mentioned above. 60 mg of protein 
was obtained per liter of cell culture. 
 
8.2.2. HPLC analysis.  HPLC analysis of the enzymatic reaction mixture was performed 
on a Hewlett-Packard 1100 instrument using a Supelcosil LC 18 T (15 cm X 4.6 mm, 
3.0 µm) column. Two different methods were used.  
Method A: Solution A contained water, solution B contained 100 mM potassium 
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phosphate buffer at pH 6.6 and solution C contained methanol. The following linear 
gradient was used. 0% to 10% solution A and 100% to 90% solution B for 0-5 min, 10% 
to 48% solution A, 90% to 40% of solution B and 0% to 12% of solution C from 5-12 
min, 48% to 50% solution A, 40% to 30% of solution B and 12% to 20% of solution C 
in 12-14 min, 50% to 30% solution A, 30% to 10% of solution B and 20% to 60% of 
solution C in 14-18 min, 30% to 0% solution A, 10% to 100% of solution B and 60% to 
0% of solution C in 18-20 min and 0% of solution A, 100% of solution B and 0% of 
solution C in 20-25 minutes. The flow rate was 1 ml/min and the absorbance was 
measured at 254 nm. Under these conditions the following compounds were readily 
separated (retention time in parenthesis): 3-ureidoacrylate (16) (2.3 min), uracil (1) (3.7 
min), NAD (12.9 min) and NADH (14.3 min).  
Method B: Solution A contained water with 0.1% TFA and solution B contained 
acetonitrile with 0.1% TFA. The following linear gradient mixing solution A with solution 
B was used: 100% solution A for 0 to 2 min, 100% to 60% solution A from 2 7 min, 60% 
to 0% solution A in 7-12 min, 0% A from 12-14 min, 0% to 100% solution A in 
14-15 min and 100% solution A  in 15-17 minutes. Flow rate was 1 ml/min and the 
absorbance was measured at 370 nm. The following compounds were readily separated 
(retention time in parenthesis): 2,4-dinitrophenylhydrazine (18) (11.6 min) and DNP 
hydrazone of malonic semialdehyde (cis/trans (19/20)  12.42 min and  trans/cis (20/19) 
14.0 min). 
 
8.2.3. Synthesis 
8.2.3.1. 3-hydroxyuracil (13)†. Literature procedure (6) was followed for the two step 
synthesis of 3-hydroxyuracil (13) from cytidine (10) figure 8.4(a). 1H NMR (300 MHz, 
D2O): δ 38.33 (d, 1H), 6.76 (d, 1H), 6.34 (d, 1H), 4.8-4.0 (m, 5H). 
                                                 
† The synthesis was done by Dr. Sameh Abdelwahed. 
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8.2.3.2. 3-ureidoacrylate (16). The synthesis of 3-ureidoacrylate (16) began with the 
known protocols for making 3-oxauracil (15) from maleic anhydride (14) (7) figure 8.4(b), 
which was converted to 3-ureidoacrylate (16) with minor modification of literature 
procedure (8). 3-Oxauracil (15) (1.13 g, 0.01 mol; well ground) was added to a solution of 
ammonia in water (20 mL) at 5 oC with constant stirring over 10 min till all of it 
dissolved, after which the reaction mixture was allowed to stand for another 12 hrs at 4˚C 
instead of 25 ˚C as reported in the literature. There was no change in the workup 
procedure and quantitative yields of 3-ureidoacrylate (16) was obtained. This is a vast 
improvement on the literature procedure where the reported yield is 12%. 1H NMR 
(DMSO, 300MHz)  δ 4.73 (d, 1H), 6.80 (br s, 2H), 7.32 (dd, 1H), 9.75 (br d, 1H). 
Figure 8.4: Synthetic schemes for the preparation of substrates and reference compounds 
(a) 3-hydroxyuracil (13), (b) 3-ureidoacrylate (16) and (e) DNP hydrazone of malonic 
semialdehyde (19/20). 
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8.2.3.3. DNP hydrazone of malonic semialdehyde (19, 20). 3,3-diethoxypropanoic 
acid (17) (10 µL) was added to 990 µL of 20 mM 2,4-dinitrophenyl hydrazine (18) 
prepared in 3 M HCl. The hydrazone formation was rapid and the orange product was 
extracted twice with 500 µL of ethyl acetate. The yellow colored ethyl acetate layer was 
washed with 1M HCl and the solvent was removed in vacuo. A yellow-orange powder was 
seen, (figure 8.4(c)). 1H NMR (CD3OD, 300MHz) δ 3.33 (d, 2H), 7.71 (t, 1H), 7.86 (d, 1H), 
8.20 (dd, 1H), 8.91 (d, Hz, 1H). 
 
8.2.4. Enzymatic Assays  
8.2.4.1. RutA and RutF catalyzed reaction of uracil (1). A 500 µL of reaction mixture 
containing 200 µM of uracil (1), 5 µM of RutA, 5 µM of RutF, 40 µM of FMN and 2 mM 
of NADH solution was incubated at room temperature for 2 hours. All solutions were 
made in 100 mM potassium phosphate buffer at pH 8.0. The reaction mixture was 
filtered to remove protein using Microcon YM10 and analyzed by HPLC (method A), 
figure 8.5. 
Figure 8.5: HPLC analysis showing the formation of a new product as a result of 
enzymatic reaction of RutA and RutF with uracil (1). 
Time (min)
2 3 4 5
Ab
s
o
rb
a
n
c
e
 
@
 
25
4 
n
m
0
500
1000
1500
2000
2500
Uracil + FMN + RutA + RutF + NADH 
Uracil + FMN + RutF + NADH
FMN + RutA + RutF + NADH 
Uracil + FMN + RutA
10 15 20 25
Uracil
FMN
New 
peak
NAD
 148 
8.2.4.2. Assay for RutB. 
8.2.4.2.1. HPLC assay. The product of RutA/F catalyzed reaction of uracil (1) was the 
substrate for RutB, which is the next enzyme in the pathway. A reaction mixture was set 
up as mentioned in section 8.2.4.1. The reaction mixture was divided into two equal 
halves. RutB was added to one of them to a final concentration of 8 µM while an equal 
volume of buffer was added to the other one. Both the reaction mixture as well as the 
control was incubated at 25˚C for 30 minutes, filtered using Microcon, YM10 and 
analyzed by HPLC (method A). The substrate was totally consumed by RutB, figure8.6. 
The product of this reaction is non-chromophoric at 254 nm and could not be observed 
by the analytical method that was employed.  
Figure 8.6: HPLC analysis showing the disappearance of the product of RutA/F catalyzed 
reaction of uracil (1) by RutB. 
 
8.2.4.2.2. UV-vis assay – depletion of substrate. A time course was determined by 
monitoring the disappearance of 3-ureidoacrylate (16) by UV-visible spectrophotometry 
as shown in figure 8.7. UV-visible scans were taken every 100 sec from 360 nm to 200 nm 
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at the rate of 100 nm/sec. The reaction mixture (500 µL) contained 64 µM 
3-ureidoacrylate (16) and 0.1 µM freshly purified enzyme in 100 mM potassium 
phosphate buffer at pH 8.0.  
Figure 8.7: UV-visible scan of the RutB enzymatic reaction mixture over time. 
 
8.2.4.2.3. Assay for ammonia production. The product of the RutA/F catalyzed 
reaction of uracil (1) was isolated by HPLC in 100 mM potassium phosphate buffer at 
pH 8.0 and the isolated sample was analyzed for the presence of ammonia. To 200 µL of 
the isolated 3-ureidoacrylate (16) (unknown concentration), 1 mM α-ketogluterate (21), 
200 µM of NADPH and 2 U of glutamate dehydrogenase (unit is defined as the amount 
of glutamate dehydrogenase that will reduce 1 µmol of α-ketoglutarate (21) to 
glutamate (22) per min at pH 8.3 at 30 ˚C), 2 µL of 0.6 mM RutB (final concentration 
2.4 µM) was added. The reduction of α-ketoglutarate (21) to glutamate (22) was not rate 
limiting under these assay conditions. The reaction was started by the addition of RutB 
and was monitored at 340 nm, characteristic for the absorbance of NADPH, figure 8.8. 
Controls were run in which one of the components of the enzymatic reaction mixture 
was missing. All the solutions were made in 100 mM potassium phosphate buffer at 
pH 8.0. 
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Figure 8.8: Coupled assay of RutB with glutamate dehydrogenase showing the production 
of ammonia as observed by the decrease in absorbance of NADPH. 
 
8.2.4.2.4. Assay for the formation of 3-oxopropionate (33). 3-ureidoacrylate (16) was 
isolated from a scaled up reaction mixture containing uracil (1), RutA/F, NADH and 
FMN, incubated overnight at 25˚C by HPLC using method A. The product was collected 
in small aliquots and frozen immediately in liquid nitrogen and stored at -20˚C. This 
sample was used in this assay. 5 µL of 0.6 mM RutB was added to 2.5 mL of 3-
ureidoacrylate (16) in 100 mM phosphate buffer at pH 7.0 at 25˚C. At various time points 
300 µL of the reaction mixture was taken and added to 300 µL of 20 mM 2,4-
dinitrophenyl hydrazine (18), mixed thoroughly and incubated at 25˚C for 5 minutes. It 
was extracted twice with ethyl acetate and the organic layer was pooled together. 100 µL 
of the organic layer was analyzed by HPLC using method B, figure 8.9. 
(16) 
(21) 
(22) 
 151 
Figure 8.9: HPLC chromatogram showing the time course of the formation of 2,4 
dinitrophenyl hydrazone of 3-oxopropionate (33) during the RutB assay. 
 
8.2.5. Steady state kinetic parameters. The 3-ureidoacrylate (16) has a λmax at 254 nm 
and the extinction coefficient at 254 nm was determined to be 12,200 M-1cm-1 in 100 mM 
phosphate buffer at pH 8.0. To a reaction mixture (500 µL) containing 100 nM enzyme, 
varying concentrations of 3-ureidoacrylate (16) were added. The rate of depletion of 3-
ureidoacrylate (16) was monitored over 5 min. The KM and kcat for the enzyme were 
determined by fitting the initial rate (less than 10% conversion) of substrate depletion as a 
function of substrate concentration to the Michaelis-Menten equation by non-linear 
regression using Grafit 5.0.11 (Erithacus Software Ltd., Surrey, UK). All solutions were 
made in 100 mM potassium phosphate buffer at pH 8.0.  
 
8.3. Results and Discusssion 
8.3.1. Background information. The first enzyme involved in this pathway is RutA 
(b1012), which is an FMN dependent mono-oxygenase (9). It requires a partner protein 
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to reduce flavin is RutF(b1007) which is a putative flavin reductase (9). However, RutF is 
not obtainable in pure soluble form. An alternative is the Fre protein which is a flavin 
reductase (10). Kustu and coworkers showed that RutA along with Fre catalyzed the first 
step in the Rut pathway. TLC assays were performed with C14 labeled uracil (1) and 
appearance of a new spot for the product was seen. The structure of the product was not 
known. They also showed that RutB(b1011) catalyzed the next step in the pathway. 
Figure 8.10: HPLC chromatogram of a time course of RutA and RutF reaction with 
uracil (1). The final concentration of uracil (1), protein, NADH and FMN are 400 mM, 20 
mM, 2 mM and 40 mM respectively. The reaction was done in 100 mM phosphate buffer 
pH 8.0 at room temperature. Each time point was obtained by heat quenching a part of 
the reaction mixture.  
 
8.3.2. Activity assay for RutA. RutA over expressed very well and purified out to near 
homogeneity (25 mg/ L of cell) by Ni-affinity chromatography. The RutF protein over 
expressed very well but had problems with its solubility. Efforts were made to solubilize it 
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by the usage of chaperone proteins, but the purity of the soluble fraction was not great. 
The RutF preparation was found to selectively use NADH instead of NADPH in order 
to reduce FMN. A coupled assay with RutF, RutA, FMN, NADH and uracil (1) showed 
product formation when each of the components of the reaction mixture was present, as 
shown in figure 8.5. No product was detected on substituting RutF with DTT and/or 
dithionite as alternative chemical reductants.  A time course of the reaction showed the 
time dependant disappearance of uracil (1) and NADH and appearance of the product 
and NAD, figure 8.10.  
 
8.3.3. Product isolation and characterization. All attempts to isolate and characterize 
the product by NMR and ESI-MS failed as the product was unstable to acid and would 
degrade on lyophilization. In order to characterize the product without isolation the 
enzymatic reaction was set up with 13C15N labeled uracil (1). 5 mM 13C15N labeled 
uracil (1) was incubated over night with 50 mM NADH, 200 µM FMN and 120 µM of 
RutA and RutF mixture, at 25 ˚C overnight. The final volume was 700 µL. A control 
reaction was set up in an identical manner with the enzymes were substituted with equal 
volume of desalting buffer. All solutions made in 25 mM D2O phosphate buffer pH 8.0. 
The enzymes were desalted into 100 mM potassium phosphate buffer at pH 8.0 
containing 100 mM NaCl and 2 mM DTT and glycerol was added to a final concentration 
of 50 %. The complete conversion of the substrate to the product was assessed by HPLC 
(data not shown). The control reaction, which is that of unreacted 13C15N labeled uracil 
(1), is shown in the top panel, figure 8.11. JC4-C5 = 65.5 Hz, JC5-C6 = 66.5 Hz, JC6-N1 = 11.6 
Hz, JN1-C2 = 24.5/20.5 Hz, JC2-N3 = 20.5/24.5 Hz and JN3-C4 = 10.6 Hz. The bottom panel 
in figure 8.11 shows the product (13C15N labeled) under identical conditions. JC4-C5 = 66.6 
Hz, JC5-C6 = 2.3 Hz, JC6-N1 = 15.5 Hz, JN1-C2 = 20.3/17.7 Hz, JC2-N3 = 17.7/20.3 Hz, JN3-C4 = 
0 Hz. The 13C NMR of the product, showed no coupling between N3 and C4, thereby  
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proving that the bond between them is broken during the enzymatic transformation. 
 
Figure 8.11: NMR (125 MHz, D2O, C
13) of the reaction mixture with and without the 
enzyme. 
 
HMBC of the labeled sample of uracil (1) (the control in section 8.3.3.) showed 
that the N1 has a chemical shift of about 140 ppm and the N3 has a chemical shift of 
about 165 ppm figure 8.12(a). The literature values of chemical shifts for N1 and N3 for 
uracil (1) are 133 ppm and 159 ppm in DMSO (11). The experiment was so set up that it 
was not be possible to see the coupling of a 13C which is bonded to two 15Ns. Thus we do 
not see the coupling between C2 (153 ppm) and either N1 (140 ppm) or N3 (165 ppm). 
We only see the N1 (140 ppm) and C6 (145 ppm) one bond coupling, N3 (165 ppm) and 
C4 (168 ppm) one bond coupling and N3 (165 ppm) and C5 (103 ppm) two bond 
coupling. HMBC of the product only shows one bond coupling between N1 (116 ppm) 
and C6 (135 ppm) figure 8.12(b). There is no coupling observed between N3 and C4 (177 
ppm) and C5 (101 ppm). The way the experiment was set up we would not see any 
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coupling between the C2 (158 ppm) and with either N1 or N3. So the HMBC tells us the 
chemical shift of only N1.  
Figure 8.12: 150 MHz. (a) HMBC of the labeled sample of uracil (1) (the control sample) 
shows that the N1 has a chemical shift of about 140 ppm and the N3 has a chemical shift 
of about 165 ppm. (b) HMBC of the product only shows one bond coupling between N1 
(113 ppm) and C6 (135 ppm). All the peaks are referenced to deuterium signal as the 
external reference. The accuracy is about ±1 ppm. 
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Figure 8.13: 150 MHz. Top row shows the  13C NMR of the product of Rut A/F 
catalyzed reaction of uracil (1) (same sample as described in 8.3.3) with 15N coupling, 
while in the bottom row the 13C NMR is decoupled from the 15N by broad band 
decoupling of the 15N. 
 
A broad band 15N decoupling was done and a 13C NMR of the product was 
acquired figure 8.13. The C5 (101 ppm) and the C4 (177 ppm) carbon peaks remained 
unaffected when we use broad band nitrogen decoupling. C5 (101 ppm) is bonded to C4 
(177 ppm) and C6 (135 ppm) and so it will not have any significant coupling with any of 
the two nitrogens (there are however 2 bond coupling – with very low J value, which is 
not present in the decoupled spectra) while the C4 (177 ppm) is disconnected from the 
N3 as shown previously. This experiment serves as another proof of the disconnection 
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between the N3 and C4 (177 ppm). The C6 (135 ppm) which is a doublet of doublet 
(because it is coupled to C5 (101 ppm) and one nitrogen, N1) gets simplified to a doublet 
on introducing the broad band coupling. The C2 (158 ppm) which is not bonded to any 
other carbons becomes a singlet on removing the coupling from two adjacent nitrogens 
(N1 and N3). This experiment also confirms the connectivity of C4-C5-C6-N1-C2-N3.  
To get the chemical shift of N3, an arrayed narrow band decoupling of the 15N on 
the 13C NMR of the product was performed. We can electronically decouple a nucleus by 
applying radio frequency at the resonance frequency of the nucleus such that a rapid 
transition between the two spin states of the nucleus is induced which would make it 
transparent to other nucleus coupling with it. The frequency at which N3 resonates in not 
known, hence the 13C NMR was taken at various potential decoupling frequencies from 
138.3 ppm to 56.3 ppm, every 4.1 ppm interval. A 90˚ decoupler pulse was provided for 
4.8 msec with the decoupling band width of 15 ppm. The result of this experiment is 
shown in figure 8.14. Each of the 13C nuceli spectra is shown and its fate at various 
potential decoupling frequencies of the 15N. The C5 (101 ppm) remains unaffected by this 
experiment as it does not couple with any nitrogen. C6 (135 ppm) is coupled with the N1 
(113 ppm). We see the decoupling for this nucleus when a decoupler pulse of 113 ppm 
was applied. From doublet of doublets it decoupled into a doublet (because it still 
coupled with C5 (101 ppm)). C2 (158 ppm) is coupled to N1 (113 ppm) and hence the 
triplet gets simplified to a doublet when a decoupler pulse of 113 ppm was applied. It is 
however also bonded with the N3. On continuing application of potential decoupler 
pulse at other frequencies we again see C5 (158 ppm) getting coupled and then 
decoupling at 80.8 ppm and then again coupling. It becomes a doublet (decoupled) at 
80.8 ppm and thus this must be the chemical shift for N3. It will decouple only when the 
decoupling frequency matches with the resonance frequency of the nucleus. Thus, N3 
must resonate at 80.8 ppm. This is a significant change in the chemical environment of 
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Figure 8.14: 150 MHz. An arrayed narrow band decoupling of 15N on the C13 NMR of the 
product of RutA/F catalyzed reaction with uracil (1) (same sample as described in 8.3.3). 
The potential decoupling frequency is labeled on top of each column. 
 
N3. In uracil (1) N3 had a chemical shift at 165 ppm and here it is nearly half of that. 
Moreover, N3 does not couple with C4. This is where the reaction has happened.  
There are four possible structures for the product of RutA/F catalyzed reaction 
of uracil (1), as shown in figure 8.15(a).  Once, the reduced form of flavin reacts with 
molecular oxygen to form the flavin hydroperoxide (12), it could act as an electrophile, as 
in the case of p-hydroxybenzoate hydroxylase (13), to form 3-hydroxyuracil (23) by the 
mechanism shown in figure 8.15 (c). This does not agree with J=0 for N3 and C4.  
Compound (24) can be produced by nucleophilic attack of the flavin hydroperoxide on 
uracil (1), as in the case of cyclohexanone monooxygenase (14), by the mechanism shown 
in figure 8.15(b), which could then undergo hydrolysis at C4 to form 3-(3-hydroxyureido 
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acrylate) (25). Both compound (24) and 3-(3-hydroxyureido acrylate) (25) do not have an 
N3-C4 bond and hence no coupling (J=0). This agrees with the NMR results. The only 
other structure that agrees with the NMR result is 3-ureidoacrylate (16), but its formation 
by flavin dependent chemistry is unprecedented.  
 
Figure 8.15: (a) Possible structures of the product of RutA/F catalyzed reaction of 
uracil (1). (b) The reaction mechanism in which flavin hydroperoxide acts as a 
nucleophile. (c) The reaction mechanism in which flavin hydroperoxide acts as an 
electrophile. 
 
8.3.4. Reactions with 3-hydroxyuracil (23). 3-hydroxyuracil (23) was analyzed by 
HPLC (method A) to see if it is the product of the RutA/F catalyzed reaction of uracil(1),  
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Figure 8.16: (a) HPLC chromatogram of 3-hydroxyuracil (23) and the product of RutA/F 
catalyzed reaction of uracil (1). (b) HPLC chromatogram of the above samples after 
incubation with RutB. (c) HPLC chromatogram after 2 hours of incubation of 
3-hydroxyuracil (23) with RutA/F. The controls are also shown. The absorbance was 
measured at 230 nm as well as 254 nm with 5 nm as the bandwidth.  
 
figure 8.16(a). Though it eluted with a retention time very close to that of the product, it 
had a totally different absorbance profile. 3-hydroxyuracil (23) had an absorbance 
maximum at 230 nm while the product of RutA/F catalyzed reaction of uracil (1) had an 
absorbance maximum of 254 nm. The product of RutA/F catalyzed reaction of uracil (1) 
was prepared by incubation of 200 µM uracil (1) with 10 µM  of enzyme in presence of 2 
mM NADH and 20 µM FMN in 100 mM potassium phosphate buffer at pH 8.0, at 25˚C 
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for 1 hour. 3-hydroxyuracil (23) was untouched on treatment with RutB, while the 
product of RutA/F catalyzed reaction of uracil (1) was converted to a non-chromophoric 
species, figure 8.16(b). The samples were prepared by incubation of RutB (10 µM) with 
200 µM of 3-hydroxyuracil (23) and the product of RutA/F catalyzed reaction of uracil 
(1) respectively for 30 min at 25˚C. 3-hydroxyuracil (23) was then tested to see if it was an 
intermediate for the reaction catalyzed by RutA/F. Incubation of 200 µM 3-hydroxyuracil 
(23) with 10 µM of RutA/F for 2 hours at 25˚C, did not yield the product of RutA/F 
catalyzed reaction of uracil (1). However under identical conditions, RutA/F catalyzed the 
transformation of uracil (1) to form the enzymatic product, figure 8.16 (c). Thus, 3-
hydroxyuracil (23) is not an intermediate in the RutA/F catalyzed reaction of uracil (1). 
 
8.3.5. RutA reaction in the presence of H2O
18 and 18O2. Two identical solutions were 
made, each (300 µL) containing 180 µL of D2O, 10 µL of 1M K2HPO4 pH 8.0, 10 µL of 
20 mM FMN and 100 µL of 1 mM RutA/F.  In one of them, 300 µL of 9.4 mM C13N15 
labeled uracil (1) solution made in H2O
18 was added. This was the ‘reaction mixture’ 
which had a final concentration of 50% H2O
18. The other sample was used as a ‘control’ 
equal volume of 9.4 mM C13N15 labeled uracil (1) solution made in H2O
16 was added. The 
cap of the eppendorf tubes were left open for atmospheric oxygen to dissolve. The 
reaction mixture was allowed to incubate at room temperature for 3 hours after which 
both the samples were analyzed by C13 NMR. Reaction carried out with 13C15N labeled 
uracil (1) in presence of 50% H2O
18 showed no isotopic shift at C4 of the product, figure 
8.17(a), which would have been observed, had 3-(3-hydroxyureido)acrylic acid (25) was 
the product of RutA and RutF catalyzed reaction of uracil (1). Thus one can rule out 3-(3-
hydroxyureido acrylate) (25) to be the product of the enzymatic reaction. 
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Figure 8.17: 13C NMR (125 MHz) of the product of RutA/F catalyzed reaction of 
uracil (1). (a) when the reaction is done in H2O
18 (control reaction done in H2O
16) and (b) 
when the reaction is done in 18O2 (control reaction done in 
16O2).  
 
Two 15 mL Nalgene tube containing 500 µL of C13N15 labeled uracil (1) dissolved in 25 
mM phosphate buffer at pH 8.0 in D2O was set up and 
18O2 was passed through one 
(reaction mixture) while 16O2 was passed through the other (control) with a long needle 
attached to the respective cylinders. The rate of the gas flow was about 1 small bubble per 
second. The solutions were purged with oxygen for half hour, after which 100 µL of 1 
mM RutA/F, 50 µL of 20 mM FMN and 75 mg of NADH was added in quick 
succession in the order mentioned. The tubes were capped tightly and vortexed briefly to 
dissolve the NADH. Both the reaction mixture as well as the control solution was 
incubated at room temperature for 2 hours after which they were analyzed by C13 NMR. 
Enzymatic reaction carried out in the presence of 18O2 shows a clear isotopic shift at C4 
for the product figure 8.17(b). 
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Figure 8.18 (a) NMR 125 MHz, D2O. Top panel shows the 
13C NMR of treatment of the 
reaction mixture in 50% H2O
18 treated with 10% TFA. The carbonyl carbon of 
trifluoroacetic acid is shown here. The bottom panel shows an identical sample prepared 
in 100 % H2O
16. Because of isotopic chemical shifts due to H2O
18 each of the peaks of 
the quartet is seen as a doublet. 22 ppb isotopic chemical shift was seen for the sample 
which had 50% H2O
18. No such isotopic shift is seen for the sample prepared in 100% 
H2O
16. Amongst the carbonyl peak a triplet can be seen in both the samples.  (b) NMR, 
500 MHz, D2O. 
13C NMR of the sample shown in (a) after spiking it with urea (7). 
 
This observation, however, did not rule out between compound (24) and 3-
ureidoacrylate (16). The enzymatic reaction product was then treated with 10% 
trifluoroacetic acid, with the hope that the structure of acid degraded product could lead 
to the structure of the parent compound. A triplet was observed at 162.7 ppm which 
corresponded to the chemical shift of urea (7), figure 8.18. The triplet clearly originated 
from C2 of uracil (1) (flanked by 2 15N nitrogens) and this observation suggested that acid 
hydrolysis of the product of RutA and RutF catalyzed reaction of uracil (1) produces 
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urea (7). The product is likely to be 3-ureidoacrylate (16) as it is susceptible to addition 
elimination reaction under acidic condition to give urea (7). Such a reaction can also 
occur for compound (24) but in that case it would have produced hydroxyl urea, which 
has a different chemical shift. 
 
8.3.6. LCMS analysis of RutA reaction product. 200 µM of uracil (1) was incubated 
with 10 µM of RutA/F in 25 mM ammonium actetate buffer at pH 7.0 in the presence of 
1 mM NADH and 40 µM FMN at 25˚C for 3 hours. All solutions were made in 25 mM 
ammonium acetate at pH 7.0. The protein was buffer exchanged to 50 mM ammonium 
acetate buffer at pH 7.0. The product of the reaction was purified out by HPLC using 
method A in which the 100 mM potassium phosphate buffer at pH 6.6 was substituted 
with 25 mM ammonium acetate at pH 6.6. A preparative column was used and the 
product peak was collected in small aliquots by HPLC (method A, where the solution B 
was 25 mM ammonium acetate buffer at pH 6.6) and frozen immediately in liquid 
nitrogen and stored at -20˚C. A control reaction was set up in which no enzyme was 
added and unreacted uracil (1) was isolated from the reaction mixture in a similar manner. 
Both the samples were subjected to LC-EMS analysis. Another set of reaction mixture as 
well as the control was made in an identical fashion and they were directly subjected to 
LCI-MS analysis, without any HPLC purification. Figure 8.19 shows the result of all the 
analysis. For the control reactions figure 8.19(a, c) the peak with m/z = 113 was isolated, 
corresponding to uracil (1), while for the reaction samples in which the product was 
expected figure 8.19(b, d) the peak with m/z =131 was isolated that corresponds to 3-
ureidoacrylate (16). No peaks with m/z = 129 corresponding to compound (24) and m/z 
= 147 corresponding to 3-(3-hydroxyureido acrylate) (25) were isolable.   
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Figure 8.19: LC-EMS of (a) HPLC purified uracil (1), (b) HPLC purified product of 
RutA/F catalyzed reaction of uracil (1), (c) a control reaction sample with uracil (1), 
NADH and FMN, incubated at 25˚C for 3 hours and (d) a reaction mixture containing 
uracil (1), NADH, FMN and RutA/F, incubated at 25˚C for 3 hours. The top panel 
shows the chromatogram and the bottom panel shows the isolated peak.  
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8.3.7. Co-injection with 3-ureidoacrylate (16). The RutA/F product was prepared by 
incubation of 200 µM of uracil (1), 1 mM NADH, 20 µM of FMN and 10 µM of RutA/F 
at 25˚C for 2 hours. All solutions were prepared in 100 mM potassium phosphate buffer 
at pH 8.0. The synthesized 3-ureidoacrylate (16) was dissolved in 100 mM potassium 
phosphate buffer at pH 8.0. Co- injection of synthesized sample of 3-ureidoacrylate (16) 
with the product of RutA/F catalyzed reaction of uracil (1) showed an increase in 
intensity of the product peak, figure 8.20, thereby ascertaining that 3-ureidoacrylate (16) 
was indeed the product of the RutA/F catalyzed reaction of uracil (1).  
Figure 8.20: HPLC trace showing the co-migration of 3-ureidoacrylate (16) with the 
product of RutA/F catalyzed reaction of uracil (1). 
 
8.3.8. Reaction of RutA/F product with RutB. The 3-ureidoacrylate (16) was prepared 
in the same manner as described in section 8.3.3. 50 µL of 0.6 mM RutB was added to it 
and the reaction was monitored by 13C NMR (arrayed experiment) over time in 500 MHz 
instrument. The 3-ureidoacrylate (16), produced enzymatically from 13C15N labeled uracil 
(1), when treated with RutB showed the growth of a singlet at 161 ppm, over time, along 
with the disappearance of the peaks of 3-ureidoacrylate (16) figure 8.21(a). 
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Figure 8.21: (a) Time course of the reaction mixture containing RutB and 3-ureidoacrylate 
(16) as monitored by 13C NMR. 250 scans were taken at each time point. (b) On addition 
of urea (7) to the above sample (c) On addition of bicarbonate to the above sample. 
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Upon addition of urea (7) (unknown concentration) to the sample a peak at 162.5 ppm 
came up showing that the new peak is not urea (7), figure 8.21(b). On addition of sodium 
bicarbonate to the sample the new peak spiked up, thereby showing that it is indeed due 
to bicarbonate formation figure 8.21(c). Since, it was a singlet, which means that the 13C 
was not bonded to either a 13C or a 15N, it is likely to be due to dissolved CO2 which 
originates from C2 of labeled uracil (1). The evolution of CO2 as a result of enzymatic 
reaction of RutB, suggests that RutB which has similarities with amidases (9), hydrolyses 
the amide bond between N1 and C2. The carbamate (29) formed would readily 
decarboxylate to give NH3 and CO2
  figure 8.25. 
 
8.3.9. Ammonia production by RutB. A coupled assay for ammonia with glutamate 
dehydrogenase in presence of α-ketogluterate (21) and NADPH was carried out to test 
the presence of ammonia in the RutB reaction sample. Ammonia liberated during the 
course of the reaction would react with α-ketogluterate (21) to form α-imminogluterate 
which would in turn be reduced by the enzyme glutamate dehydrogenase to glutamate 
(22). This enzyme requires NADPH as a cofactor which will get oxidized to NADP 
during the course of the reaction thereby showing a change in the absorbance at 340 nm, 
indicating the presence of ammonia in the solution. When all the reaction components (as 
described in 8.2.4.2.3) were present a huge decrease in the absorbance at 340 nm was seen 
due to production of ammonia. Such large decrease is not seen in any of the controls, 
figure 8.8.  
The amount of ammonia produced per unit of uracil (1) was determined by two 
simultaneous experiments. A 500 µL reaction mixture containing 200 µM of uracil (1), 
400 µM of NADH, 10 µM of RutA/F, 20 µM of FMN and 5 µM of RutB was incubated 
at 25˚C for 2 hours. It was then filtered using Microcon YM10 centrifugal filters to 
remove the protein. 50 µL of the filtrate was assayed for ammonia by its addition to a  
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Figure 8.22: (a) UV-visible spectra showing the decrease in absorbance at 340 nm 
quantifying the total amount of ammonia production in the reaction of RutA/F/B and 
uracil (1) in presence of NADH and FMN. The reaction was assayed by the coupled assay 
mentioned in the text. (b) HPLC chromatogram of the reaction mixture and the controls 
of the above samples.  
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450 µL solution of 1 mM α-ketogluterate (21), 200 µM of NADPH and 2 U of glutamate 
dehydrogenase and monitoring the decrease in the absorbance at 340 nm over 5 min. All 
the solutions were made in 100 mM potassium phosphate buffer at pH 8.0. 50 µL of 
filtrate was analyzed by HPLC following method A.  Two identical control reactions were 
run in parallel and treated in identical fashions. One control sample did not have RutB 
(this sample would give us the estimate of background ammonia in the reaction mixture 
by UV-vis assay) and the other did not have RutA/F (this would give us an estimate of 
the amount of uracil (1) consumed during the reaction by HPLC). The results of the 
ammonia assay are shown in figure 8.22(a). From the difference in the amplitude of the 
reaction mixture and the control the amount of ammonia present in the reaction mixture 
was estimated to be 370 µM. The HPLC chromatogram shown in figure 8.22(b) showed 
about 80% conversion of uracil (1). Thus 160 µM of uracil (1) in presence of RutA/F/B 
produces 370 µM of ammonia thereby proving that RutB reaction produces 2 molecule 
of ammonia per molecule of 3-ureidoacrylate (16) produced. The second molecule of 
ammonia could come from the addition–elimination reaction of 3-aminoacrylate (31) with 
water, forming 3-oxoproionate (33) figure 8.25.  
 
8.3.10. 3-oxopropionate (33) formation over time. The formation of 3-oxopropionate 
(33) was observed by derivatization of the RutB reaction mixture with 2,4- dinitrophenyl 
hydrazine (18) and analyzing by HPLC (Method B). The elution time of the hydrazone 
was identical with the elution time of the synthetically prepared 2,4- dinitrophenyl 
hydrazone of 3-oxopropionate (19/20), figure 8.9.  
 
8.3.11. RutA –Fre reaction with uracil (1). Since the RutF preparation was not very 
pure, it was substituted with a pure preparation of Fre which is a flavin reductase (10).  
Assays were set up with Fre (in place of RutF) in an identical way as described in 8.2.4.1.  
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The reaction mixture was allowed to incubate for 30 min at 25˚C, filtered using Microcon 
YM10 and analyzed by HPLC (Method A). The result was identical as seen with the 
impure preparation of RutF, figure 8.23 (a). The product formed had the exact retention 
time as the chemically synthesized 3-ureidoacrylate (16) figure 8.23(b). On treatment with 
RutB the product disappears, figure 8.23 (c). Thus the impure sample of RutF had a flavin 
reductase activity. 
Figure 8.23: HPLC chromatogram of the assay mixture of RutA-Fre catalyzed reaction of 
uracil (1). (a) Co-injection of chemically synthesized 3-ureidoacrylate (16) with the 
reaction mixture set up in an identical manner as described in 8.2.4.1. (b) Reaction 
mixture showing unreacted uracil (1) and the 3-ureidoacrylate (16). (c)  On treatment of 
the above sample with RutB. 
 
8.3.12. Steady State Kinetic parameters of RutB.  The 3-ureidoacrylate (16) has a λmax 
at 254 nm and the extinction coefficient at 254 nm was determined as 12,200 M-1 cm-1 in 
100 mM phosphate buffer at pH 8.0. Steady state kinetic parameters were obtained from 
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the concentration dependence of the rate of depletion of 3-ureidoacrylate (16) at constant 
concentration of the RutB. The enzymatic reaction exhibited Michealis Menten kinetics 
with KM and kcat of 28 µM and 0.4 s-1 respectively. The kcat/KM for RutB was determined to 
be 14285 M-1s-1, figure 8.24.  
 
Figure 8.24: The steady state kinetic parameters for RutB with 3-ureidoacrylate (16) as a 
substrate was determined by monitoring the absorbance at 254 nm.  
 
8.4. Conclusion: 
The entire pathway is represented in the figure 8.25 based on all the experimental 
evidences. In order to form 3-hydroxypropionate (9) an oxidoreductase was required to 
do the last transformation. Sequence similarities revealed that RutE, which was a putative 
oxioreductase could be catalyzing the last step. No 3-hydroxy propionate (9) was 
observed when RutE was added to the enzymatic reaction mixture of 3-ureidoacrylate 
(16) and RutB in the presence of both NADH as well as NADPH.  
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Figure 8.25: The Rut pathway of the degradation of pyrimidines. 
 
This result makes one wonder if 3-hydroxy propionate (9) is indeed the last 
intermediate in the novel degradative pathway of uracil (1). Escherichia coli has a 
3-hydroxypropionate dehydrogenase (15), which could very well do this transformation 
in vivo. Moreover, 3-oxopropionate (33) is a readily utilizable metabolite in bacteria. It can 
be transformed to acetyl CoA, by malonate-semialdehyde dehydrogenase and to malonyl 
CoA by malonic semialdehyde oxidative decarboxylase and used up for energy 
production via the TCA cycle as well as in fatty acid biosynthesis. It can be converted to 
β-alanine by 3-aminopropanoate:2-oxoglutarate aminotransferase, which is a precursor to 
pantothenate and CoA biosynthesis. Thus, we propose that 3-oxopropionate is the end 
product of the Rut pathway of degradation of uracil (1).  
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CHAPTER 9 
Mechanistic studies on RutA from Escherichia coli K12∗ 
9.1 Introduction 
RutA catalyzes the first step in the degradation of uracil (1) (or thymine) to form 
3-ureidoacrylate (2) with the assistance of RutF, which is a flavin reductase. This new 
pathway of pyrimidine degradation was recently discovered in Escherichia coliK12 (1, 2).  It 
utilizes flavin mono nucleotide (5) as a cofactor, figure 9.1. The reduced form of the 
cofactor is required for the catalysis. Thus RutA requires the assistance of a partner 
protein which would be able to supply the reducing equivalents to FMN (5) in order to 
convert it into FMNH2
 (6), the active form of the cofactor. This partner protein is RutF, 
which is a flavin reductase (3) which oxidizes NADH (3) to NAD (4) and transfers the 
reducing equivalent to FMN (5). It over expresses well, but has poor solubility. It can also 
be substituted by  Fre which is a flavin reductase from E.coli (4).  
Figure 9.1: (a) Overall reaction catalyzed by RutA. (b) Two sub reactions catalyzed by 
RutF and RutA respectively. 
                                                 
∗ The synthesis of 3-ureidoacrylic peracid and its stability was done by Dr. Sameh Abdelwahed. The 
crystallographic studies and analysis were done by Dr. Yang Zhang. 
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The experimental details for the characterization of the product of this enzymatic 
reaction have been provided in the previous chapter. However, the mechanism of the 
formation of 3-ureidoacrylate (2) is not known. This chapter details the efforts towards 
understanding the reaction mechanism. 
 
9.2 Experimental Section 
9.2.1. Cloning over-expression and purification. The protein overexpression and 
purification was done following the procedure described in section 8.2.1. SDS-PAGE 
analysis showed over 95% pure protein for RutA and Fre. The yield of the purified RutA 
and Fre was 25 and 60 mg per liter of cell culture respectively. The protein concentration 
was measured by the Bradford assay (5). 
 
9.2.2. HPLC analysis.  HPLC analysis of the enzymatic reaction mixture was performed 
on a Hewlett-Packard 1100 instrument using a Supelcosil LC 18 T (15 cm X 4.6 mm, 
3.0 µm) column. Solution A contained water, solution B contained 100 mM potassium 
phosphate buffer at pH 6.6 and solution C contained methanol. The following linear 
gradient was used. 0% to 10% solution A and 100% to 90% solution B for 0-5 min, 10% 
to 48% solution A, 90% to 40% of solution B and 0% to 12% of solution C from 5-12 
min, 48% to 50% solution A, 40% to 30% of solution B and 12% to 20% of solution C 
in 12-14 min, 50% to 30% solution A, 30% to 10% of solution B and 20% to 60% of 
solution C in 14-18 min, 30% to 0% solution A, 10% to 100% of solution B and 60% to 
0% of solution C in 18-20 min and 0% of solution A, 100% of solution B and 0% of 
solution C in 20-25 minutes. The flow rate was 1 ml/min and the absorbance was 
measured at 254 nm and 450 nm. Under these conditions the following compounds were 
readily separated (retention time in parenthesis): 254 nm: 3-ureidoacrylate (16) (2.3 min), 
 179 
uracil (1) (3.7 min), NAD (12.9 min) and NADH (14.3 min), 450 nm: p-nitrophenol (20.7 
min). 
 
9.2.3. Synthesis† 
9.2.3.1. (Z)-4-nitrophenyl-3-ureidoacrylate (9). The synthesis of (Z)-4-nitrophenyl 3-
ureidoacrylate (9) was adapted from known literature procedures of similar compounds 
(6, 7) . To a solution of (Z)-3-ureidoacrylic acid (2) (100 mg, 0.77 mmol) and 4-
dimethylaminopyridine (DMAP) (10 mg, 0.08 mmol) in anhydrous dimethylformamide 
(DMF) (2 mL), 4-nitrophenol (8) (130 mg, 0.92 mmol) was added, followed by 
dicylcohexylcarbodiimide (DCC) (190 mg, 0.93 mmol). The reaction mixture was stirred 
at room temperature overnight. N,N-dicyclohexylurea (DCU) was removed by filtration, 
and DMF was evaporated from the filtrate under reduced pressure. The residue, which 
contained some DCU that was partially soluble in DMF, was dissolved in ethyl acetate 
(30 mL), the insoluble DCU was removed by filtration and the solvent was removed 
under reduced pressure. The product was washed with water and filtered under vacuum 
and dried to give yellow colored 4-nitrophenyl 3-ureidoacrylate (55 mg, 30%). 1H NMR 
(300 MHz, DMSO): δ 5.14 (d, 1H), 6.85 (br s, 1H), 7.31 (br s, 1H), 7.47 (d, 2H), 7.67 (dd, 
1H), 8.32 (d, 2H), 9.80 (d, 1H). GC-MS: m/z = 251.1 (M+.) calculated for C10H9N3O5. 
 
9.2.3.2. 3-ureidoacrylic peracid (10). The synthesis of (Z)-3-ureidoacrylic peracid (10) 
was adapted from known literature procedures with significant modifications. To a 
suspension of 4-nitrophenyl 3-ureidoacrylate (9) (30 mg, 0.12 mmol) in D2O (0.5 mL) 
Na2O2 (16 mg, 0.14 mmol) was added at 4
o C and the reaction mixture was stirred for 5 
min. (Z)-3-ureidoacrylic peracid (10)  was identified by NMR without any further 
                                                 
† The synthesis was done by Dr. Sameh Abdelwahed. The stability of the peracid was also determined by 
him. 
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purification which was not possible due to its instability. 1H NMR (300 MHz, D2O): σ 
5.03 (d, 1H), 7.23 (d, 1H). 
 
Figure 9.2: Synthetic scheme for the preparation of (a) (Z)-4-nitrophenyl 3-ureidoacrylate 
(9) and (b) (Z)-3-ureidoacrylic peracid (10).   
 
9.2.4. Protein Crystallization and structure determination. † Crystals of RutA were 
grown from 2 mM FMN, 1.5 M ammonium sulfate, and 100 mM MES pH 6.0 using the 
hanging drop vapor diffusion method at 18 °C.  Crystals in yellow color appeared after 1 
month with a maximum size of approximately 50 µm × 50 µm × 50 µm.  Prior to flash 
freezing in liquid nitrogen, these crystals were cryo-protected by a quick sock in a solution 
containing 11% glycerol, 10% ethylene glycol, 2.0 M ammonium sulfate, and 100 mM 
MES pH 6.0.  X-ray diffraction data of RuA at 1.8 Å resolution were collected at the 
Advanced Photon Source NE-CAT beamline ID24-E using an ADSC Quantum 315 
detector. The data were integrated and scaled using HKL2000 (8).  Crystals of RutA 
belong to the space group P3121 with unit cell parameters a = 87.85 Å and c = 96.37 Å.  
                                                 
†
 The crystallographic studies and analysis were done in Dr. Yang Zhang.  
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The unit cell contains one protomer per asymmetric unit with a solvent content of 49% 
and Matthews coefficient of 2.41 Å3/Da.  The structure of RutA was determined using 
automated molecular replacement program MrBUMP (9).  The top solution was obtained 
using one protomer of protein Yntj (1YW1) as the search model, which has 
approximately 21% sequence identity to RutA.  The initial model had an R factor of 50% 
and Rfree of 55%.  The phases were gradually improved by iterative cycles of manually 
rebuilding in COOT (10) and restrained refinement in REFMAC5 (11) and PHENIX 
(12).  Water molecules and ligand FMN were included after the refinement of the protein 
molecule converged.  The final structure has an R factor of 16.2% and Rfree of 19.0%.  
 
9.3. Results  
9.3.1. Structure of RutA. The structure of RutA was determined at 1.8 Å resolution 
using molecular replacement.  The final model of the protein monomer is shown in figure 
9.3(a) and contains residues 17 – 293 and 310 – 377 of the protein and one molecule of 
FMN.  One protomer is found within the asymmetric unit and the biological unit dimer 
shown in figure 9.3(b) is generated using a crystallographic two-fold symmetry.  RutA, 
which has a TIM barrel fold, shows strong structural similarity to other members of the 
FMN-dependent alkane sulfonate monooxygenase family.  Each protomer of RutA 
contains a complete active site at the center of the β-barrel and the two active sites are 
independent of each other.  FMN is tightly bound at the active site in a non-covalent 
fashion, figure 9.3(c).  The phosphate group of FMN is anchored by five hydrogen bonds 
from residues Arg159, Tyr160, and Ser209.  The ribose moiety is additionally stabilized 
through a hydrogen bond to the backbone carbonyl oxygen atom of Ala206.  The 
isoalloxazine ring stacks against the inner surface of the β-barrel and also make a 
hydrogen bond to the backbone amine of Ile68.  The substrate binding cavity is located 
above the isoalloxazine ring where one side has hydrophilic residues Arg69 and Glu143 
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and the other side are lined with hydrophobic residues including Phe25, Trp33, Met67, 
Trp80, Phe224, Phe226, Leu259, and Leu347.  In addition, residues 294 – 309, which lack 
interpretable electron density therefore are not built in the final model, presumably are 
flexible and can serve as a flap coving the substrate binding site as in the case of other 
sulfonate monooxygenase family members. 
Figure 9.3 (a) Monomeric (b) dimeric and (c) active site structure of RutA 
 
9.3.2. Stability of the 3-ureidoacrylic peracid (10). There are many procedures that 
describe the preparation of peracids from the corresponding acid using hydrogen 
peroxide in an acidic medium (13, 14). The (Z)-3-ureidoacrylic acid (2) was found to be 
susceptible to addition elimination reaction under acidic condition to produce urea 
(section 8.3.4). A similar reaction is likely to occur for (Z)-3-ureidoacrylic peracid (10) if it 
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is prepared under acidic conditions, hence basic conditions were employed for its 
synthesis.  
Figure 9.4: 1H NMR for (Z)-3-ureidoacrylic peracid (10) over time1H NMR (300 MHz, 
D2O): δ 5.03 (d, J=9 Hz, 1H), 7.23 (d, J=9 Hz, 1H), decomposed to it acid: σ 4.92 (d, J=9 
Hz, 1H), 7.07 (d, J=9 Hz, 1H) and uracil: δ 5.70 (d, J=7 Hz, 1H), 7.50 (d, J=7 Hz, 1H).
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Unfortunately, the (Z)-3-ureidoacrylic peracid (10) is not stable for purification as it 
decomposed over time to form (Z)-3-ureidoacrylic acid (2) and uracil (1) along with some 
unidentified species, figure 9.4. The half life of the (Z)-3-ureidoacrylic peracid (10) was 
calculated to be 3 hrs at 25 ˚C, pH 10.0. The degradation of (Z)-3-ureidoacrylic peracid 
(10) to (Z)-3-ureidoacrylic acid (2) and uracil was confirmed by HPLC analysis of the 
degraded sample, figure 9.5 as well as spiking the degraded sample with (Z)-3-ureidoacrylic 
acid (2) and uracil (data not shown).  
Figure 9.5: HPLC trace of the sample of (Z)-3-ureidoacrylic peracid (10) kept at 25 ˚C for 
over 5 hours  
 
9.4. Discussion. A mechanism of the formation of (Z)-3-ureidoacrylic peracid (10) by a 
flavin dependent enzymatic reaction can be hypothesized figure 9.6. The flavin is first 
reduced to its active form FMNH2 (6) by transferring of the reducing equivalent from 
NADH (3) by RutF (or Fre) which then reacts with molecular oxygen to form the flavin 
hydroperoxide (11) (15). The C4 of uracil (1) then undergoes a nucleophilic attack by the 
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flavin hydroperoxide (11) to form the tetrahedral intermediate (12) which then collapses 
to break the bond between N3 and C4 of uracil (1). C13NMR experiments done with the 
product of this reaction mixture shows that the bond between N3 and C4 is broken 
(section 8.3.3). The lone pair on N of the isoaloxazine ring of (13) then kicks out the (Z)-
3-ureidoacrylic peracid (10) to regenerate flavin in its oxidized form which is then ready to 
do the second round of catalysis. This is a novel reaction in terms of flavin dependent 
enzymology. 
No evidence of the (Z)-3-ureidoacrylic peracid (10) was seen during the analysis of 
the enzymatic reactions (by NMR or HPLC). The reaction of RutA and RutF with uracil 
(1) done in the presence of H2O
18 did not show any C13 isotopic shift at C4 of (Z)-3-
ureidoacrylic acid (2). The C13 isotopic shift was only observed when the reaction was 
done in the presence of 18O2 (section 8.3.4). Washing away of the O
18 label was not 
observed over a period of 4 days. The reactions were done in pH 8.0. This suggests that 
the (Z)-3-ureidoacrylic acid (2) was not formed as a result of a hydrolysis reaction but 
reduction of the (Z)-3-ureidoacrylic peracid (10).  
Figure 9.6: A plausible mechanism of the formation of (Z)-3-ureidoacrylic peracid (10). 
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The active site of RutA does not show the presence of any cysteine residues 
which could potentially have reduced the (Z)-3-ureidoacrylic peracid (10) to form (Z)-3-
ureidoacrylic acid (2). Thus it is reasonable to assume that the RutA does not play any 
role in the reduction of the (Z)-3-ureidoacrylic peracid (10) to form (Z)-3-ureidoacrylic 
acid (2). The half life of the (Z)-3-ureidoacrylic peracid (10) is 3 hours at pH 10.0 at 25 ˚C. 
In the enzymatic reaction mixture there is an excess of NADH which in principal could 
reduce the (Z)-3-ureidoacrylic peracid (10). 1.5 equivalents of NADH was added to a 
freshly prepared sample of chemically synthesized (Z)-3-ureidoacrylic peracid (10) and 
within 5 minutes all the (Z)-3-ureidoacrylic peracid (10) was converted to (Z)-3-
ureidoacrylic acid (2) figure 9.7. No peaks corresponding to uracil was observed, which 
suggested that the (Z)-3-ureidoacrylic peracid (10) was indeed reduced to form (Z)-3-
ureidoacrylic acid (2). Had the presence of NADH catalyzed the degradation of the (Z)-3-
ureidoacrylic peracid (10), we would have observed the formation of uracil (1) as well. 
This reaction was carried out at a pH>8.0.  
Figure 9.7: 1H NMR of the peracid in presence and absence of NADH at 25 ˚C. 
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 DTT was also present in the enzymatic reaction mixture which can also reduce 
the (Z)-3-ureidoacrylic peracid (10) to (Z)-3-ureidoacrylic acid (2), figure 9.8. Two 
equivalents of DTT was added to a freshly prepared solution of (Z)-3-ureidoacrylic 
peracid (10) which was instantaneously reduced to the (Z)-3-ureidoacrylic acid (2). No 
uracil (1) was seen in this case as well.  
Figure 9.8: 1H NMR of the peracid in presence and absence of DTT at 25 ˚C. 
 
These results suggests that the (Z)-3-ureidoacrylic peracid (10) formed during the 
enzymatic reaction of RutA was spontaneously reduced to the (Z)-3-ureidoacrylic acid (2) 
non-enzymatically under the reaction condition. 
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CHAPTER 10 
Summary and Outlook  
10.1 Tryptophan 2,3-dioxygenase 
10.1.1. 18O labeling experiments. Tryptophan2,3-dioxygenase (TDO) is the first enzyme  
in the kynurenine pathway of tryptophan degradation which catalyzes the formation of 
N-formyl kynurenine (NFK) from tryptophan (1). We have directed our efforts towards 
the investigation of the mechanism of TDO by looking into the 18O incorporation into 
the product of the enzymatic reaction. A similar experiment was done by Hayashi (2) but 
it is very costly to run an analogus experiment today and is not sensitive enough to detect 
low level of 18O incorporation. Our experimental design is a marked improvement in 
terms of effciency, sensitivity and cost. The product NFK, was analyzed for 18O 
incorporation by positive mode ESI-MS. The results of these experiments showed that 
there were no 18O incorporation from water, both the oxygen atom in NFK came from 
molecular oxygen. This could happen via a Criegee rearrangement (3) or a dioxetane 
intermediate (4, 5). In case it is the former and if the putative carbocation generated is 
stable enough to allow for the exchange of oxygen bound to the iron with water before 
recombination, then we would be able to see it by our experimental procedure. In order 
to facilitate the exchange of the oxygen bound to iron with water, efforts were made to 
stabilize the putative carbocation by introducing an electron donating group at C-6 of 
tryptophan and so 6-hydroxytryptophan was synthesized as a possible candidate. It was 
however, not accepted as a substrate by TDO. While TDO is localized in the liver, 
indoleamine-2,3-dioxygenase, IDO, which substitutes TDO in the kynurenine 
degradation pathway of tryptophan, is present ubiquitously in the body. IDO is known to 
have a much higher tolerance to substrate modifications (6, 7). 6-hydroxytryptophan was 
accepted as a substrate by IDO. Positive mode ESI-MS analysis of the product(s) formed 
upon IDO catalyzed oxidation of 6-hydroxytryptophan, in presence of H2O
18, showed no 
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incorporation of 18O label from the solvent. This, however, was not conclusive evidence 
in favor of the dioxetane formation as the rate of exchange of the oxygen bound to iron 
with the solvent might still be much slower with respect to the rate of recombination with 
the putative carbocation formed during the Criegee rearrangement.  
 
10.1.2. Dioxetane intermediate. If the reaction went via a dioxetane intermediate that 
decomposed by retro [2+2] cycloaddition, a light emission might be associated with it. 
Efforts were directed towards detection of light emission during the course of the TDO 
reaction, if any, by stopped flow experiments. No light emission was observed during the 
course of the reaction catalyzed by both TDO and IDO. Luciferase from firefly, Photinus 
pyralis, which catalyzes the oxidation of D-luciferin to oxy-luciferin is believed to go via a 
dioxetane intermediate and emits light(8). The minimum concentration of luciferase for 
which light could be detected under the experimental condition was 109 times less than 
the concentration of TDO used. However, this did not rule out the possibility of the 
dioxetane intermediate as the dioxetane intermediate, once formed, could open up in a 
non-concerted manner, in which case there would be no light emission. 
 
10.1.3. Modeling and mutation studies on TDO. The crystal structure of TDO from 
R. metallidurans was solved at 2.4 Å resolution (9). Although the crystal structure revealed 
heme bound at the active site, there was no substrate bound to it. Models of the 
hydroperoxide intermediate were built into the active site and energy minimization 
revealed that the S-hydroperoxides were energetically more favored than the R-
hydroperoxides. Mutants of all the relevant amino acid residues in the active site that 
interacted with the modeled in hydroperoxide were constructed and their activities were 
tested and steady state kinetic parameters were determined for the active ones. The 
results suggest that the S-antiperiplanar hydroperoxide could be the intermediate involved 
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in the reaction catalyzed by TDO. This suggests that the reaction route involving Criegee 
rearrangement might be the actual route of formation of NFK from tryptophan. 
 
10.1.4. Outlook. No definitive proof for the Criegee rearrangement as the preferred 
route of oxidation of tryptophan has been shown. In order to see 18O incorporation from 
the solvent the intermediate carbocation must be stabilized long enough to allow for the 
exchange of the oxygen bound to the iron with water before recombination. The 18O 
labeling experiment was carried out at neutral pH, where the exchange of the oxygen 
bound to the heme with water will be very slow. Likelihood of the exchange could be 
enhanced at a lower pH. However the labiality of the ketonic oxygen in NFK would also 
increase under these conditions, and this would pose a problem in accurate determination 
of whether the oxygen incorporated in the ketonic position of NFK is due to exchange of 
the oxygen bound to heme or due to non-enzymatic exchange of the labile oxygen with 
the solvent. If the two rates mentioned above are sufficiently different and if the reaction 
indeed went via the Criegee intermediate then we would be able to observe 18O 
incorporation in the product. The crystal structure, failure to detect light emission during 
the course of the reaction as well as the modeling studies favors the Criegee 
rearrangement. Thus it is worth the effort to repeat the labeling experiment at lower pH 
for the enzymatic reaction to see if there is any 18O incorporation from water in the NFK 
generated. If 18O incorporation is observed then repeating the same experiment with 
synthesized NFK  in absence of the enzyme would tell us whether the 18O exchange was 
indeed enzymatic or not.  
 
10.2. Vitamin B6 catabolism  
10.2.1. 4-Pyridoxic acid dehydrogenase. The function of the mlr6793 gene from 
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Mesorhizobium loti MAFF303099 was identified (10). This gene encodes 4-Pyridoxic acid 
dehydrogenase, an enzyme involved in the catabolism of PLP (Vitamin B6). This enzyme 
was overexpressed in Escherichia coli and characterized. 4-Pyridoxic acid dehydrogenase is a 
33 kDa protein that catalyzes the four electron oxidation of 4-pyridoxic acid to 3-
hydroxy-2-methylpyridine-4,5-dicarboxylate, using nicotinamide adenine dinucleotide as a 
cofactor. The kcat for NADH production is 0.01 s
-1. The KM values for 4-pyridoxic acid 
and NAD are 5.8 µM and 6.6 µM respectively. 
 
10.2.2. 3 hydroxy-2-methylpyridine-4,5-dicarboxylate decarboxylase. The function 
of the mlr6791 gene from Mesorhizobium loti MAFF303099 was identified (11). This gene 
encodes 3 hydroxy-2-methylpyridine-4,5-dicarboxylate decarboxylase (HMPDdc), an 
enzyme involved in the catabolism of pyridoxal 5-phosphate (Vitamin B6). This enzyme 
was overexpressed in Escherichia coli and characterized. HMPDdc is a 26 kDa protein that 
catalyzes the decarboxylation of 3-hydroxy-2-methylpyridine-4,5-dicarboxylate  to 3-
hydroxy-2-methylpyridine-5-carboxylate. The KM and kcat were found to be 366 µM and 
0.6 s-1 respectively. The structure of this enzyme was determined at 1.9 Å resolution using 
SAD phasing and belongs to the class II aldolase/adducin superfamily. While the 
decarboxylation of hydroxy-substituted benzene rings is a common motif in biosynthesis, 
the mechanism of this reaction was characterized. The structural studies suggested that 
catalysis of such decarboxylations proceeded by an aldolase-like mechanism. 
  
10.2.3. E- 2-(acetamidomethylene)succinate hydrolase. The function of the mlr6787 
gene from Mesorhizobium loti MAFF303099 was identified (12). This gene encodes 2-
(acetamidomethylene)succinate hydrolase, an enzyme involved in the catabolism of 
pyridoxal 5′-phosphate (Vitamin B6). This enzyme was overexpressed in Escherichia coli, 
purified to homogeneity and characterized. 2-(Acetamidomethylene)succinate hydrolase 
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catalyzes the hydrolysis of 2-(acetamidomethylene)succinate to yield succinic 
semialdehyde, acetic acid, carbon dioxide and ammonia. The kcat and KM for this reaction 
were 0.6 s-1 and 143 µM, respectively. The enzyme was shown to utilize the E isomer of 
2-(acetamidomethylene)succinate.  
 
10.2.4. 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase.  One of the 
enzymes on the PLP degradative pathway, 2-methyl-3-hydroxypyridine-5-carboxylic acid 
oxygenase, is a flavin-dependent enzyme and catalyzes the ring opening of 2-methyl-3-
hydroxypyridine-5-carboxylic acid to form E-2-acetaminomethylene succinate. The gene 
for this enzyme was cloned and the corresponding protein was overexpressed in 
Escherichia coli and purified.  The crystal structure of MHPCO has been solved to 2.1 Å 
using SAD phasing with and without the substrate MHPC bound (13).  These crystal 
structures provide insight into the reaction mechanism and suggest roles for active site 
residues in the catalysis of a novel oxidative ring-opening reaction.  Chemical reactions 
mimicking the enzymatic reaction with substrate analogues were performed which 
through some light on the reaction mechanism of MHPCO.  
 
10.2.5. Outlook.  
10.2.5.1. Mechanistic studies on MHPCO. The mechanism of the ring cleavage 
reaction performed by the MHPCO is not yet established. The chemical model reactions 
that were done with 3-methoxy-5-(methoxycarbonyl)-1-methylpyridinium suggested that 
the enzymatic reaction could occur by a nucleophilic attack of the flavin hydroperoxide 
on the pyridine ring. The end product of this chemical transformation has not been 
characterized. If it is characterized to be E-dimethyl 2-((N-
methylformamido)methylene)succinate then it is a definitive proof that the reaction does 
not go via a ketene intermediate as no such intermediate can be formed from the starting 
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material. Attempts to isolate and characterize the product of the chemical reaction of 3-
methoxy-5-(methoxycarbonyl)-1-methylpyridinium with H2O2 failed. It is thus necessary 
to synthesize E-dimethyl 2-((N-methylformamido)methylene)succinate and see if it 
co-elutes with the product of the chemical reaction by HPLC. A mass spectrum of this 
HPLC peak corresponding to the product would also characterize the product. This study 
will lead to further experiments in assigning the most likely mechanism for the catalytic 
transformation by MHPCO. 
10.2.5.2. Identification of PLP catabolic genes in other organisms. Mesorhizobium loti 
MAFF303099 is the first organism in which all the genes participating in the PLP 
degradative pathway have been identified. Surprisingly however, when we search for an 
equivalent pathway in the available sequenced bacterial genomes using the SEED 
database (14), we find that this pathway is unique to Mesorhizobium loti suggesting that 
other vitamin B6 catabolic pathways still remain to be discovered. Apart from gene 
identification in Mesorhizobium loti, two genes encoding for pyridoxal 4-dehydrogenase (15) 
and pyridoxine 4-oxidase (16, 17) have been identified and characterized in Microbacterium 
luteolum YK-1. The gene coding for pyridoxal 4-dehydrogenase has also been observed in 
Aureobacterium luteolum (18). The remaining genes encoding for the protein participating in 
the degradation of vitamin B6 in these two organisms are yet to be discovered. In 
Pseudomonas IA and Arthrobacter Cr-7 a slightly different pathway of vitamin B6 degradation 
occurs. The participating genes and their respective gene products have not been 
characterized. Characterization of the genes of the above three organisms would throw 
light upon the diversified vitamin B6 degradative pathway.  
10.2.5.3. Characterization of 5-pyridoxic acid oxygenase.  MHPCO and 5-pyridoxic 
acid oxygenase are the only two known enzymes which catalyzes ring cleavage reaction of 
aromatic compounds without the use of metal cofactor (19). The latter enzyme is from 
Pseudomonas IA and Arthrobacter Cr-7 (20). MHPCO has been characterized significantly 
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(19, 21-26), but very little characterization of the 5-pyridoxic acid oxygenase has been 
done(20). This will also be an interesting enzyme to perform crystallographic studies on 
as the substrate for the two enzymes are significantly different at C4 of the pyridine ring. 
The carboxyl group at C4 of the pyridine ring is first removed by the decarboxylase (11) 
to produce 3-hydroxy-2-methylpyridine-5-carboxylate which is the substrate for 
MHPCO. The 5-pyridoxic acid oxygenase seems to tolerate substitution at C4 of the 
pyridine ring. Since these are the only two enzymes of its kind and accepts slightly 
different substrates it would be important to understand the structural similarities and 
their differences. The substrate tolerance of both these enzymes has not been rigorously 
tested. If the 5-pyridoxic acid oxygenase has a more open active site, this enzyme would 
be the ideal candidate to study the mechanism for the oxidative ring opening reaction by 
using substrate analogous. 
10.2.5.4. Identification of a PLP transporter.  The PLP catabolic pathway is induced 
under stress condition where the vitamin B6 is the sole source of carbon and nitrogen 
(27). This is an ideal system to look for a PLP transporter in microorganisms as it is 
reasonable to assume that under the stress condition there will be an increase in the 
transcription of the transporter gene. Two ABC transporters (mlr6799 and mlr6804) are 
present in the neighborhood of the PLP catabolic genes. Preliminary studies show that 
the mlr6799 is not the ideal candidate; however it has not been shown rigorously. The 
other gene product has not been analyzed. A transcription profile of this organism under 
stress condition needs to be completed in order to identify any the suitable candidate 
genes which would serve as a transporter for vitamin B6 in cells. 
 
10.3. Pyrimidine catabolism – the rut pathway.  
10.3.1. Characterization of the rut genes. The rut genes were shown to be involved in 
the degradation of uracil (and thymine) in Escherichia coli K12 (28, 29). No functions were 
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assigned to the genes. Our work showed that rutA catalyzes the ring opening reaction of 
uracil via a flavin dependent hydrolysis at C4 to form 3-ureidoacrylate which is 
subsequently taken up by rutB to form two molecules of ammonia, carbon dioxide and 
3-oxopropionate. We have shown that rutF clarified lysate has the flavin reductase 
activity and assists rutA in the first step of pyridine degradation.  
 
10.3.2. Mechanistic analysis. The mechanism of the reaction catalyzed by rutA has 
been looked into and evidences suggest that 3-ureidoacrylic peracid is the actual product 
of the enzymatic reaction, which is reduced by DTT and/or NADH present in the 
enzymatic assay mixture. The crystal structure of the enzyme has been solved at 1.9 Å 
resolution. 
 
10.3.3. Outlook. The 3-ureidoacrylic peracid is not very stable and hence it is difficult to 
isolate and characterize. An HPLC method needs to be developed at pH = 10.0, where 
the peracid is stable long enough for characterization. This will provide for a direct 
evidence of its formation. Complete kinetic characterization of rutA needs to be done. 
Effort should be directed towards obtaining a pure preparation of rutF. Subcloning it into 
a THT vector from pCA24N vector, fusing it with SUMO protein and coexpressing it 
with chaperone proteins were done, but nothing yielded pure preparation of rutF. A C-
terminal His-tag construct needs to be made and purified to see if soluble pure 
preparation of the protein is obtained. The activity of the other genes in the pathway 
(rutC, rutD and rutE) has not been assigned. Their characterization is necessary to 
complete the characterization of the entire operon. There are two steps in the pathway 
that are happening non-enzymatically – the reduction of the 3-ureidoacrylate peracid to 3-
ureidoacrylate and the hydrolysis of 3-aminoacrylate to 3-oxo-propionate. These steps 
could be easily catalyzed by the other enzymes in the operon.  
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